**Cochrane
Library**

Cochrane Database of Systematic Reviews

Adverse effects of biologics: a network meta-analysis and Cochrane overview (Review)

Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell LJ, MacDonald JK, Filippini G, Skoetz N, Francis DK, Lopes LC, Guyatt GH, Schmitt J, La Mantia L, Weberschock T, Roos JF, Siebert H, Hershan S, Cameron C, Lunn MPT, Tugwell P, Buchbinder R

Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell LJ, MacDonald JK, Filippini G, Skoetz N, Francis DK, Lopes LC, Guyatt GH, Schmitt J, La Mantia L, Weberschock T, Roos JF, Siebert H, Hershan S, Cameron C, Lunn MPT, Tugwell P, Buchbinder R.

Adverse effects of biologics: a network meta-analysis and Cochrane overview.

Cochrane Database of Systematic Reviews 2011, Issue 2. Art. No.: CD008794.

DOI: [10.1002/14651858.CD008794.pub2](https://doi.org/10.1002/14651858.CD008794.pub2).

www.cochranelibrary.com

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
BACKGROUND	4
OBJECTIVES	5
METHODS	5
RESULTS	7
Figure 1.	8
Figure 2.	11
Figure 3.	12
Figure 4.	13
Figure 5.	14
Figure 6.	15
DISCUSSION	24
AUTHORS' CONCLUSIONS	27
ACKNOWLEDGEMENTS	27
REFERENCES	28
ADDITIONAL TABLES	44
APPENDICES	69
FEEDBACK	84
WHAT'S NEW	85
HISTORY	85
CONTRIBUTIONS OF AUTHORS	86
DECLARATIONS OF INTEREST	86
SOURCES OF SUPPORT	87
INDEX TERMS	87

[Overview of Reviews]

Adverse effects of biologics: a network meta-analysis and Cochrane overview

Jasvinder A Singh¹, George A Wells², Robin Christensen³, Elizabeth Tanjong Ghogomu⁴, Lara J Maxwell⁵, John K MacDonald⁶, Graziella Filippini⁷, Nicole Skoetz⁸, Damian K Francis⁹, Luciane C Lopes¹⁰, Gordon H Guyatt¹¹, Jochen Schmitt¹², Loredana La Mantia¹³, Tobias Weberschock^{14,15}, Juliana F Roos¹⁶, Hendrik Siebert¹⁷, Sarah Hershan¹⁸, Chris Cameron², Michael PT Lunn¹⁹, Peter Tugwell^{20,21,22}, Rachelle Buchbinder²³

¹Department of Medicine, Birmingham VA Medical Center, Birmingham, AL, USA. ²Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Canada. ³Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Bispebjerg og Frederiksberg, Copenhagen, Denmark. ⁴Brüyère Research Institute, University of Ottawa, Ottawa, Canada. ⁵Centre for Practice-Changing Research (CPCR), Ottawa Hospital Research Institute (OHRI), The Ottawa Hospital - General Campus, Ottawa, Canada. ⁶Cochrane IBD Group, Robarts Clinical Trials, London, Canada. ⁷Scientific Direction, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milano, Italy. ⁸Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany. ⁹Epidemiology Research Unit, University of West Indies, Mona Kingston 7, Jamaica. ¹⁰Sciences of Pharmaceutical Program, University of Sorocaba, São Paulo, Sorocaba, Brazil. ¹¹Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada. ¹²Center for Evidence-Based Healthcare, Faculty of Medicine Carl Gustav Carus, Technischen Universität (TU) Dresden, Dresden, Germany. ¹³Unit of Neurorehabilitation - Multiple Sclerosis Center, I.R.C.C.S. Santa Maria Nascente - Fondazione Don Gnocchi, Milano, Italy. ¹⁴Evidence-Based Medicine Frankfurt, Institute of General Practice, Goethe University, Frankfurt, Germany. ¹⁵Department of Dermatology, Venereology, and Allergology, J.W. Goethe-University Hospital, Frankfurt, Germany. ¹⁶Dept of Clinical Pharmacy & Pharmacy Practice, Dubai Pharmacy College, Dubai, United Arab Emirates. ¹⁷Cochrane Haematological Malignancies Group, University Hospital Cologne, Cologne, Germany. ¹⁸Monash Department of Clinical Epidemiology at Cabrini Hospital, Department of Epidemiology and Preventive Medicine, Monash University, Malvern, Australia. ¹⁹Department of Neurology and MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, UK. ²⁰Department of Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada. ²¹Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, Canada. ²²Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada. ²³Monash Department of Clinical Epidemiology, Cabrini Hospital, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Malvern, Australia

Contact address: Jasvinder A Singh, Department of Medicine, Birmingham VA Medical Center, Faculty Office Tower 805B, 510 20th Street South, Birmingham, AL, 35294, USA. jasvinder.md@gmail.com.

Editorial group: Cochrane Musculoskeletal Group.

Publication status and date: Edited (no change to conclusions), published in Issue 4, 2016.

Citation: Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell LJ, MacDonald JK, Filippini G, Skoetz N, Francis DK, Lopes LC, Guyatt GH, Schmitt J, La Mantia L, Weberschock T, Roos JF, Siebert H, Hershan S, Cameron C, Lunn MPT, Tugwell P, Buchbinder R. Adverse effects of biologics: a network meta-analysis and Cochrane overview. *Cochrane Database of Systematic Reviews* 2011, Issue 2. Art. No.: CD008794. DOI: [10.1002/14651858.CD008794.pub2](https://doi.org/10.1002/14651858.CD008794.pub2).

Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Biologics are used for the treatment of rheumatoid arthritis and many other conditions. While the efficacy of biologics has been established, there is uncertainty regarding the adverse effects of this treatment. Since important risks such as lymphomas, serious infections and tuberculosis (TB) reactivation may be more common to the biologics but occur in small numbers across the various indications, we planned to combine the results from biologics used in many conditions to obtain much needed risk estimates.

Objectives

To compare the potential adverse effects of tumor necrosis factor inhibitor (adalimumab, certolizumab, etanercept, golimumab, infliximab), interleukin (IL)-1 antagonist (anakinra), IL-6 antagonist (tocilizumab), anti-CD28 (abatacept), and anti-B cell (rituximab) therapy in patients with any disease condition except human immunodeficiency disease (HIV/AIDS).

Methods

Randomized controlled trials (RCTs), controlled clinical trials (CCTs) and open-label extension (OLE) studies that studied one of the nine biologics for use in any indication (with the exception of HIV/AIDS) and that reported our pre-specified adverse outcomes (serious adverse events (SAEs), withdrawals due to adverse events (AEs), total AEs, serious infections; specific AEs, namely, tuberculosis (TB) reactivation, lymphoma and congestive heart failure) were considered for inclusion. We searched *The Cochrane Library*, MEDLINE, and EMBASE (to January 2010). Identifying search results and data extraction were performed independently and in duplicate. For the network meta-analysis, we performed both Bayesian mixed-treatment comparison models and arm-based generalized linear mixed models.

Main results

We included 160 RCTs with 48,676 participants and 46 extension studies with 11,954 participants. The median duration of RCTs was six months and 13 months for OLEs. Data were limited for TB reactivation, lymphoma, and congestive heart failure. Using standard dose, compared with control, biologics as a group were associated with a statistically significant higher rate of total AEs (odds ratio (OR) 1.28, 95% credible interval (CI) 1.09 to 1.50; number needed to treat to harm (NNTH) = 22, 95% confidence interval (CI) 14 to 60), withdrawals due to AEs (OR 1.47, 95% CI 1.20 to 1.86; NNTH = 26, 95% CI 15 to 58), serious infections (OR, 1.37, 95% CI 1.04 to 1.82, NNTH = 108 95% CI, 50 to 989) and TB reactivation (OR 4.68, 95% CI 1.18 to 18.60; NNTH = 681, 95% CI 143 to 14706).

The rate of SAEs, lymphoma and congestive heart failure were not statistically significantly different between biologics and control treatment.

Certolizumab pegol (OR 4.75, 95% CI 1.52 to 18.65; NNTH = 12, 95% CI 4 to 79) and anakinra (OR 4.05, 95% CI 1.22 to 16.84; NNTH = 14, 95% CI 4 to 181) were associated with a statistically significantly higher risk of serious infections compared with control treatment. Compared with control, certolizumab was associated with a statistically significantly higher risk of SAEs (as defined in included studies: OR 1.57, 95% CI 1.06 to 2.32; NNTH = 18, 95% CI 9 to 162). Infliximab was associated with a statistically significantly higher risk of total AEs OR 1.55, 95% CI 1.01 to 2.35; NNTH = 13, 95% CI 8 to 505) and withdrawals due to AEs compared with control (OR 2.34, 95% CI 1.40 to 4.14; NNTH = 10, 95% CI 5 to 30).

The overall numbers were relatively small for indirect comparisons. Indirect comparisons revealed that certolizumab pegol was associated with a statistically significantly higher odds of serious infections compared with abatacept, adalimumab, etanercept, golimumab and rituximab; and anakinra was statistically significantly more likely than rituximab to be associated with serious infections. Certolizumab pegol was associated with a statistically significant higher odds of SAEs compared with adalimumab and abatacept. No statistically significant differences were noted between biologics in total AEs or withdrawals due to AEs in indirect comparisons.

Authors' conclusions

Overall, in the short term biologics were associated with statistically significantly higher rates of serious infections, TB reactivation, total AEs and withdrawals due to AEs. Serious infections included opportunistic infections as well as bacterial infections in most studies. Some biologics had a statistically higher association with certain adverse outcomes compared with control, but there was no consistency across the outcomes so caution is needed in interpreting these results.

There is a need for more research regarding the long-term safety of biologics and an urgent need for comparative safety reports of different biologics; preferably without industry involvement. National and international registries and other types of large databases are relevant sources for providing complementary evidence regarding the short- and longer-term safety of biologics.

PLAIN LANGUAGE SUMMARY

Side effects of nine commonly used biologics

This summary of a Cochrane review presents what we know from research about the side effects of biologics used for many conditions including inflammatory arthritis and other inflammatory conditions, cancer, and neurological conditions. We did not include studies on HIV/AIDS. The nine biologics we studied were: abatacept (Orencia®), adalimumab (Humira®), anakinra (Kineret®), certolizumab pegol (Cimzia®), etanercept (Enbrel®), golimumab (Simponi®), infliximab (Remicade®), rituximab (Rituxan or Mabthera®) and tocilizumab (Actemra®).

The review shows that people using these biologics in the short term:

- will probably be a little more likely to experience more serious infections or tuberculosis than people who take placebo (fake drug);
- will probably be a little more likely to experience side effects or drop out of the study due to side effects than people who take placebo;

- will probably not experience more serious side effects* (other than serious infections), cancer, or congestive heart failure than people who take placebo.

(*A serious side effect is a life threatening adverse event that can result in death or hospitalization and disability or permanent damage).

We do not have precise information about other possible side effects and complications, including rare or long-term side effects.

What are biologics?

Biologics are a group of medications that suppress the immune system and reduce the inflammation, even though suppressing the immune system can make it slightly harder to fight off infections.

Best estimate of what happens to people who take biologics in the short term (range: 1 to 63 months)

Serious side effects

Among people who took any biologic, 127 out of 1,000 had serious side effects compared with 118 people out of 1,000 who took placebo (1% absolute harm).

All side effects reported

Among people who took any biologic, 770 out of 1,000 had side effects compared with 724 people out of 1,000 who took placebo (5% absolute harm).

Drop-out of study due to side effects

Among people who took any biologic, 137 out of 1,000 dropped out of the study due to side effects compared with 98 people out of 1,000 who took placebo (4% absolute harm).

Serious infections

Among people who took any biologic, 35 people out of 1000 experienced serious infections compared with 26 people out of 1000 who took placebo (1% absolute harm).

Tuberculosis

Among people who took any biologic, 20 out of 10,000 had tuberculosis compared with 4 people out of 10,000 who took placebo (0.16% absolute harm). However, there were not many cases of tuberculosis so our confidence in this result is low.

Lymphoma (Cancer of the blood)

Over the short time frame of these trials, there may be little or no difference in the number of people who experienced cancer while taking any biologic compared with people who took placebo. However, there were not many cases of cancer so our confidence in this result is low.

Congestive heart failure

There may be little or no difference in the number of people who experienced heart failure taking any biologic compared with people who took placebo. However, there were not many cases of congestive heart failure so our confidence in this result is low.

BACKGROUND

Description of the condition

Many biologic agents have been introduced to treat rheumatoid arthritis (RA) in the last two decades. RA is an inflammatory arthritis characterized by joint and systemic inflammation; joint pain, deformity and destruction (Harris 1990). RA affects 0.5% to 1.0% of the adult population worldwide (Kvien 2004) and is associated with significant work disability, functional limitation, and deficits in health-related quality of life (HRQoL) (Kvien 2005; Lubeck 2004; Odegard 2005; Pincus 1983; Yelin 2007).

Many biologics initially introduced for treatment of RA have also been used for several other conditions, such as psoriasis (Rozenblit 2009), psoriatic arthritis (Golicki 2009), ankylosing spondylitis (Zochling J) and inflammatory bowel disease (IBD) (Behm 2008). Additionally, some biologics such as rituximab were initially used for treatment of lymphoproliferative disorders (Schulz 2007; Vidal 2009) before being used for the treatment of RA. Biologics have also been used in the treatment of neurological disorders (Menge 2008). Thus, biologics commonly used for treatment of RA are also being used for treatment of several other diseases.

Description of the interventions

The main objective of this review was to review the safety of the nine biologics available for treatment of RA by including all data for these nine biologics in RA and other conditions. We included the following nine biologics.

1. Five tumor necrosis factor (TNF) inhibitors (Scott 2006): infliximab (Remicade®), approved for RA in the US in 1998 (FDA 1999; FDA 2009e); etanercept (Enbrel®), approved for RA in 1998 (FDA 1998a; FDA 1998b); adalimumab (Humira®), approved for RA in 2002 (FDA 2002a; FDA 2002b); certolizumab pegol (Cimzia®), approved for RA in 2008 (FDA 2009c); and golimumab (Simponi®), approved for RA in 2009 (FDA 2009a; FDA 2009b).
2. Anti-interleukin (IL)1 therapy: anakinra (Kineret®), approved for RA in 2001 (FDA 2001).
3. Anti-CTLA4 therapy: abatacept (Orencia®), approved for RA in 2005 (FDA 2005; FDA 2009d).
4. Anti-CD20 therapy: rituximab (Rituxan® or Mabthera®), approved for lymphoma in 1997 and for RA in 2006 (Drugs.com 2006; FDA 2006).
5. Anti-IL6 therapy: tocilizumab (Actemra®), approved for RA in 2010 (FDA 2010).

Medications are administered subcutaneously except for infliximab, abatacept, rituximab, and tocilizumab which are administered as intravenous infusions.

How the intervention might work

These biologics target various immune cells or cytokines that play a key role in local and systemic inflammation. Several biologics target tumor necrosis factor (TNF)-alpha in the joint lining, bone, and other tissues; while others target T-cells, B-cells and interleukins (IL). Anti-TNF biologics include both soluble receptors that serve as decoy receptors competing with TNF-receptors (etanercept) and monoclonal antibodies targeting the TNF-receptors (infliximab, adalimumab, golimumab, and certolizumab pegol). Anakinra is an

IL-1 receptor antagonist, targeting another cytokine important in RA pathogenesis. Rituximab is a monoclonal antibody against CD20, which is found primarily on B-cells. Abatacept is a man-made fusion protein, inhibiting co-stimulation of T-cells. Due to the different mechanisms of action for these biologics, several adverse events (SAEs) such as tuberculosis (TB) reactivation with TNF-inhibitors and neutropenia and lipid abnormalities with tocilizumab are drug specific. However, some adverse events (AEs) such as increased risk of infection are related to a general immunomodulator or immunosuppressive effect and are common to all biologics.

Why it is important to do this overview

Placebo-controlled trials have demonstrated that biologics are effective in decreasing joint and systemic inflammation, delaying radiographic joint destruction, preventing disability, and improving productivity in patients with RA and other types of inflammatory arthritis (Blumenauer 2002; Blumenauer 2003; Doherty 2009; Keystone 2009b; Maxwell 2009; Mertens 2009; Navarro-Sarabia 2005; Ruiz Garcia 2011; Singh 2009a; Singh 2009b; Singh 2010a; Singh 2010b; Strand 2008; Strand 2010). Safety is an important issue and with a limited number of RCTs included in each condition it is prudent to pool safety data across conditions to provide a better understanding of toxicity. This uses an approach recommended by The Cochrane Collaboration (Becker 2008) and will assist clinicians and patients in making more informed treatment choices. As evidence accumulates, even rare adverse events (AEs) with a medication may become apparent. An example of the strength of cumulative evidence is the recent recognition of the risk of infections including TB with anti-TNF biologics by the US Food and Drug Administration (FDA) as larger numbers of patients are exposed to treatment over time. We believe that most AEs from medications are independent of the underlying diagnoses for which the medication is being used, therefore, pooling the safety data from studies of biologics from different conditions is worthwhile.

Several of the AEs of interest are thought to be definitely linked to exposure to biologics. These include infusion reactions, an increased risk of infections including fungal infections, and TB reactivation. For several of these AEs, a biological rationale exists. For example, TNF is important in the immune response against infections, suggesting that medications that inhibit TNF may increase the risk of infections and reactivation of TB. The linkage to other AEs such as congestive heart failure and cancers is not as strong.

A systematic assessment of the safety of these nine biologics that are used for the treatment of RA has not been done. This network meta-analysis systematically assessed the adverse effects of the nine biologics using evidence from controlled trials of the treatment of any indicated condition (rheumatological and non-rheumatological), with the exception of human immunodeficiency disease (HIV/AIDS), for which these biologics are used. We recognize that since some of the AEs of interest are rare but serious, and occur during long-term use of biologics, we need to also look at non-randomized studies to fully address our question. We plan to do a systematic review of non-randomized studies as a second phase to this project.

OBJECTIVES

The primary objective was to assess the potential adverse effects of the nine biologics abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, and tocilizumab across different indications of use except human immunodeficiency disease (HIV/AIDS).

METHODS

Criteria for considering reviews for inclusion

Randomized controlled trials (RCTs), controlled clinical trials (CCTs) and open-label extension studies (OLEs) that studied one of the nine biologics for use in any indication (with the exception of HIV/AIDS) and that reported any adverse outcome were considered for inclusion. These nine biologics were chosen since they are approved for the treatment of RA and other conditions in Europe, UK, USA, Canada, and Australia. All Cochrane and non-Cochrane systematic reviews were screened to identify additional RCTs, CCTs, and OLEs.

Search methods for identification of reviews

We searched the Cochrane Database of Systematic Reviews (*The Cochrane Library*), Health Technology Assessment Database (HTA), and Database of Abstracts of Reviews of Effects (DARE) to identify existing systematic reviews (see [Appendix 1](#)). We scanned the lists of studies included in these systematic reviews to assemble a list of known RCTs. Taking the date of the oldest of the systematic reviews we then ran searches in CENTRAL (*The Cochrane Library*), MEDLINE, and EMBASE to find RCTs, CCTs and OLEs which have been published since then, using the search strategies described in [Appendix 2](#). We also ran a search with a filter for finding adverse effects as described in [Appendix 3](#).

Types of studies

We considered RCTs, CCTs, and OLEs for inclusion.

Types of participants

Adults (aged 16 years or older) with any disease (except HIV/AIDS) included in studies of any of the nine biologics were considered for inclusion. As we were interested in adverse events that may occur rarely, we did not exclude studies based on disease. The only disease that we excluded from our review was HIV/AIDS due to the complexity of treating this condition.

Types of interventions

Interventions included abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, and tocilizumab alone or in combination with other therapies for any medical condition (other than HIV/AIDS) compared to any other therapy or placebo.

Types of outcome measures

Major outcomes

1. Number of serious adverse events (SAEs): counted as the total number of SAEs, as listed in each study. Most studies use good clinical practices and standard definitions, even when not explicitly specified. One of the common definitions used in studies is the U.S. Food and Drug Administration's

(FDA) definition for SAE, that includes death, life-threatening event, initial or prolonged hospitalization, disability, congenital anomaly or an adverse event requiring intervention to prevent permanent impairment or damage ([FDA 2010b](#)). If the total number of SAEs was not presented, we took the number of patients with any ($\geq$ one) SAEs in a study (as defined in the study) for this outcome.

2. Withdrawals due to adverse events (AEs): defined in a standard manner in studies.
3. Number of AEs: defined as the total number of AEs. If the total number of AEs was not presented, we took the number of patients with any ($\geq$ one) AEs in a study (as defined in the study) for this outcome.
4. Number of serious infections: defined as 'serious infections' in each study (definitions varied but usually included infections associated with death, hospitalization, and use of intravenous antibiotics).
5. Tuberculosis (TB): diagnosis of TB, TB reactivation, miliary or cavitary TB of the lung or any other body organ. If TB for the different organ systems was provided separately, we took the total of all cases in all organ systems. One patient could only contribute one case of TB, even if they had more than one organ with TB. Some studies presented the number of TB diagnoses; we assumed that this was the number of unique patients with TB.
6. Leukemia or lymphoma: a new diagnosis of leukemia or lymphoma.
7. Congestive heart failure (CHF): any diagnosis of CHF or CHF exacerbation

Minor outcomes

1. All cardiac AEs: these included the presence of any of the diagnoses CHF or CHF exacerbation, a new diagnosis of coronary heart disease (CAD) or angina, acute CAD event characterized by myocardial infarction or unstable angina, arrhythmia, malignant hypertension.
2. Infusion and injection site reactions: for intravenous medications, the number of infusion reactions and for subcutaneous medications, injection site reactions were included.
3. Allergic reactions: included skin rash or allergic reactions. If a study provided both anaphylactic and allergic reactions separately, we planned to add them to obtain the value for all allergic reactions.
4. Neurologic: these included a new diagnosis of one or more of multiple sclerosis, Guillain-Barre syndrome (GBS), chronic immune demyelinating polyneuropathy (CIDP), multifocal motor neuropathy, progressive multifocal leukoencephalopathy (PML), or other demyelinating neurologic disease. If a study presented both specific and grouped neurologic AEs, we planned to include the grouped data.
5. Death.
6. All cancers: all cancers including leukemia or lymphoma were extracted. If a study provided the total number of cancers and the number of lymphoproliferative cancers, we planned to include the total number of cancers. If a study only provided type- or site-specific cancers, we planned to calculate the total number of cancers. Where possible, we planned to extract the

number of patients with cancers rather than the number of cancers (one patient may have more than one cancer).

7. Serious lung infection or pneumonia: serious lung infections as defined in each study were extracted. These are usually defined as lung infection with use of intravenous antibiotics, hospitalization, intubation, or death and could include pneumonia, lung abscess, and pyothorax. If not provided, we planned to calculate the total number of serious lung infections. If a study provided numbers for pneumonia and serious lung infections separately, then the number of cases of pneumonia were planned for inclusion.
8. Fungal infections: all fungal infections including but not limited to histoplasmosis, cryptococcosis, candidiasis, aspergillosis, mucormycosis, blastomycosis, and coccidioidomycosis. We planned to extract the total number of fungal infections if specified, or calculated the total number from the data provided.
9. Opportunistic infections: opportunistic infections as labeled in each study was extracted. If no opportunistic infections were reported, the value would be set to missing, since these were not being routinely reported specifically in initial trials of biologics.

As outlined above, for any adverse outcome in either the major or minor categories, if the number of cases of specific AEs and the overall number of AEs within a specific category were provided within a study, we extracted the overall number of AEs within the specific category except for the outcome of pneumonia and serious lung infection, where numbers for pneumonia rather than serious lung infection were extracted.

All outcomes were expressed as a percentage of the patients randomized (intention-to-treat analysis). For open-label extension studies, the number of patients entering the open-label phase was used as the denominator.

For each study, the duration of observation was extracted to calculate the person-years of exposure.

Data collection and analysis

Selection of reviews

Two teams of review authors (DF and JKM; EG and GF) independently assessed titles and abstracts to identify relevant studies for inclusion. The full text of the study was obtained when necessary to confirm inclusion. We included all completed RCTs, CCTs, or OLEs if the studies contained clinically relevant safety outcomes for any of the nine biologics and met the inclusion criteria listed above. We also screened the reference lists of systematic reviews to identify any studies missed by the electronic database search.

Data extraction and management

The data were extracted independently and in duplicate by the 10 review authors and an extraction partner. There was an overlap of two articles across all 10 review author teams to assess the inter-rater reliability of data extraction across the different teams (JS, ETG, NS, JKM, GF, LL, ML, LM, JS, RB). We performed data extraction using an Excel sheet that was piloted on 10 articles. Disagreements on extractions were resolved by discussion.

Assessment of methodological quality of included reviews

To assess the risk of bias of each included study, we used The Cochrane Collaboration recommendations for assessment. The criteria applied to measure the risk of bias included: allocation concealment, random sequence generation, presence of blinding in the studies (patients, assessors and physicians), incomplete outcome data, selective outcome reporting, and evidence of major baseline imbalance (Higgins 2011). In addition, the following criteria, specific to the assessment of adverse effects, were assessed.

- Adverse event definition: did the study provide a definition for 'serious adverse events'?
- Method of adverse event assessment: did the researchers actively monitor for AEs (low risk of bias) or did they simply provide spontaneous reporting of AEs that arose (high risk of bias)?
- The risk of bias of each study was explicitly judged on each criterion using the following: low risk of bias, high risk of bias, or unclear risk (either lack of information or uncertainty over the potential for bias).

Data synthesis

Statistical analysis

Methods for the Bayesian mixed treatment comparison

Following assessment of heterogeneity across trials in terms of patient characteristics, trial methodologies, and treatment protocols, we conducted Bayesian network meta-analyses for outcomes pre-specified in the PICO (Participants, Interventions, Comparisons, Outcomes) statement: withdrawal due to adverse event (WdAE), serious infection (SIInf), serious adverse events (SAEs) and adverse events (AEs). The effect estimate chosen depends on the outcome of interest and the availability of data. WdAE is a simple binary variable, and SIInf and SAE are essentially a simple binary event since the occurrence of multiple events of this nature is unlikely; for these outcomes the effect estimate chosen is the odds ratio (OR). For the outcome AE, multiple events are likely in which case the rate of the occurrence of the event is of interest. In the dose-adjusted analysis, we considered the following standard FDA doses as approved for use in RA patients (column two in Table 1) for calculating dose multiples for each biologic (last column in Table 1). Three general models were considered for including dose, namely: the standard dose model in which only the arms of the trials in which the standard dose equivalent was compared to control are included; considered; the unadjusted dose model in which all dose arms of the trials are included; and the dose-adjusted model in which all dose arms of the trials are included as a covariate in the model. The primary analysis was based on the standard dose model; sensitivity analyses were performed using unadjusted and dose-adjusted models. We conducted both fixed- and random-effects models; model selection was based on the deviance information criterion (DIC) and residual deviance. R (R Foundation for Statistical Computing, Vienna, Austria) and WinBUGS (MRC Biostatistics Unit, Cambridge, UK) were used for Bayesian network meta-analyses according to the routine which accommodates evidence structures which may consist of multi-arm trials as developed at the Universities of Bristol and Leicester. Posterior densities for unknown parameters were estimated using Markov Chain Monte Carlo methods. Basic parameters were assigned non-informative or

vague prior distributions; more informative priors were considered after evaluation of the information base and clinical expert advice. Point estimates and 95% credible intervals (conceptually similar to confidence intervals used in the frequentist approach) were used to summarize findings. Consistency between direct and indirect evidence were formally assessed using back-calculation and node splitting techniques. Model diagnostics included trace plots and the Brooks-Gelman-Rubin statistic (Ntzoufras 2008; Spiegelhalter 2003) to assess and ensure model convergence. Two chains were fitted in WinBUGS for each analysis, each usually employing $\geq 20,000$ iterations, with a burn-in of $\geq 20,000$ iterations.

Methods for the frequentist general linear mixed model

We also conducted generalized linear mixed models (GLMM) as part of the network meta-analysis for outcomes pre-specified in the PICO statement. We analyzed the outcome that follows a binomial distribution using a mixed log-binomial model with the logit link function to generate the OR estimates. We analyzed the outcome that follows a Poisson distribution using a mixed Poisson regression model. Again, three general models were considered when including dose. We conducted the random-effects GLMM model. We considered two random-effects in the model. The random-effects trial accounts for the response variables of patients within a given trial being correlated. The random-effects trial* treatment accounts for the correlation of responses between any two patients from the same treatment arm within a given study. However, the inclusion of the random-effects trial* treatment depends on the composition of the data. In cases where the number of observations was lower than the number of model parameters to be estimated, then the model cannot sustain the inclusion of the trial* treatment random-effects, and it is therefore, excluded from the model. The GLIMMIX procedure in SAS/STAT (SAS Institute Inc., Cary, NC, USA) was used for generalized linear mixed model network meta-analyses. We used point estimates and 95% confidence intervals to summarize findings. We evaluated model diagnostics evaluated using the diagnostic plots (e.g. residual plots) to assess and ensure model convergence.

We evaluated heterogeneity for the indirect comparison analyses using tau-squared, which examines heterogeneity because of study and study* drug interaction (smaller values indicate a better model). There is no specific range for this measure.

Value of Information Analyses

We performed value of information analyses to evaluate the precision of the estimate and whether the data on which our analyses were based had enough information for us to draw conclusions. This was based on an adaptation of classical monitoring boundaries for use in cumulative meta-analysis as guidelines for deciding when accumulating evidence is statistically significant and clinically relevant (Guyatt 2011). To inform this decision, we calculated the number of patients required for an adequately powered individual trial (termed the “optimal information size” [OIS]) (Pogue 1997).

Subgroup analyses, planned comparisons

The main analyses were of nine biologics compared with placebo and with each other.

The planned subgroup analyses were the following, if data were available:

1. TNF inhibitors versus nonTNF-inhibitors.
2. Medications targeting TNF receptor (etanercept) versus monoclonal antibodies against TNF (adalimumab, certolizumab pegol, golimumab, infliximab) versus other (tocilizumab, rituximab, abatacept).
3. Duration of randomized blinded study: < six months, six to 12 months, > 12 months.
4. Concomitant methotrexate or other disease modifying anti-rheumatic drug (DMARD) use versus no concomitant therapy versus 'other' therapy. The 'other' types of concomitant medication included DMARDs, steroids or non-steroidal anti-inflammatory drugs (NSAIDs), and chemotherapy.
5. Analysis by drug dose (different doses have been approved for different conditions).
6. Ethnicity.
7. Gender.
8. Age ≤ 65 years versus > 65 years.

In response to peer reviewer comments, we undertook a post hoc analysis stratifying by disease condition (ankylosing spondylitis, cancer, IBD, psoriatic arthritis, psoriasis, RA, and other) to assess our underlying assumption that it is appropriate to pool results across all disease conditions.

Presentation of key results

The main results of the review are presented in the 'Summary of findings' (SoF) tables, as recommended by The Cochrane Collaboration (Schünemann 2008a). The SoF table includes an overall grading of the evidence related to each of the main outcomes, using the GRADE approach (Schünemann 2008b). The control event rates used in the calculation of absolute risks were: 118 per 1000 for SAEs; 724 per 1000 for total AEs; 98 per 1000 for withdrawals due to AEs; 26 per 1000 for serious infections; four per 10,000 for tuberculosis reactivation; nine per 10,000 for lymphoma; and eight per 1000 for congestive heart failure. These control event rates were calculated based on the number of events in the included studies.

This amendment focuses on the analyses related to major outcomes, SAEs, AEs, withdrawals due to AEs and serious infections. We did not amend the analyses for congestive heart failure, lymphoma, and TB reactivation, which will be done in the future.

RESULTS

A flow diagram describes the results of the electronic search (Figure 1).

Figure 1. Flow diagram.

Description of included reviews

We included a total of 160 RCTs with 48,676 participants and 46 OLEs with 11,954 participants in this review. Four CCTs were found and analyzed with the RCT data. The median duration of the RCTs was six months and the majority of the RCTs assessed etanercept or infliximab in people with RA or cancer. [Table 2](#) provides further details on the characteristics of the included studies.

Concordance of assessment of included studies

There were 10 review groups each providing two review authors. The articles were randomly distributed to the review

groups and the articles within a review group were assessed independently by each of the two review authors and consensus was obtained. To evaluate agreement across the 10 review groups, two articles were assessed by each of the groups who were unaware that these two articles were being assessed across the groups for quality assurance purposes. The results of this assessment indicated a high degree of agreement with the safety data being extracted, with concordance; the kappa exceeded 0.9 and the only area of discrepancy concerned the assessment of the risk of bias.

Methodological quality of included reviews

We presented summaries of the methodological quality of the included studies for each of the domains we assessed. Results are presented separately for RCTs and OLEs. Details on the judgement for each included study and the reason for that judgement are available at the following website: [Cochrane Musculoskeletal Group website](#).

Randomized controlled trials

Allocation sequence: 45 of 160 RCTs (28.1%) reported adequate methods for allocation sequence and were judged to be at low risk of bias. One hundred and twelve RCTs (70 %) did not provide enough information to assess allocation sequence and the risk of bias was judged to be unclear for these studies. Three of the RCTs (1.9%), reported inadequate methods for allocation concealment including biased coin assignment ([Menter 2007](#)), simple block randomization ([Pavelka 2009](#)), and sequential allocation ([Cassano 2006](#)). These three studies were judged to be at high risk of bias for allocation sequence.

Allocation concealment: 60 of 160 RCTs (37.5%) reported adequate methods for allocation concealment and were judged to be at low risk of bias. Ninety-six RCTs (60%), did not provide enough information to assess allocation concealment and the risk of bias was judged to be unclear for these studies. Four studies (2.5%) were judged to be at high risk of bias for allocation concealment. Three of these RCTs were open-label studies ([Buske 2009](#); [Eve 2009](#); [Hiddemann 2005](#)) and one study used sequential allocation to assign patients to treatment ([Cassano 2006](#)).

Blinding of personnel: 65 of 160 RCTs (40.6%) reported adequate methods for blinding personnel to treatment allocation. Seventy-eight RCTs (48.8%) did not provide enough information to assess the blinding of personnel and the risk of bias was judged to be unclear for these studies. Seventeen studies (10.6%) were judged to be at high risk of bias for blinding of personnel. Nine of these RCTs were open-label studies ([Buske 2009](#); [Coiffier 1998](#); [Eve 2009](#); [Forstpointner 2002](#); [Forstpointner 2004](#); [Herold 2007](#); [Hiddemann 2005](#); [Ortonne 2008](#); [Salles 2007](#));, no blinding was reported in one study ([Hainsworth 2005](#)), unmasking or unblinding was reported in four studies ([Genovese 2002a](#); [Kavanaugh 2000](#); [Pavelka 2009](#); [Pfreundschuh 2006](#)). Patients and doctors were aware of treatment allocation in the [Van Vollenhoven 2009](#) study. In the [Schrieber 2005](#) study the treatment and placebo looked different. In the [Van der Bijl 2009](#) study, injections were given by a non-blinded independent investigator.

Blinding of participants: 75 of 160 RCTs (46.9%) reported adequate methods for blinding participants to treatment allocation. Sixty-nine RCTs (43.1%) did not provide enough information to assess the blinding of participants and the risk of bias was judged to be unclear for these studies. Sixteen studies (10%) were judged to be at high risk of bias for blinding of participants. Nine of these RCTs were open-label studies ([Buske 2009](#); [Coiffier 1998](#); [Eve 2009](#); [Forstpointner 2002](#); [Forstpointner 2004](#); [Hiddemann 2005](#); [Ortonne 2008](#); [Salles 2007](#)); no blinding was reported in one study ([Hainsworth 2005](#)), unmasking or unblinding was reported in two studies ([Genovese 2002a](#); [Pfreundschuh 2006](#)). Patients were aware of treatment allocation in three studies ([Cassano 2006](#); [Durez 2007](#); [Van Vollenhoven 2009](#)). In the [Schrieber 2005](#) study the treatment and placebo were of a different color and viscosity.

Blinding of outcome assessors: 61 of 160 RCTs (38.1%) reported adequate methods for blinding outcome assessors to treatment allocation. Ninety RCTs (56.3%) did not provide enough information to assess the blinding of outcome assessors and the risk of bias was judged to be unclear for these studies. Nine studies (5.6%) were judged to be at high risk of bias for blinding of outcome assessors. Six of these RCTs were open-label studies ([Coiffier 1998](#); [Eve 2009](#); [Forstpointner 2004](#); [Herold 2007](#); [Hiddemann 2005](#); [Ortonne 2008](#)), no blinding was reported in one study ([Hainsworth 2005](#)), and unmasking or unblinding was reported in two studies ([Genovese 2002a](#); [Pfreundschuh 2006](#)).

Incomplete outcome data: the majority of included studies (115 of 160; 71.9%) were judged to be at a low risk of bias. In these trials, missing outcome data were less than 20% and balanced in numbers across intervention groups with similar reasons for missing data across groups. Analysis was either by intention-to-treat or safety analysis, including all patients receiving at least one dose of study drug. In 25 trials (15.6%), the flow of patients was not fully reported or more than 20% of patients dropped out, indicating a high risk of bias. In the remaining 20 studies (12.5%), insufficient information about the flow of data within studies was reported so that it was uncertain whether or not the handling of incomplete data was appropriate. We judged risk of bias for these trials to be unclear.

Selective outcome reporting: the majority of included studies (102 of 160; 63.8%) were judged to be at low risk of bias. The study protocols were not available but the published reports included all expected outcomes including important side effects and those outcomes that were pre-specified in the methods section. In 21 trials (13.1%), risk of bias was judged to be high. In these trials, the majority of adverse events were not reported or it was impossible to assign them to the comparison groups. In 37 trials (23.1%), there was insufficient information on adverse events to judge whether selective reporting occurred.

Major baseline imbalance: most included studies (137 of 160; 85.6%) were judged to be at low risk of bias. The demographic and baseline characteristics of the study populations were generally similar and appeared to be balanced for all treatment groups. In eight studies (5%), unequally distributed demographic or baseline characteristics were reported, indicating a high risk of bias. For 15 studies (9.4%), no baseline measures were reported or insufficient information was given to make a judgement.

Serious adverse event definitions: in the majority of included studies (106 of 160; 66.2%), insufficient information on serious AEs definition was given and we judged the risk of bias to be unclear. In the remaining 54 trials (33.8%), a serious AE definition was provided and risk of bias was judged to be low.

Method of adverse event monitoring: most included trials (105 of 160; 65.6%) reported that AEs were actively monitored. The risk of bias was therefore judged to be low. In 49 trials (30.6%), insufficient information about the method of AE monitoring was reported so that it was uncertain whether or not adverse events were monitored appropriately. Risk of bias was judged to be unclear in these studies. In the remaining six trials (3.8%), AEs were reported as they occurred indicating a high risk of bias.

Open-label extension studies (OLEs)

Allocation sequence: all 46 OLEs were judged to be at high risk of bias for allocation sequence because there was no random assignment to the open-label treatment groups.

Allocation concealment: all 46 OLEs were judged to be at high risk of bias because there was no allocation concealment with respect to assignment to the open-label treatment groups.

Blinding of personnel: personnel were not blinded to treatment allocation in the 46 OLEs. These studies were judged to be at high risk of bias for blinding of personnel.

Blinding of participants: patients were not blinded to treatment allocation in 44 of 46 OLEs. These studies were judged to be at high risk of bias for blinding of participants. [Gordon 2006b](#) reported that patients who relapsed began receiving blinded etanercept treatment at the same dose they received at week 24 of the double-blind period. [Braun 2008a](#) reported that patients remained blinded throughout the extension phase. These two studies were judged to be at low risk of bias for blinding of participants.

Blinding of outcome assessors: outcome assessors were not blinded to treatment allocation in 43 of 46 OLEs. These studies were judged to be at high risk of bias for blinding of outcome assessors. Three studies did not provide enough information to assess the blinding of outcome assessors and the risk of bias was judged to be unclear for these studies ([Genovese 2008b](#); [Gordon 2006a](#); [Mease 2009](#)). One study was judged to be at low risk of bias for blinding of outcomes assessors. [Genovese 2002b](#) reported that the readers remained blinded to treatment group assignment and chronological order.

Incomplete outcome data: just over half the studies (25/46; 54.3%) were likely to be at high risk of attrition bias as more than 20% of participants dropped out. Some participants who were lost to follow-up may have had adverse events that were not included in the analyses, which could underestimate the adverse effect estimates. In 18 studies (39.1%), the majority of participants (80% or more) contributed outcome data and thus we judged these studies to be at low risk of attrition bias. In the remaining three studies (6.5%) the number of participants who were lost to follow-up was not reported, thus we were unclear if these studies were at risk of attrition bias.

Selective outcome reporting: we judged over half of the included studies (25 of 46; 54.3%) to be at low risk of selective reporting bias. We did not check if study protocols were available but judged published reports to be at low risk of this type of reporting bias if they reported all expected outcomes, including important AEs and those outcomes pre-specified in the methods section. Ten (21.7%) of 46 studies were likely to be at high risk of selective reporting bias because these studies either did not specify in the methods that they intended to report AEs or specified that only AEs that occurred in more than one participant were reported (for example [Braun 2003](#)). In 11 studies (23.9%) there was insufficient information on the types of adverse events to judge whether selective reporting

occurred or adverse events that are usually associated with the drug were not addressed.

Serious adverse event definitions: the majority of studies (29 of 46; 63%) did not clearly define 'serious adverse events', thus we were unclear on the risk of bias for this domain in those studies. In the remaining 17 studies (36.9%) the authors defined which adverse events were 'serious adverse events' and thus we judged these as having a low risk of bias.

Method of adverse event monitoring: we judged most studies (27 of 46; 58.6%) to be at low risk of missing important adverse effect as they reported active monitoring of AEs during follow-up. Four studies (8.7%) had a high risk of bias as they either reported AEs only as they occurred ([Dijkmans 2009](#); [Furst 2007](#); [Haibel 2008](#)) or, in one study, did not collect reports of non-serious adverse events for all of the open-label extension period of the study ([Genovese 2005b](#)). The remaining 15 studies (32.6%) reported insufficient information to judge if AEs were monitored appropriately or not.

Effect of interventions

We analyzed only the major outcomes of interest that were pre-specified in our protocol as major outcomes and those presented in the 'Summary of findings' table (that is, the seven outcomes as recommended in Chapter 11 of the *Cochrane Handbook for Systematic Reviews of Interventions* ([Higgins 2011](#))). Minor outcomes were not analyzed in the Cochrane overview, since there were fewer studies providing data for these outcomes and the number of events was too low to allow meaningful comparisons. For example, data for allergic reaction was provided in 38 out of 160 RCTs, neurological adverse events in 31 RCTs, and fungal infections in 12. Only 25 patients in the biologic group versus 23 patients in the control group had fungal infections.

A summary of the risk estimates for each major outcome and the grading of the evidence are provided in [Table 3](#) (overall biologics) and [Table 4](#) (individual biologics).

Results from randomized controlled trials

The majority of included RCTs were of short duration with the median length being six months. Thus, all the results below should be interpreted as applying to a fairly short time frame (that is a few weeks to a few months).

The number of events for each of the four outcomes (SAEs, AEs, withdrawals due to AEs and serious infections) are shown in [Table 5](#).

Using the standard dose model with the Bayesian mixed treatment comparison approach, compared to control the biologics as a group were associated with a statistically significant higher rate of total AEs (odds ratio (OR) 1.28, 95% credible interval (CI) 1.09 to 1.50; $P = 0.00013$) ([Table 3](#); [Figure 2](#)), withdrawals due to AEs (OR 1.47, 95% CI 1.20 to 1.86; $P = 0.012$) ([Table 3](#); [Figure 3](#)), serious infections (OR 1.37, 95% CI 1.04 to 1.82; $P = 0.015$) ([Table 3](#); [Figure 4](#)), and an increased risk of TB reactivation (OR 4.68, 95% CI 1.18 to 18.60; $P = 0.028$) ([Table 3](#)).

Figure 2. Forest plot of network meta-analysis: total adverse events

Figure 3. Forest plot of network meta-analysis: withdrawals due to adverse events

Figure 4. Forest plot of network meta-analysis: serious infections

The rate of serious adverse events (OR 1.09, 95% CI 0.97 to 1.24; $P = 0.20$) (Table 3; Figure 5), lymphoma (OR 0.53, 95% CI 0.17 to 1.66; $P = 0.27$) (Table 3), and congestive heart failure (OR 0.69, 95% CI 0.18 to

2.69; $P = 0.60$) (Table 3) were not statistically significantly different between biologics and control treatment.

Figure 5. Forest plot of network meta-analysis: serious adverse events

The results of standard meta-analyses were similar to those from the Bayesian models described above (Table 6; Figure 6) In particular, the odds ratio estimates were very similar.

Figure 6. Forest plots of standard meta-analyses

6a. Serious adverse events

Figure 6. (Continued)

6b. Total adverse events

Study or Subgroup	Experimental		Control		Weight	Odds Ratio	Odds Ratio
	Events	Total	Events	Total			
1.1.1 Abatacept							
Genovese 2005	205	258	95	133	2.9%	1.55 [0.96, 2.51]	

Figure 6. (Continued)

Figure 6. (Continued)

6c. Withdrawals due to adverse events

Figure 6. (Continued)

Test for overall effect: $Z = 1.02$ ($P = 0.31$)

1.7.3 Anakinra

Cohen 2002	2	63	33	251	1.2%	0.22 [0.05, 0.93]
Cohen 2004	35	250	0	0		Not estimable
Fleishmann 2003	150	1116	26	283	3.9%	1.53 [0.99, 2.38]
Subtotal (95% CI)		1429		534	5.1%	0.65 [0.09, 4.50]

Total events

Heterogeneity: $\tau^2 = 1.67$; $\chi^2 = 6.57$, $df = 1$ ($P = 0.01$); $I^2 = 85\%$

Test for overall effect: $Z = 0.43$ ($P = 0.67$)

1.7.4 Certolizumab

Fleishmann 2009	5	111	2	109	1.0%	2.52 [0.48, 13.29]
Keystone 2008	17	393	3	199	1.5%	2.95 [0.86, 10.20]
Sandborn 2007a	36	333	39	329	3.7%	0.90 [0.56, 1.46]
Schreiber 2005	7	73	7	73	1.8%	1.00 [0.33, 3.01]
Schreiber 2007	18	216	28	212	3.2%	0.60 [0.32, 1.12]
Smolen 2009a	12	246	2	127	1.1%	3.21 [0.71, 14.55]
Subtotal (95% CI)		1372		1049	12.3%	1.17 [0.69, 1.97]

Total events

Heterogeneity: $\tau^2 = 0.18$; $\chi^2 = 9.26$, $df = 5$ ($P = 0.10$); $I^2 = 46\%$

Test for overall effect: $Z = 0.57$ ($P = 0.57$)

1.7.5 Etanercept

Bliddal 2006	0	18	0	21		Not estimable
Boetticher 2008	4	26	0	22	0.4%	9.00 [0.46, 177.12]
Brandt 2003	0	16	0	17		Not estimable
Cassano 2006	0	55	0	53		Not estimable
Combe 2009	10	103	4	50	1.6%	1.24 [0.37, 4.16]
Davis 2003	7	138	1	139	0.7%	7.37 [0.90, 60.76]
Emery 2008a	28	274	34	268	3.5%	0.78 [0.46, 1.33]
Foster 2003	2	10	0	10	0.3%	6.18 [0.26, 146.78]
Genovese 2002a	15	207	27	217	3.0%	0.55 [0.28, 1.07]
Gorman 2002	0	20	0	20		Not estimable
Gottlieb 2003	2	57	6	55	1.0%	0.30 [0.06, 1.54]
Klareskog 2004	25	223	32	228	3.4%	0.77 [0.44, 1.35]
Lan 2004	1	29	1	29	0.4%	1.00 [0.06, 16.79]
Marinez Taboada 2008	1	8	1	9	0.4%	1.14 [0.06, 21.87]
Mease 2004	1	101	1	104	0.4%	1.03 [0.06, 16.69]
Moreland 1999	2	78	3	80	0.9%	0.68 [0.11, 4.16]
Ortonne 2008	25	357	14	363	3.0%	1.88 [0.96, 3.67]
Papp 2005	3	196	2	193	0.9%	1.48 [0.25, 8.98]
Rouhani 2005	1	12	0	9	0.3%	2.48 [0.09, 68.14]
Sandborn 2001	2	23	0	20	0.3%	4.77 [0.22, 105.41]
van der Heijde 2006	6	155	0	51	0.4%	4.48 [0.25, 80.89]
van der Heijde 2007	0	223	0	228		Not estimable
Weinblatt 1999	0	59	0	30		Not estimable
Weisman 2007	13	266	17	269	2.7%	0.76 [0.36, 1.60]
Zen 2005	2	25	1	25	0.5%	2.09 [0.18, 24.61]
Subtotal (95% CI)		2679		2510	24.0%	0.98 [0.73, 1.32]

Total events

Heterogeneity: $\tau^2 = 0.05$; $\chi^2 = 20.59$, $df = 18$ ($P = 0.30$); $I^2 = 13\%$

Test for overall effect: $Z = 0.15$ ($P = 0.88$)

1.7.6 Golimumab

Emery 2009	12	159	5	160	1.9%	2.53 [0.87, 7.36]
Inman 2008	4	138	1	77	0.6%	2.27 [0.25, 20.67]
Kavanaugh 2009	2	146	4	113	0.9%	0.38 [0.07, 2.10]
Kay 2008	4	37	2	34	0.9%	1.94 [0.33, 11.34]
Keystone 2009	2	89	4	133	0.9%	0.74 [0.13, 4.14]
Smolen 2009b	4	153	9	155	1.6%	0.44 [0.13, 1.45]
Wenzel 2009	7	77	1	78	0.7%	7.70 [0.92, 64.16]
Subtotal (95% CI)		799		750	7.5%	1.26 [0.57, 2.79]

Total events

Heterogeneity: $\tau^2 = 0.45$; $\chi^2 = 10.25$, $df = 6$ ($P = 0.11$); $I^2 = 41\%$

Test for overall effect: $Z = 0.58$ ($P = 0.56$)

1.7.7 Infliximab

Abe 2006	1	49	1	47	0.4%	0.96 [0.06, 15.78]
Durez 2007	1	15	0	14	0.3%	3.00 [0.11, 79.91]
Gottlieb 2004	7	99	1	51	0.7%	3.80 [0.46, 31.80]
Maini 1998	0	14	0	14		Not estimable
Mariette 2004	6	54	1	49	0.6%	6.00 [0.70, 51.74]
Menter 2007	13	2	2	207		Not estimable
Pavelka 2009	4	69	5	71	1.3%	0.81 [0.21, 3.16]
Rennard 2007	22	78	6	77	2.1%	4.65 [1.77, 12.24]

Figure 6. (Continued)

6d. Serious infections

Figure 6. (Continued)

Figure 6. (Continued)

Individual safety of the nine biologics compared to control treatment

The statistical models for the network meta-analysis did not converge when modeling each of the biologics, in particular for TB reactivation, congestive heart failure, and lymphoma. This was due to a low number of events. Thus for these estimates we were unable to provide estimates for each individual biologic. Details on the overall incidence estimates are provided in [Table 5](#).

Serious adverse events ([Table 7](#); [Figure 5](#)): comparing individual biologics to control, only one biologic was statistically significantly different from control in terms of the number of SAEs. Certolizumab pegol was associated with a higher odds of SAEs (OR 1.57, 95% CI 1.06 to 2.32). In sensitivity analyses, the OR for certolizumab pegol was statistically significant in the unadjusted model (OR 1.66, 95% CI 1.08 to 2.59), but not statistically significant in the model that was adjusted for dose (OR 1.57; 95% CI 0.96 to 2.57) ([Appendix 4](#)).

Total adverse events ([Table 8](#); [Figure 2](#)): as illustrated in the forest plot, infliximab was associated with statistically significantly higher odds of total AEs compared with control treatment (OR 1.55, 95% CI 1.01 to 2.35). None of other biologics were statistically significantly different from control groups regarding total AEs, with odds ratios ranging from 1.03 to 1.54. In sensitivity analyses, infliximab was associated with significantly higher odds of total AEs compared with control in the unadjusted model (OR 1.54, 95% CI 1.17 to 2.03); differences showed a trend, but were not significant in the dose-adjusted model (OR 1.45, 95% CI 0.98 to 2.11) ([Appendix 5](#)).

Withdrawals due to adverse events ([Table 9](#); [Figure 3](#)): infliximab was associated with a statistically significantly increased odds of withdrawal due to AEs compared with control (OR 2.34, 95% CI 1.40 to 4.14). None of other biologics were statistically significantly

different from control groups regarding withdrawals due to adverse events, with odds ratios ranging from 1.17 to 2.74. In sensitivity analyses, infliximab was associated with statistically significantly higher odds of withdrawal due to adverse events compared to control in both the unadjusted (OR 2.32, 95% CI 1.63 to 3.37) and the dose-adjusted model (OR 2.29, 95% CI 1.45 to 3.73) ([Appendix 6](#)).

Serious infections ([Table 10](#); [Figure 4](#)): in comparing the individual biologics to control, two biologics had statistically significantly higher odds of association with serious infections compared with control treatment - certolizumab pegol (OR 4.75, 95% CI 1.52 to 18.45) and anakinra (OR, 4.05, 95% CI 1.22 to 16.84). Although none of the results for the other biologics reached statistical significance, rituximab was associated with the lowest numerical odds for serious infections compared with control treatment (OR 0.26, 95% CI 0.03 to 2.16). In sensitivity analyses, the ORs for certolizumab pegol and anakinra were statistically significant in the unadjusted models (OR 4.65, 95% CI 1.61 to 16.22; and OR 3.96, 95% CI 1.27 to 15.75, respectively), as well as the dose-adjusted models (OR 4.67, 95% CI 1.58 to 16.15; and OR 4.03, 95% CI 1.29 to 16.22, respectively) ([Appendix 7](#)). As an example of robustness of our findings using several other statistical approaches (five more approaches) and performing sensitivity analyses, we found that OR for certolizumab pegol ranged between 4.12 and 4.81, a statistically significant result in each instance ([Appendix 8](#)).

Safety of individual biologics compared to each other: indirect comparisons

In order to examine the comparative effectiveness of one biologic against another, as pre-specified in the protocol, we also considered pairwise indirect comparisons across the network in cases where the statistical model converged (that is, where the model allowed us to output inferential statistics). The models

did not converge for congestive heart failure, lymphoma, and TB reactivation outcomes. The primary analyses for these models was the standard dose model, for which results were presented in detail as below; sensitivity analyses were performed using the unadjusted model and dose-adjusted model (presented in the tables, but not discussed in detail).

Serious adverse events (Table 11): Certolizumab pegol was statistically significantly more likely to be associated with SAEs compared to adalimumab (OR 1.63, 95% CI 1.01 to 2.62). Abatacept was statistically significantly less likely to be associated with SAEs compared to certolizumab (OR 0.56, 95% CI 0.33 to 0.94). In sensitivity analyses in unadjusted model, neither differences were significant. Golimumab was statistically significantly less likely to be associated with SAEs compared to adalimumab (OR 1.18, 95% CI 1.10 to 3.14) (Appendix 9). There were no other statistically significant differences between the biologics in both the unadjusted model and dose-adjusted model (Appendix 9).

Total adverse events (Table 12): There were no statistically significant differences between any biologics for total AEs in indirect comparisons with each other in any of the models (Appendix 10).

Withdrawals due to adverse events (Table 13): There were no statistically significant differences between any biologics for withdrawals due to adverse events in indirect comparisons with each other. In sensitivity analyses in unadjusted model, infliximab was more likely to be associated with withdrawals due to AEs compared with abatacept (OR 1.92, 95% CI 1.01 to 3.71), adalimumab (OR 2.00, 95% CI 1.17 to 3.49), and etanercept (OR 1.72, 95% CI 1.02 to 2.91). Rituximab was also more likely to be associated with withdrawals due to AEs than adalimumab (OR 2.17, 95% CI 1.04 to 4.74) (Appendix 11).

Serious infections (Table 14): Certolizumab pegol was associated with higher odds of serious infections than abatacept, adalimumab, etanercept, golimumab and rituximab. The odds ratio were roughly 0.25-times or lower for each of the five biologic compared with certolizumab, in the indirect comparisons (Table 14). These differences persisted in sensitivity analyses in the unadjusted model and dose-adjusted models for each of the five biologics versus certolizumab, with one minor exception of certolizumab versus golimumab, where the confidence interval crossed one (OR 0.28, 95% CI 0.07 to 1.01) in unadjusted dose model (Appendix 12). Anakinra was associated with a statistically significantly higher odds of serious infections compared with rituximab (Table 14).

A priori specified stratified meta-analyses

These analyses were performed using the frequentist network meta-analyses. The results of the six pre-specified subgroup analyses (by individual biologic; TNF inhibitor or not; TNF antibody or TNF receptor inhibitor or other class; trial duration (short, intermediate or long duration); concomitant medication (MTX + other DMARD, MTX, other DMARD, none); and disease condition (ankylosing spondylitis, cancer, IBD, psoriasis, psoriatic arthritis, RA, other conditions) are shown in Table 15 [Note: these analyses were not adjusted for drug dose]. Only significant differences are noted in the text below.

Serious adverse events (Table 15): There were no statistically significant differences by individual biologic ($P = 0.3126$). No

statistically significant differences were noted according to whether the biologic was a TNF inhibitor or not, a TNF antibody or TNF receptor inhibitor or other class of biologic. Statistically significant differences were noted with lower odds of SAEs with trial duration longer than 12 months ($P < 0.0001$). We also noted no statistically significant differences by the type of concomitant medication. When stratified by disease condition, no disease condition was associated with a statistically significant higher risk of SAEs. Overall, there was no statistically significant effect of biologics as a group compared with control groups.

Total adverse events (Table 15): Statistically significant differences were noted for each subgroup comparison. There were statistically significant differences by each biologic ($P = 0.0216$), with etanercept and infliximab being statistically significantly different than control. We also noted statistically significant differences based on whether the biologic was TNF inhibitor or not ($P = 0.0021$), the biologic was a TNF antibody or TNF receptor inhibitor or other class of biologic ($P = 0.0097$), trial duration ($P < 0.001$), concomitant medication ($P = 0.0723$) and by disease condition ($P = 0.0166$). When stratified by disease condition, patients with ankylosing spondylitis and psoriasis had a statistically significant higher risk of serious adverse events, while those with other conditions had non-significant differences. Overall, there was a statistically significant effect of biologics as a group compared to control groups ($P = 0.0006$).

Withdrawals due to adverse effects (Table 15): Significant differences were noted in all six subgroup comparisons. Significant differences were noted by biologic ($P = 0.0006$), since infliximab was associated with significantly higher odds, while other biologics were not. While both TNF inhibitors and non-TNF inhibitors were associated with significantly higher odds, they differed from each other significantly ($P < 0.0001$). Significant differences were also noted according to whether the biologic was a TNF antibody or TNF receptor inhibitor or other class of biologic ($P < 0.0001$), trial duration ($P < 0.0001$), the type of concomitant medication ($P = 0.0004$) and by the disease condition ($P < 0.001$). When stratified by concomitant medication, patients receiving other non-MTX DMARDs as concomitant medications had a statistically significant higher risk of withdrawals due to adverse events, while the MTX group and those that received no concomitant medications had no significant differences compared with the control group. Overall, there was a statistically significant effect of biologics as a group compared to control groups ($P < 0.0001$).

Serious infections (Table 15): Statistically significant differences were noted in all six subgroup comparisons. Statistically significant differences were noted by individual biologic ($P = 0.0003$) since certolizumab pegol and infliximab were associated with significantly higher odds, while other biologics were not. While both TNF inhibitors and non-TNF inhibitors were associated with statistically significantly higher odds, they differed from each other statistically significantly ($P = 0.0002$). Statistically significant differences were also noted according to whether the biologic was a TNF antibody or TNF receptor inhibitor or other class of biologic ($P = 0.0004$), trial duration ($P < 0.0001$), the type of concomitant medication ($P = 0.0176$) and by the disease condition ($P = 0.0001$). In particular, biologics in patients with RA were associated with statistically significantly higher risk of serious infections compared with controls, whereas odds in other disease conditions did not differ statistically significantly from controls. Overall, there was a

statistically significant effect of biologics as a group compared with control groups ($P = 0.0003$).

Sensitivity analyses: Only four RCTs were judged to be at high risk of bias of allocation concealment while the majority (61%) were marked as unclear given the lack of details on concealment of allocation in the trial reports. Although we did not undertake a stratified analyses by risk of bias of allocation concealment, we expect that the effect estimate would not change dramatically by only taking out the four studies at high risk of allocation concealment bias. In those trials that were pivotal studies used for FDA or European Agency approval, allocation concealment was required in their protocols so although it is troubling that the details were not recorded in the trial report publications this may not be a major bias.

We did not have enough data for the models to run with the stratified analysis for congestive heart failure, lymphoma, and TB reactivation outcomes. The model could not run for a stratified analysis by trial duration for SAEs and by disease for serious infections, respectively.

Heterogeneity: Inconsistency of the results of the network meta-analysis was assessed, as described in the methods section. We found no evidence of inconsistency for all of the outcomes with the exception of 'withdrawals due to adverse events', and the source of heterogeneity could not be clearly identified.

'Optimal Information Size' (OIS)

Serious adverse events: certolizumab pegol versus control

In calculating the OIS, we used empirical data from Table 4. For a comparison of two independent binomial proportions using Pearson's χ^2 statistic with a χ^2 approximation with a two-sided significance level of 0.05, a sample size 1,246 patients in total achieves a power of at least 0.8 when the proportions are 0.174 and 0.118. Thus, the calculated OIS was substantially lower than the total sample size included (1,246 versus 2,421 patients). As this meta-analysis, meets the OIS criteria, there is no reason to rate down for imprecision.

Serious infections: certolizumab pegol versus control

In calculating the OIS, we used empirical data from Table 4. For a comparison of two independent binomial proportions using Pearson's χ^2 statistic with a χ^2 approximation with a two-sided significance level of 0.05, a sample size of 266 patients in total achieves a power of at least 0.8 when the proportions are 0.113 and 0.026. Thus, the calculated OIS was substantially lower than the total sample size included (266 versus 1,683 patients). As this meta-analysis, meets the OIS criteria, there is no reason to rate down for imprecision.

Withdrawals due to adverse events: infliximab versus control

In calculating the OIS, we used empirical data from Table 4. For a comparison of two independent binomial proportions using Pearson's χ^2 statistic with a χ^2 approximation with a two-sided significance level of 0.05, a sample size of 362 patients in total achieves a power of at least 0.8 when the proportions are 0.203 and 0.098. Thus, the calculated OIS was substantially lower than the total sample size included (362 versus 2,973 patients). As this meta-analysis, meets the OIS criteria, there is no reason to rate down for imprecision.

Results from extension studies of randomized trials

We analyzed the open-label extensions (OLEs) of randomized trials. Data from 59 study arms were available. These included 11,954 patients with 325,904 person-months of observation (Table 16). Serious adverse events were reported in 9% to 54% of patients receiving biologics. Serious infections were noted in 1% to 18%. TB reactivation was reported in 0% to 0.6%. Lymphoproliferative cancer was reported in 0% to 0.4%, and congestive heart failure in 0.1% to 0.7% of patients.

DISCUSSION

Summary of main results

This review of the safety of nine biologics commonly used to treat rheumatoid arthritis (RA) and other conditions included 160 randomized controlled trials with 48,676 participants that investigated the efficacy and safety of these drugs across a variety of conditions including RA. The majority of studies were of fairly short duration, with the median RCT duration being six months (range, one to 63 months), so the results should be considered with this time frame in mind. We combined data across diseases according to the premise that the adverse event profile of biologics would be similar irrespective of the condition being treated. We found that compared with control treatments, biologics were associated with statistically significantly higher rates of total adverse events, withdrawals due to adverse events, serious infections and tuberculosis (TB) reactivation. In most studies, serious infections included opportunistic infections in addition to bacterial and other infections. Specifically, infliximab was associated with a statistically significantly higher rate of total adverse events and withdrawals due to adverse events compared with control treatment. Certolizumab pegol and anakinra were associated with a statistically significantly higher risk of serious infections compared with control treatment. Certolizumab pegol was associated with a significantly higher risk of serious adverse events compared with control treatment. Since models did not converge for TB reactivation, lymphoma and congestive heart failure, comparative risk estimates of each biologic compared with control could not be calculated.

The open-label data provided estimates on rare adverse events related to biologics, such as serious infections and TB reactivation. The open-label data provides important safety data by providing a longer duration of follow-up and larger sample size in many cases thus complimenting data from clinical registries. The latter have been extremely helpful in providing safety data. The open-label extension studies included in this review ranged from three to 60 months duration, with the median being 13 months. However, this time frame may still be too short to address serious but rare adverse events and long-term adverse events such as cancer. The estimates from the open-label phases of clinical trials may be lower than those noted from registry studies since the populations recruited in clinical trials tend to be healthier than the general population due to strict inclusion criteria. Patients recruited in trials of each biologic may differ from each other, which may partially explain the differences in rates of certain adverse events.

Indirect comparisons revealed that the biologics differed from each other with respect to the odds of serious infections and serious adverse events. Certolizumab pegol was associated

with statistically significantly higher odds of serious infections compared with abatacept, adalimumab, etanercept, golimumab and rituximab. Anakinra was associated with statistically significantly higher odds of serious infections compared with rituximab. Certolizumab pegol was associated with statistically significantly higher odds of serious adverse events compared with abatacept and adalimumab. No significant differences were noted for adverse events or withdrawals due to adverse events between biologics in indirect comparisons.

Stratified meta-analyses based on a priori subgroups revealed interesting findings. Compared with control, serious infections, total adverse events, and withdrawals due to adverse events differed statistically significantly by the individual biologic. Compared with control, TNF inhibitors and non-TNF biologics differed statistically significantly with respect to serious infections and total adverse events with odds numerically slightly higher for TNF inhibitors, and in withdrawals due to adverse events with odds slightly higher for non-TNF biologics. In shorter trials (< six months), biologics were associated with statistically significantly higher odds of serious infections, total adverse events and withdrawals due to adverse events compared with controls. Data were insufficient for congestive heart failure, lymphoma, and TB reactivation. Type of concomitant medication was associated with statistically significant differences for serious infections, total adverse events and withdrawals due to adverse events. When stratified by disease, we found that there were some differences in the risk of these outcomes across different diseases, with the most consistent finding being that ankylosing spondylitis and psoriasis were associated with a higher risk of total adverse events, and RA with a higher risk of serious infections. It is not clear from our analysis why this may be although in view of the multiple analyses performed this finding should be interpreted with caution. It is unclear how these differences in risk across the different conditions may affect our pre-specified decision to pool data across different conditions.

The US FDA's black box warning regarding increased serious infections with most biologics, except abatacept, needs to be considered when prescribing these biologics. Similar observations have been made by observational and registry studies. The lack of statistically significant differences for individual biologics compared to control and overall biologics compared to control in our analyses likely indicates a lack of power (beta-error) due to small numbers of patients and a short follow-up in the RCTs, as described in the limitations section.

Overall completeness and applicability of evidence

Our published protocol described our plan to analyze a series of major and minor outcomes. We analyzed all seven major outcomes and all other analyses related to them, as pre-specified. All eligible RCTs and open-label extensions up to March 2010 were included. However, due to the complexity of analyses for the major outcomes and the few studies with low numbers of events reporting this data, we decided not to add to the complexity of this review by analyzing the minor outcomes. This decision was made prior to embarking upon any analyses of minor outcomes to avoid any bias in the decision-making process.

Quality of the evidence

There were 160 RCTs with 48,676 participants included in this analysis. In the majority of studies generation of the allocation sequence and allocation concealment were judged to be 'unclear' due to lack of details provided in the study reports. Only four RCTs were clearly at a high risk of bias for allocation concealment. Blinding was also not clearly described in many of the included studies; however, only 10 RCTs were clearly at a high risk of bias as they were described as 'open-label'. There was greater than 80% follow-up in the majority of studies and most were judged to have a low risk of bias due to major baseline imbalances. Although we did not search for study protocols, the majority of included studies were judged to be at a low risk of bias for selective outcome reporting due to the fact that important side effects were often reported. Most included trials reported that adverse events were actively monitored. When assessing and combining serious adverse event data, it is important that a definition is provided for how the trialists defined a serious adverse event (SAE); the majority of trials in this review did not provide sufficient information on how a SAE was defined in the study. We combined data on SAEs regardless of the definition and whether it was provided, so caution is needed in interpreting this outcome.

We assessed whether trials reported undertaking active monitoring for adverse events, as a risk of bias criterion specific to adverse effects. The majority of included RCTs were judged to be at low risk of bias for this item, mainly because published trial reports included a statement to the effect that they monitored for adverse effects. However, it should be noted that this is a difficult criterion to assess as many different monitoring techniques may have been used, with varying reliability of the different approaches. As well, the method of monitoring may need to be specific to the different adverse events of interest and this would not have been captured in our broadly defined criteria.

Although the majority of included studies were judged to be at low risk of bias for selective outcome reporting (54%), this was based on the judgement of the data extractors that most of the adverse events of interest to this review (as pre-specified in our protocol) were reported adequately. We did not have the resources to find and review the protocols or full clinical trial reports (if either was even available) of the 160 included studies, which would have been the best way to assess this criterion. As well, given the problems as described above with detecting adverse events, it is difficult to discriminate between being sure that an event actually did not happen and whether it happened but was not detected due to the method of monitoring used during the trial, or if it was selectively not reported. The judgement was made across all adverse events included in our review rather than by specific adverse event, so we are unable to determine if there are specific adverse events which may be more susceptible to selective outcome reporting. Another issue is how adverse events are defined and counted in trials. For the most part the adverse events included in this review are fairly straightforward to define clinically, with the exception perhaps of CHF. The lack of reporting and consensus of the definition of SAE were noted as potential sources of bias since 63% of included studies did not provide a clear definition.

We included 46 extension studies with 11,954 participants. Given the nature of extension studies, in which a highly selected group of participants continue on from the RCT and the majority of participants and outcome assessors are not blinded, most of these

studies were judged to be at a high risk of bias. As well, more than half of the studies were judged to be at a high risk of attrition bias due to withdrawal rates greater than 20%. The majority of studies either reported expected adverse effects or there was insufficient information to judge whether they were at risk of selective outcome reporting. As with RCTs, serious adverse events were not clearly defined in most studies but the majority reported some type of active monitoring for adverse events.

For the overall results of biologics as a group versus placebo for the major outcomes of serious adverse events, serious infections, total adverse events, and withdrawals due to adverse events, our confidence in the results was graded as 'moderate' using the GRADE approach. Due mainly to lack of data, our confidence in the results for TB reactivation, lymphoma, and congestive heart failure was graded as 'low', implying that further research is likely to have an important impact on the confidence in an estimated effect and may change that estimate.

Potential biases in the overview process

Our review has limitations. Despite inclusion of a large number of RCTs across conditions, which allowed analyses for four of our pre-specified major outcomes (that is, serious adverse events, serious infections, total adverse events, and withdrawals due to adverse events), for three major outcomes (that is, TB reactivation, lymphoma, and congestive heart failure), events were too few to allow meaningful indirect comparisons or stratified meta-analyses.

In view of the lack of head-to-head studies of biologics, we performed indirect comparisons cognizant of the limitations of this approach. Use of this methodology requires assumptions about the comparability of the included RCTs in terms of similarity of patient characteristics and methodological quality. However, clinicians and patients are faced with the dilemma of choosing from among these biologics in the absence of robust comparative data about their relative safety. While we included trials which differed in patient populations, prior failed therapies, concomitant use of disease modifying anti-rheumatic drug (DMARDs), trial duration, and biologic dose, we attempted to adjust for these differences in the analysis. We performed standard dose models as our main analyses, tested the robustness of results by performing sensitivity analyses with unadjusted dose and dose-adjusted models and performed additional stratified meta-analyses to explore differences in other important characteristics (that is, concomitant DMARDs, trial duration). We also performed standard meta-analysis, which also confirmed the robustness of our findings, with minimal changes in odds ratios and no change in interpretation of main effects of biologics compared with control treatment. We performed additional sensitivity analyses (five additional models) to test the robustness of our findings, with the example of higher serious infections with certolizumab pegol compared with control. We did not find evidence of inconsistency in the majority of the results from our indirect comparison analyses, however, these findings should be interpreted with caution. We may be underpowered for several stratified meta-analyses.

For this review, we limited inclusion to RCTs and their open-label extensions. However long-term observational studies, including population-based registries, can provide realistic longer-term estimates of the risks of biologics in the 'real world', although they too have their limitations. These may include indication bias and differences in healthcare setting, country of origin of study,

which may impact the choice of biologic and make generalizability challenging. We intend to undertake a second phase of this project which will include observational studies, to try and address the issue of assessing rare or long-term adverse effects.

The analyses are limited by limitations in trial designs. One example is the use of rescue design in some studies where patients are allowed to switch to active medication if they have not responded in the placebo or control arm. This can impact the estimates, since one arm has a continuous exposure to the biologic, whereas in the other arm, the exposure is first to the control treatment and then the biologic.

We performed multiple comparisons and therefore, it is possible that some findings may be due to chance only; however it is far more likely that for several analyses there was a lack of power leading to Type-II error (that is, missing a statistically significant difference due to small sample size). Some of these issues may also explain instances where the point estimates for risk appeared large but did not reach statistical significance.

Another limitation of these analyses is that high drop-out rates in some studies may influence the observable adverse event rate; this may have a differential effect depending on whether the drop out rate is higher in placebo versus intervention arm.

We assessed the risk of leukemia and lymphoma across all trials and all biologics to be consistent with the overall strategy we used to assess safety in this overview. However, we recognize that this may be inappropriate in this case for several reasons. We combined all trials including those that assessed efficacy of rituximab to treat lymphoproliferative disorders. As well, different biologics (e.g. TNF inhibitors versus non TNF inhibitors) and different diseases may be associated with different risk profiles for different malignancies. We plan further analyses to explore these issues.

Finally, while all data were independently extracted by ten pairs of review authors, the level of interrater agreement was found to be high, and the data were checked for errors during the course of writing the manuscript, we acknowledge that, due to the large amount of data that was included in this review and the large number of review authors, there is a possibility of chance errors.

Agreements and disagreements with other studies or reviews

In our study that included RCTs of nine biologics used in any disease condition (except HIV/AIDS), we found that compared with control, only infliximab was associated with a significantly higher risk of withdrawals due to adverse events, with no statistically significant differences between other biologics and control; indirect comparisons did not reveal any differences between infliximab and other biologics in the main standard-dose adjusted analysis. Our findings agree with and extend the findings of a previous review that examined 13 randomized controlled trials of at least six months duration of etanercept, infliximab, and adalimumab for RA ([Alonso-Ruiz 2008](#)). They also reported that infliximab and adalimumab had higher than control withdrawal rates due to adverse events; similarly in this study we found that infliximab was associated with higher odds of withdrawals due to adverse events compared with control treatment. However, indirect comparisons found no significant differences between biologics in withdrawals due to adverse events. In our previous

Cochrane review of RCTs, including only trials of approved doses of six biologics for treatment of RA, we found that adalimumab, anakinra, and infliximab were more likely than etanercept to lead to withdrawals due to adverse events (Singh 2009a; Singh 2009b). Lee et al reported no differences for withdrawals due to adverse events (Lee 2008), however only three studies were included, which was likely to lead to type-II error. The indirect comparisons presented in our study add to the current literature.

In two meta-analyses of nine (Bongartz 2006) and 13 RCTs (Alonso-Ruiz 2008) of TNF biologics, which included some of the same RCTs, infliximab was associated with twice the risk of serious adverse events and infections as the control (Alonso-Ruiz 2008). Pooled odds ratios for infliximab and adalimumab were significantly higher for serious infections (Bongartz 2006) with odds ratios ranging from 1.2 to 2.0. In contrast, Wiens et al performed a meta-analysis of 21 RCTs of standard (or their equivalent) doses of adalimumab (40 mg every two weeks), etanercept (25 mg every two weeks), and infliximab (3 mg/kg) in RA and reported no differences between each drug and the control for serious infections or serious adverse events (Wiens 2010). The RCTs included in Wiens et al were not identical to the studies included in the other two meta-analyses mentioned above. We noted that compared with control, the odds ratio of serious infections for infliximab was 1.41, similar to previous studies, but this was not statistically significantly different from control in our analyses.

We found that certolizumab pegol was associated with a statistically significantly higher risk of serious infections compared with control. However, there was often a zero event rate in the control group of the certolizumab pegol studies. Indirect comparisons (that used a control event rate across all studies) showed that certolizumab pegol was associated with significantly higher odds of serious infections compared with abatacept, adalimumab, etanercept, golimumab and rituximab.

Certolizumab pegol was associated with statistically significantly higher odds of serious adverse events compared with control. In indirect comparisons, certolizumab was more likely than abatacept and adalimumab to be associated with serious adverse events.

Most of our findings from indirect comparisons cannot be compared to previous studies since most previous meta-analyses, other than those described above, have focused on efficacy outcomes, and have been limited to a fewer studies, restricted to a particular disease (most commonly, only RA) and were limited to select biologics (i.e., did not include all nine available biologics). These findings should be interpreted with caution in light of the limitations we have described.

AUTHORS' CONCLUSIONS

Implications for practice

Several meta-analyses have been published that assessed efficacy of biologics but few have assessed safety. Our review included

indirect comparisons of the safety of biologics and should provide some guidance to clinicians and patients until head-to-head comparisons become available.

Our study has several salient findings. Our findings should be interpreted with caution, given study limitations. In short-term RCTs (median duration six months) the overall use of biologics was associated with a statistically significantly higher risk of total adverse events, withdrawals due to adverse events, serious infections and tuberculosis reactivation compared with control.

Specifically, in direct comparisons to control, infliximab was associated with statistically significantly higher numbers of total adverse events, and withdrawals due to adverse events compared with control. Certolizumab pegol was associated with a statistically significantly higher risk of serious infections and serious adverse events compared with control treatment. Since models did not converge for congestive heart failure, lymphoma and TB reactivation, estimates of each biologic compared to control could not be calculated.

Indirect comparisons revealed that although the overall numbers are relatively small, certolizumab pegol was associated with a statistically significantly higher odds of serious infections compared with abatacept, adalimumab, etanercept, golimumab and rituximab; rituximab was statistically significantly less likely than anakinra to be associated with serious infections. No differences were noted between biologics in indirect comparisons for total adverse events and withdrawals due to adverse events.

Implications for research

Our network meta-analysis provides estimates regarding the overall comparative safety of the biologics. We believe that there is an urgent need for more research regarding the long-term safety of biologics and comparative safety of different biologics. As the number of biologics that are available for treatment of these conditions increases, more options will become available to patients and clinicians. This progress in RA therapeutics provides more options for patients and physicians but offers even more challenges in choosing the best treatment for a given patient. In the absence of comparative effectiveness trials, national and international registries and other types of large databases are the relevant sources for providing complementary evidence regarding the short- and longer-term safety of biologics.

ACKNOWLEDGEMENTS

We thank Louise Falzon for developing the search strategies and assisting with full text article retrieval. We thank Michelle Fiander and Carolyn Wayne for assisting with full text article retrieval. We thank Michelle Foote, Bharghooor Dhaliwal and Joseph Kundukulam for assisting with data extraction.

REFERENCES

References to included reviews

Abe 2006

Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, et al. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. *Journal of Rheumatology* 2006;**33**:37-44.

Antoni 2005a

Antoni C, Krueger GG, De Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. *Annals of the Rheumatic Diseases* 2005;**64**:1150-7.

Antoni 2005b

Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). [Erratum appears in *Arthritis Rheum.* 2005 Sep;52(9):2951]. *Arthritis and Rheumatism* 2005;**52**:1227-36.

Antoni 2008

Antoni CE, Kavanaugh A, Van der Heijde D, Beutler A, Keenan G, Zhou B, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). *Journal of Rheumatology* 2008;**35**:869-76.

Aviles 2007a

Aviles A, Nambo MJ, Castaneda C, Cleto S, Neri N, Murillo E, et al. Rituximab and escalated chemotherapy in elderly patients with aggressive diffuse large-cell lymphoma: a controlled clinical trial. *Cancer Biotherapy and Radiopharmaceuticals* 2007;**22**(2):194-9.

Aviles 2007b

Aviles A, Nambo MJ, Neri N, Cleto S, Castaneda C, Huerta-Guzman J, et al. Dose dense (CEOP-14) vs dose dense and rituximab (CEOP-14 +R) in high-risk diffuse large cell lymphoma. *Medical Oncology* 2007;**24**:85-9.

Barkham 2009

Barkham N, Keen HI, Coates LC, O'Connor P, Hensor E, Fraser AD, et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. *Arthritis and Rheumatism* 2009;**60**:946-54.

Bathon 2000

Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. *New England Journal of Medicine* 2000;**343**(22):1586-93.

Bliddal 2006

Bliddal H, Terslev L, Qvistgaard E, Konig M, Holm CC, Rogind H, et al. A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis. *Scandinavian Journal of Rheumatology* 2006;**35**:341-5.

Boetticher 2008

Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. *Gastroenterology* 2008;**135**:1953-60.

Bozkurt 2001

Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM, et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (Enbrel) in patients with advanced heart failure. *Circulation* 2001;**103**(8):1044-7.

Brandt 2003

Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. *Arthritis and Rheumatism* 2003;**48**(6):1667-75.

Brandt 2005

Brandt J, Listing J, Haibel H, Sörensen H, Schwebig A, Rudwaleit M, et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. [Erratum appears in *Rheumatology (Oxford)*. 2005 Apr;44(4):569]. *Rheumatology* 2005;**44**:342-8.

Braun 2002

Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. *Lancet* 2002;**359**(9313):1187-93.

Braun 2003

Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. *Arthritis and Rheumatism* 2003;**48**(8):2224-33.

Braun 2005

Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. *Annals of the Rheumatic Diseases* 2005;**64**:229-34.

Braun 2008a

Braun J, Deodhar A, Dijkmans B, Geusens P, Sieper J, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. *Arthritis and Rheumatism* 2008;**59**:1270-8.

Braun 2008b

Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. *Annals of the Rheumatic Diseases* 2008;**67**:340-5.

Breedveld 2006

Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. *Arthritis and Rheumatism* 2006;**54**:26-37.

Buske 2009

Buske C, Hoster E, Dreyling M, Eimermacher H, Wandt H, Metzner B, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). *Leukemia* 2009;**23**:153-61.

Calin 2004

Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. *Annals of the Rheumatic Diseases* 2004;**63**(12):1594-600.

Cassano 2006

Cassano N, Loconsole F, Galluccio A, Miracapillo A, Pezza M, Vena GA. Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study). *International Journal of Immunopathology and Pharmacology* 2006;**19**:225-9.

Chaudhari 2001

Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. *Lancet* 2001;**357**(9271):1842-7.

Chen 2009

Chen DY, Chou SJ, Hsieh TY, Chen YH, Chen HH, Hsieh CW, et al. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. *Journal of the Formosan Medical Association* 2009;**108**:310-9.

Chevalier 2009

Chevalier X, Goupille P, Beaulieu AD, Burch FX, Bensen WG, Conrozier T, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. *Arthritis and Rheumatism* 2009;**61**:344-52.

Chung 2003

Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. *Circulation* 2003;**107**(25):3133-40.

Cohen 2002

Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis and Rheumatism* 2002;**46**(3):614-24.

Cohen 2004

Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. *Annals of the Rheumatic Diseases* 2004;**63**(9):1062-8.

Cohen 2005

Cohen S, Shoup A, Weisman MH, Harris J. Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study. *Otology & Neurotology* 2005;**26**:903-7.

Cohen 2006

Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. *Arthritis and Rheumatism* 2006;**54**(9):2793-806.

Coiffier 1998

Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. *Blood* 1998;**92**(6):1927-32.

Coiffier 2002

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. *New England Journal of Medicine* 2002;**346**(4):235-42.

Colombel 2007

Colombel J-F, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. *Gastroenterology* 2007;**132**:52-65.

Combe 2009

Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept

alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. *Annals of the Rheumatic Diseases* 2009;**68**:1146-52.

Copelan 2009

Copelan E, Pohlman B, Rybicki L, Kalaycio M, Sobecks R, Andresen S, et al. A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma. *Bone Marrow Transplantation* 2009;**43**:101-5.

Davis 2003

Davis JC, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. *Arthritis and Rheumatism* 2003;**48**(11):3230-6.

Davis 2004

Davis J, Webb A, Lund S, Sack K. Results from an open-label extension study of etanercept in ankylosing spondylitis. *Arthritis and Rheumatism* 2004;**51**(2):302-4.

Davis 2008

Davis J C Jr, Van der Heijde D M, Braun J, Dougados M, Clegg D O, Kivitz A J, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. *Annals of the Rheumatic Diseases* 2008;**67**:346-52.

Den Broeder 2002

Den Broeder A, Van de Putte L, Rau R, Schattenkirchner M, Van Riel P, Sander O, et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. *Journal of Rheumatology* 2002;**29**(11):2288-98.

Dijkmans 2009

Dijkmans B, Emery P, Hakala M, Leirisalo-Repo M, Mola E M, Paolozzi L, et al. Etanercept in the longterm treatment of patients with ankylosing spondylitis. *Journal of Rheumatology* 2009;**36**(6):1256-64.

Durez 2007

Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens R, et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. *Arthritis and Rheumatism* 2007;**56**:3919-27.

Edwards 2004

Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. *New England Journal of Medicine* 2004;**350**(25):2572-81.

Emery 2006

Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy

and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. *Arthritis and Rheumatism* 2006;**54**(5):1390-400.

Emery 2008a

Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. *Lancet* 2008;**372**:375-82.

Emery 2008b

Emery P, Keystone E, Tony HP, Cantagrel A, Van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.[Erratum appears in Ann Rheum Dis. 2009 Feb;68(2):296]. *Annals of the Rheumatic Diseases* 2008;**67**(11):1516-23.

Emery 2009

Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naïve patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. *Arthritis and Rheumatism* 2009;**60**:2272-83.

Eve 2009

Eve HE, Linch D, Qian W, Ross M, Seymour JF, Smith P, et al. Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study. *Leukemia and Lymphoma* 2009;**50**:211-5.

Feugier 2005

Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. *Journal of Clinical Oncology* 2005;**23**:4117-26.

Fleischmann 2003

Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. *Arthritis and Rheumatism* 2003;**48**(8):927-34.

Fleischmann 2006

Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. *Annals of the Rheumatic Diseases* 2006;**65**(8):1006-12.

Fleischmann 2009

Fleischmann R, Vencovsky J, Van Vollenhoven R F, Borenstein D, Box J, Coteur G, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. *Annals of the Rheumatic Diseases* 2009;**68**:805-11.

Forstpointner 2002

Forstpointner R, Hänel A, Repp R, Hermann S, Metzner B, Pott C, et al. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas - results of a prospective randomized study of the German Low-Grade Lymphoma Study Group] [Rituximab zur remissionsinduktion bei rezidierten und refraktären indolenten Lymphomen und mantelzell-lymphomen - Ergebnisse einer prospektiv randomisierten studie der deutschen studiengruppe für niedrig maligne lymphome (GLSG)]. *Deutsche Medizinische Wochenschrift* 2002;**127**(43):2253-8.

Forstpointner 2004

Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. *Blood* 2004;**104**(10):3064-71.

Foster 2003

Foster CS, Tufail F, Waheed NK, Chu D, Miserocchi E, Baltatzis S, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. *Archives of Ophthalmology* 2003;**121**(4):437-40.

Freedman 2009

Freedman A, Neelapu SS, Nichols C, Robertson MJ, Djulbegovic B, Winter JN, et al. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. *Journal of Clinical Oncology* 2009;**27**:3036-43.

Furst 2003

Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). *Journal of Rheumatology* 2003;**30**(12):2563-71.

Furst 2007

Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. *Annals of the Rheumatic Diseases* 2007;**66**:893-9.

Gavalas 2007

Gavalas E, Kountouras J, Stergiopoulos C, Zavos C, Gisakis D, Nikolaidis N, et al. Efficacy and safety of infliximab in steroid-dependent ulcerative colitis patients. *Hepato-Gastroenterology* 2007;**54**(76):1074-9.

Genovese 2002

Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. *Arthritis and Rheumatism* 2002;**46**(6):1443-50.

Genovese 2005a

Genovese MC, Becker J-C, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.[Erratum appears in N Engl J Med. 2005 Nov 24;353(21):2311]. *New England Journal of Medicine* 2005;**353**:1114-23.

Genovese 2005b

Genovese MC, Bathon JM, Fleischmann RM, Moreland LW, Martin RW, Whitmore JB, et al. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. *Journal of Rheumatology* 2005;**32**:1232-42.

Genovese 2007

Genovese MC, Mease PJ, Thomson GTD, Kivitz AJ, Perdok RJ, Weinberg MA, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.[Erratum appears in J Rheumatol. 2007 Jun;34(6):1439]. *Journal of Rheumatology* 2007;**34**:1040-50.

Genovese 2008a

Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. *Arthritis and Rheumatism* 2008;**58**:2968-80.

Genovese 2008b

Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. *Annals of the Rheumatic Diseases* 2008;**67**:547-54.

Ghielmini 2004

Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. *Blood* 2004;**103**(12):4416-23.

Ghielmini 2005

Ghielmini M, Rufibach K, Salles G, Leoncini-Francini L, Leger-Falandry C, Cogliatti S, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). *Annals of Oncology* 2005;**16**(10):1675-82.

Gladman 2007

Gladman DD, Mease PJ, Ritchlin CT, Choy EHS, Sharp JT, Ory PA, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. *Arthritis and Rheumatism* 2007;**56**:476-88.

Gordon 2006a

Gordon KB, Gottlieb AB, Leonardi CL, Elewski BE, Wang A, Jahreis A, et al. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. [Erratum appears in *J Dermatolog Treat.* 2006;17(3):192]. *Journal of Dermatological Treatment* 2006;**17**:9-17.

Gordon 2006b

Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. *Journal of the American Academy of Dermatology* 2006;**55**:598-606.

Gorman 2002

Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. *New England Journal of Medicine* 2002;**346**(18):1349-56.

Gottlieb 2003a

Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. *Journal of the American Academy of Dermatology* 2003;**48**(6):829-35.

Gottlieb 2003b

Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, et al. A randomized trial of etanercept as monotherapy for psoriasis. *Archives of Dermatology* 2003;**139**(12):1627-32.

Gottlieb 2004

Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. *Journal of the American Academy of Dermatology* 2004;**51**(4):534-42.

Haibel 2008

Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. *Arthritis and Rheumatism* 2008;**58**:1981-91.

Hainsworth 2005

Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network. *Journal of Clinical Oncology* 2005;**23**:1088-95.

Hanauer 2002

Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. *Lancet* 2002;**359**(9317):1541-9.

Hanauer 2006

Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. *Gastroenterology* 2006;**130**:323-33.

Hauser 2008

Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. *New England Journal of Medicine* 2008;**358**:676-88.

Hawker 2009

Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. *Annals of Neurology* 2009;**66**:460-71.

Herold 2000

Herold M, Strohl J, Assmann M, Eschenburg H, Franke A, Freund M, et al. Acute toxicity of mitoxantrone, chlorambucil and prednisolone (MCP) versus MCP plus rituximab in low-grade non-Hodgkin's lymphoma - Interim results of a phase III trial [Akute Toxizität von Mitoxantron, Chlorambucil und Prednisolon (MCP) versus MCP plus Rituximab bei niedrig-malignen Non-Hodgkin-Lymphomen - erste Ergebnisse einer Phase-III Studie]. *Onkologie* 2000;**23**(2):164-6.

Herold 2007

Herold M, Haas A, Srock S, Nesper S, Al-Ali K, Neubauer A, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. *Journal of Clinical Oncology* 2007;**25**:1986-92.

Hiddemann 2005

Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. *Blood* 2005;**106**:3725-32.

Inman 2008

Inman RD, Davis JC Jr, Van der Heijde D, Diekman L, Sieper J, Kim S II, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. *Arthritis and Rheumatism* 2008;**58**:3402-12.

Jarnerot 2005

Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. *Gastroenterology* 2005;**128**:1805-11.

Jatoi 2007

Jatoi A, Dakhil SR, Nguyen PL, Sloan JA, Kugler JW, Rowland KM Jr, et al. A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group. *Cancer* 2007;**110**:1396-403.

Johnsen 2006

Johnsen AK, Schiff MH, Mease PJ, Moreland LW, Maier AL, Coblyn JS, et al. Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. *Journal of Rheumatology* 2006;**33**:659-64.

Jones 2008

Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. *Annals of the Rheumatic Diseases* 2008;**69**:88-96.

Kavanaugh 2000

Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. *Journal of Rheumatology* 2000;**27**(4):841-50.

Kavanaugh 2007

Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. *Annals of the Rheumatic Diseases* 2007;**66**:498-505.

Kavanaugh 2009

Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. *Arthritis and Rheumatism* 2009;**60**:976-86.

Kay 2008

Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. *Arthritis and Rheumatism* 2008;**58**:964-75.

Keystone 2004a

Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. *Arthritis and Rheumatism* 2004;**50**(5):1400-11.

Keystone 2004b

Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis and Rheumatism* 2004;**50**(2):353-63.

Keystone 2007

Keystone E, Fleischmann R, Emery P, Furst DE, Van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis. *Arthritis and Rheumatism* 2007;**56**:3896-908.

Keystone 2008

Keystone E, Van der Heijde D, Mason D Jr, Landewe R, Vollenhoven RV, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.[Erratum appears in Arthritis Rheum. 2009 May;60(5):1249]. *Arthritis and Rheumatism* 2008;**58**:3319-29.

Keystone 2009a

Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. *Annals of the Rheumatic Diseases* 2009;**68**:789-96.

Kim 2007

Kim HY, Lee SK, Song YW, Yoo DH, Koh EM, Yoo B, et al. A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate. *APLAR Journal of Rheumatology* 2007;**10**:9-16.

Klareskog 2004

Klareskog L, Van der Heijde D, De Jager J P, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. *Lancet* 2004;**363**(9410):675-81.

Klareskog 2006

Klareskog L, Gaubitz M, Rodriguez-Valverde V, Malaise M, Dougados M, Wajdula J, et al. A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-

modifying antirheumatic drugs. *Annals of the Rheumatic Diseases* 2006;**65**:1578-84.

Kremer 2003

Kremer JM, Weinblatt ME, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Jackson CG, et al. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. *Arthritis and Rheumatism* 2003;**48**(6):1493-9.

Kremer 2005

Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. [Erratum appears in *Arthritis Rheum.* 2005 Oct;**52**(10):3321]. *Arthritis and Rheumatism* 2005;**52**:2263-71.

Kremer 2006

Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.[Summary for patients in *Ann Intern Med.* 2006 Jun 20;**144**(12):118; PMID: 16785473]. *Annals of Internal Medicine* 2006;**144**:865-76.

Krueger 2006

Krueger GG, Elewski B, Papp K, Wang A, Zitnik R, Jahreis A. Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial. *Journal of the American Academy of Dermatology* 2006;**54**:S112-9.

Lan 2004

Lan JL, Chou SJ, Chen DY, Chen YH, Hsieh TY, Young M. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study. *Journal of the Formosan Medical Association* 2004;**103**(8):618-23.

Leonardi 2003

Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. *New England Journal of Medicine* 2003;**349**(21):2014-22.

Lin 2005

Lin T-Y, Zhang H-Y, Huang Y, Guan Z-Z, Shen T, Shi Y-K, et al. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China - a multi-center randomized trial]. *Aizheng: Chinese Journal of Cancer* 2005;**24**(12):1421-6.

Maini 1998

Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. *Arthritis and Rheumatism* 1998;**41**(9):1552-63.

Maini 1999

Maini R, St Clair E W, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. *Lancet* 1999;**354**(9194):1932-9.

Maini 2006

Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.[Erratum appears in *Arthritis Rheum.* 2008 Mar;**58**(3):887]. *Arthritis and Rheumatism* 2006;**54**(9):2817-29.

Marcus 2005

Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. *Blood* 2005;**105**(4):1417-23.

Mariette 2004

Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). *Arthritis and Rheumatism* 2004;**50**(4):1270-6.

Martinez-Taboada 2008

Martinez-Taboada VM, Rodriguez-Valverde V, Carreno L, Lopez-Longo J, Figueroa M, Belzunegui J, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. *Annals of the Rheumatic Diseases* 2008;**67**(5):625-30.

Marzo-Ortega 2005

Marzo-Ortega H, McGonagle D, Jarrett S, Haugeberg G, Hensor E, O'Connor P, et al. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. *Annals of the Rheumatic Diseases* 2005;**64**(11):1568-75.

Mease 2000

Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. *Lancet* 2000;**356**(9227):385-90.

Mease 2004

Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. *Arthritis and Rheumatism* 2004;**50**(7):2264-72.

Mease 2005

Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EHS, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. *Arthritis and Rheumatism* 2005;**52**(10):3279-89.

Mease 2006

Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. *Journal of Rheumatology* 2006;**33**(4):712-21.

Mease 2009

Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). *Annals of the Rheumatic Diseases* 2009;**68**(5):702-9.

Menter 2007

Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. *Journal of the American Academy of Dermatology* 2007;**56**(1):31.e1-15.

Menter 2008

Menter A, Tying SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. *Journal of the American Academy of Dermatology* 2008;**58**(1):106-15.

Miyasaka 2008

Miyasaka N, Change Study Investigators. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. *Modern Rheumatology* 2008;**18**(3):252-62.

Monk 2006

Monk JL, Phillips G, Waite R, Kuhn J, Schaaf LJ, Otterson GA, et al. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. *Journal of Clinical Oncology* 2006;**24**(12):1852-9.

Moreland 1999

Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. *Annals of Internal Medicine* 1999;**130**(6):478-86.

Naveau 2004

Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. *Hepatology* 2004;**39**(5):1390-7.

Nishimoto 2009

Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. *Annals of the Rheumatic Diseases* 2009;**68**(10):1580-4.

Nuki 2002

Nuki G, Bresnihan B, Bear MB, McCabe D, European Group Of Clinical Investigators. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. *Arthritis and Rheumatism* 2002;**46**(11):2838-46.

Ortonne 2008

Ortonne JP, Griffiths CEM, Dauden E, Strohal R, Robertson D, Pedersen R, et al. Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: The CRYSTEL study. *Expert Review of Dermatology* 2008;**3**(6):657-65.

Papp 2005

Papp KA, Tying S, Lahfa M, Prinz J, Griffiths CEM, Nakanishi AM, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. *British Journal of Dermatology* 2005;**152**(6):1304-12.

Pavelka 2009

Pavelka K, Jarosova K, Suchy D, Senolt L, Chroust K, Dusek L, et al. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. *Annals of the Rheumatic Diseases* 2009;**68**(8):1285-9.

Pescovitz 2009

Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Golland R, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. *New England Journal of Medicine* 2009;**361**(22):2143-52.

Pfreundschuh 2006

Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. *Lancet: Oncology* 2006;**7**(5):379-91.

Present 1999

Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, Van Hogezaand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. *New England Journal of Medicine* 1999;**340**(18):1398-405.

Rau 2004

Rau R, Simianer S, Van Riel PL, Van de Putte LB, Krüger K, Schattenkirchner M, et al. Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate. *Scandinavian Journal of Rheumatology* 2004;**33**(3):145-53.

Reich 2005

Reich K, Nestle F, Papp K, Ortonne J-P, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. *Lancet* 2005;**366**(9494):1367-74.

Rennard 2007

Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine* 2007;**175**(9):926-34.

Rossman 2006

Rossman MD, Newman LS, Baughman RP, Teirstein A, Weinberger SE, Miller W Jr, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. *Sarcoidosis, Vasculitis, and Diffuse Lung Diseases* 2006;**23**(3):201-8.

Rouhani 2005

Rouhani FN, Meitin CA, Kaler M, Miskinis-Hilligoss D, Stylianou M, Levine SJ. Effect of tumor necrosis factor antagonism on allergen-mediated asthmatic airway inflammation. *Respiratory Medicine* 2005;**99**(9):1175-82.

Rutgeerts 1999

Rutgeerts P, D'Haens G, Targan S, Vasilias E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. *Gastroenterology* 1999;**117**(4):761-9.

Salles 2008

Salles GA, Mounier N, De Guibert S, Morschhauser F, Doyen C, Rossi J, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. *Blood* 2007;**112**(13):4824-31.

Salvarani 2007

Salvarani C, Macchioni P, Manzini C, Paolazzi G, Trotta A, Manganelli P, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial.[Summary for patients in Ann Intern Med. 2007 May 1;146(9):120; PMID: 17470827]. *Annals of Internal Medicine* 2007;**146**(9):631-9.

Sandborn 2001

Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. *Gastroenterology* 2001;**121**(5):1088-94.

Sandborn 2007a

Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al. Certolizumab pegol for the treatment of Crohn's disease. *New England Journal of Medicine* 2007;**357**(3):228-38.

Sandborn 2007b

Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. *Gut* 2007;**56**(9):1232-9.

Sandborn 2007c

Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel J-F, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized

trial.[Summary for patients in Ann Intern Med. 2007 Jun 19;146(12):120; PMID: 17470825]. *Annals of Internal Medicine* 2007;**146**(12):829-38.

Sandborn 2009

Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. *Gastroenterology* 2009;**137**(4):1250-60.

Sands 2001

Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. *Inflammatory Bowel Diseases* 2001;**7**(2):83-8.

Sany 2005

Sany J, Kaiser MJ, Jorgensen C, Trape G. Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis. *Annals of the Rheumatic Diseases* 2005;**64**(11):1647-9.

Schiff 2004

Schiff MH, DiVittorio G, Tesser J, Fleischmann R, Schechtman J, Hartman S, et al. The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. *Arthritis and Rheumatism* 2004;**50**(6):1752-60.

Schiff 2008

Schiff M, Keiserman M, Coddling C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. *Annals of the Rheumatic Diseases* 2008;**67**(8):1096-103.

Schreiber 2005

Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.[Erratum appears in Gastroenterology. 2005 Nov;129(5):1808 Note: Dosage error in article text]. *Gastroenterology* 2005;**129**(3):807-18.

Schreiber 2007

Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, et al. Maintenance therapy with certolizumab pegol for Crohn's disease.[Erratum appears in N Engl J Med. 2007 Sep 27;357(13):1357]. *New England Journal of Medicine* 2007;**357**(3):239-50.

Smolen 2008

Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. *Lancet* 2008;**371**(9617):987-97.

Smolen 2009a

Smolen J, Landewe RB, Mease P, Brzezicki J, Mason D, Luijckens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. *Annals of the Rheumatic Diseases* 2009;**68**(6):797-804.

Smolen 2009b

Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. [Erratum appears in *Lancet*. 2009 Oct 24;374(9699):1422]. *Lancet* 2009;**374**(9685):210-21.

Spahr 2002

Spahr L, Rubbia-Brandt L, Frossard JL, Giostra E, Rougemont AL, Pugin J, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. *Journal of Hepatology* 2002;**37**(4):448-55.

St Clair 2004

St Clair EW, Van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. *Arthritis and Rheumatism* 2004;**50**(11):3432-43.

Torre-Amione 2007

Torre-Amione G, Wallace CK, Young JB, Koerner MM, Thohan V, McRee S, et al. The effect of etanercept on cardiac transplant recipients: a study of TNFalpha antagonism and cardiac allograft hypertrophy. *Transplantation* 2007;**84**(4):480-3.

Tyden 2009

Tyden G, Genberg H, Tollemar J, Ekberg H, Persson NH, Tufveson G, et al. A randomized, double blind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. *Transplantation* 2009;**87**(9):1325-9.

Tyring 2007

Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. *Archives of Dermatology* 2007;**143**(6):719-26.

Uppal 2009

Uppal SS, Hayat SJ, Raghupathy R. Efficacy and safety of infliximab in active SLE: a pilot study. *Lupus* 2009;**18**(8):690-7.

Van de Kerkhof 2008

Van de Kerkhof PC, Segaeert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. *British Journal of Dermatology* 2008;**159**(5):1177-85.

Van de Putte 2003

Van de Putte LB, Rau R, Breedveld FC, Kalden JR, Malaise MG, Van Riel PL, et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. *Annals of the Rheumatic Diseases* 2003;**62**(12):1168-77.

Van de Putte 2004

Van de Putte L B, Atkins C, Malaise M, Sany J, Russell A S, Van Riel P L, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. *Annals of the Rheumatic Diseases* 2004;**63**(5):508-16.

Van Den Bosch 2002

Van Den Bosch F, Kruithof E, Baeten D, Herseens A, De Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. *Arthritis and Rheumatism* 2002;**46**(3):755-65.

Van der Bijl 2009

Van der Bijl AE, Teng YK, Van Oosterhout M, Breedveld FC, Allaart CF, Huizinga TW, et al. Efficacy of intraarticular infliximab in patients with chronic or recurrent gonarthritis: a clinical randomized trial. *Arthritis and Rheumatism* 2009;**61**(7):974-8.

Van der Heijde 2005

Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). *Arthritis and Rheumatism* 2005;**52**(2):582-91.

Van der Heijde 2006a

Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BAC, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis and Rheumatism* 2006;**54**(7):2136-46.

Van der Heijde 2006b

Van der Heijde D, Da Silva JC, Dougados M, Geher P, Van der Horst-Bruinsma I, Juanola X, et al. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. *Annals of the Rheumatic Diseases* 2006;**65**(12):1572-7.

Van der Heijde 2007

Van der Heijde D, Klareskog L, Landewe R, Bruyn GA, Cantagrel A, Durez P, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. *Arthritis and Rheumatism* 2007;**56**(12):3928-39.

Van der Heijde 2008a

Van der Heijde D, Burmester G, Melo-Gomes J, Codreanu C, Mola EM, Pedersen R, et al. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously

treated with monotherapy. *Annals of the Rheumatic Diseases* 2008;**67**(2):182-8.

Van der Heijde 2009

Van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. *Annals of the Rheumatic Diseases* 2009;**68**(6):922-9.

Van der Vaart 2005

Van der Vaart H, Koeter GH, Postma DS, Kauffman HF, ten Hacken NHT. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine* 2005;**172**(4):465-9.

Van Vollenhoven 2009

Van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Coster L, Waltbrand E, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. *Lancet* 2009;**374**(9688):459-66.

Wegener's 2005

Wegener's Granulomatosis Etanercept Trial Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. *New England Journal of Medicine* 2005;**352**(4):351-61.

Weinblatt 1999

Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. *New England Journal of Medicine* 1999;**340**(4):253-9.

Weinblatt 2003

Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. *Arthritis and Rheumatism* 2003;**48**(1):35-45.

Weinblatt 2006a

Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. *Arthritis and Rheumatism* 2006;**54**(9):2807-16.

Weinblatt 2006b

Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. *Annals of the Rheumatic Diseases* 2006;**65**(6):753-9.

Weinblatt 2007

Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. *Annals of the Rheumatic Diseases* 2007;**66**:228-34.

Weinblatt 2008

Weinblatt ME, Schiff MH, Ruderman EM, Bingham CO 3rd, Li J, Louie J, et al. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. *Arthritis and Rheumatism* 2008;**58**(7):1921-30.

Weisman 2003

Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. *Clinical Therapeutics* 2003;**25**(6):1700-21.

Weisman 2007

Weisman MH, Paulus HE, Burch FX, Kivitz AJ, Fierer J, Dunn M, et al. A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. *Rheumatology* 2007;**46**(7):1122-5.

Wenzel 2009

Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlen SE, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. *American Journal of Respiratory and Critical Care Medicine* 2009;**179**(7):549-58.

Westhovens 2006

Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial.[Erratum appears in *Arthritis Rheum.* 2007 May;**56**(5):1675 Note: Dosage error in article text]. *Arthritis and Rheumatism* 2006;**54**(4):1075-86.

Westhovens 2009a

Westhovens R, Kremer JM, Moreland LW, Emery P, Russell AS, Li T, et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. *Journal of Rheumatology* 2009;**36**(4):736-42.

Westhovens 2009b

Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al. Clinical efficacy and safety of abatacept in methotrexate-naïve patients with early rheumatoid arthritis and poor prognostic factors. *Annals of the Rheumatic Diseases* 2009;**68**(12):1870-7.

Wiedenmann 2008

Wiedenmann B, Malfertheiner P, Friess H, Ritch P, Arseneau J, Mantovani G, et al. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. *Journal of Supportive Oncology* 2008;**6**(1):18-25.

Witzig 2002

Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. *Journal of Clinical Oncology* 2002;**20**(10):2453-63.

Zein 2005

Zein NN, Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naïve patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. *Journal of Hepatology* 2005;**42**(3):315-22.

Zhou 2007

Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. *Journal of Clinical Pharmacology* 2007;**47**(3):383-96.

References to excluded reviews

Ansell 2006

Ansell SM, Geyer SM, Maurer MJ, Kurtin PJ, Micallef INM, Stella P, et al. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients. *Clinical Cancer Research* 2006;**12**(20 Pt 1):6056-63.

Bathon 2006

Bathon JM, Fleischmann RM, Van der Heijde D, Tesser JR, Peloso PM, Chon Y, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. *Journal of Rheumatology* 2006;**33**(2):234-43.

Bienvenu 2001

Bienvenu J, Chvetzoff R, Salles G, Balter C, Tilly H, Herbrecht R, et al. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. *The Hematology Journal: the official journal of the European Hematology Association / EHA* 2001;**2**(6):378-84.

Boehme 2009

Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). *Blood* 2009;**113**(17):3896-902.

Cohen 2007

Cohen SP, Wenzell D, Hurley RW, Kurihara C, Buckenmaier CC 3rd, Griffith S, et al. A double-blind, placebo-controlled, dose-response pilot study evaluating intradiscal etanercept in patients with chronic discogenic low back pain or lumbosacral radiculopathy. *Anesthesiology* 2007;**107**(1):99-105.

Cohen 2009

Cohen S P, Bogduk N, Dragovich A, Buckenmaier C C, Griffith S, Kurihara C, et al. Randomized, double-blind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica. *Anesthesiology* 2009;**110**(5):1116-26.

Combe 2006

Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. *Annals of the Rheumatic Diseases* 2006;**65**:1357-62.

D'Haens 2008

D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. *Lancet* 2008;**371**:660-7.

De Vos 2009

De Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R, et al. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. *Journal of Clinical Oncology* 2009;**27**(30):5023-30.

Erin 2006

Erin EM, Leaker BR, Nicholson GC, Tan AJ, Green LM, Neighbour H, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. *American Journal of Respiratory and Critical Care Medicine* 2006;**174**:753-62.

Feist 2009

Feist E, Burmester GR. Is tocilizumab in combination with traditional DMARDs safe and effective for patients with active RA?. *Nature Clinical Practice Rheumatology* 2009;**5**:128-9.

Fernandez-Lopez 2006

Fernandez-Lopez C, Blanco FJ. ATTAIN study: Efficacy of abatacept in patients with rheumatoid arthritis and inadequate response to anti-TNF-alpha. [Spanish]. *Reumatologia Clinica Suplementos* 2006;**1**:34-43.

Genovese 2004

Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. *Arthritis and Rheumatism* 2004;**50**(5):1412-9.

Goekoop-Ruiterman 2005

Goekoop-Ruiterman YPM, De Vries-Bouwstra JK, Allaart CF, Van Zeven D, Kerstens PJSM, Hazes JMW, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. *Arthritis and Rheumatism* 2005;**52**:3381-90.

Goekoop-Ruiterman 2007

Goekoop-Ruiterman YPM, De Vries-Bouwstra JK, Allaart CF, Van Zeven D, Kerstens PJSM, Hazes JMW, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. *Annals of Internal Medicine*: 2007;**146**:406-15.

Gottlieb 2006

Gottlieb AB, Kircik L, Eisen D, Jackson JM, Boh EE, Strober BE, et al. Use of etanercept for psoriatic arthritis in the dermatology clinic: The Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. *Journal of Dermatological Treatment* 2006;**17**:343-52.

Griffiths 2010

Griffiths CE, Strober BE, Van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. *New England Journal of Medicine* 2010;**362**:118-28.

Kaplan 2005

Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. *Blood* 2005;**106**:1538-43.

Kimby 2008

Kimby E, Jurlander J, Geisler C, Hagberg H, Holte H, Lehtinen T, et al. Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group. *Leukemia and Lymphoma* 2008;**49**:102-12.

Kremer 2008

Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. *Arthritis and Rheumatism* 2008;**58**:953-63.

Lee 2009

Lee RA, Dommasch E, Treat J, Sciacca-Kirby J, Chachkin S, Williams J, et al. A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. *Journal of the American Academy of Dermatology* 2009;**60**(4):565-73.

Li 2008

Li EK, Griffith JF, Lee VW, Wang YX, Li TK, Lee KK, et al. Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. *Rheumatology* 2008;**47**:1358-63.

Maini 2004

Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. *Arthritis and Rheumatism* 2004;**50**(4):1051-65.

Moore 2007

Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. *Journal of the American Academy of Dermatology* 2007;**56**(4):598-603.

Moreland 2006

Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH, et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. *Journal of Rheumatology* 2006;**33**(5):854-61.

Nikas 2006

Nikas SN, Voulgari PV, Alamanos Y, Papadopoulos CG, Venetsanopoulou AI, Georgiadis AN, et al. Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. *Annals of the Rheumatic Diseases* 2006;**65**(2):257-60.

Ogura 2006

Ogura M, Morishima Y, Kagami Y, Watanabe T, Itoh K, Igarashi T, et al. Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma. *Cancer Science* 2006;**97**(4):305-12.

Ramos-Remus 2008

Ramos-Remus C, Muriel-Vizcaino R. The OPTION trial: Inhibition of the interleukin-6 receptor with tocilizumab in patients with rheumatoid arthritis <http://dx.doi.org/10.2217/17460816.3.5.429>. *Future Rheumatology* 2008;**3**(5):429-34.

Ribrag 2009

Ribrag V, Gisselbrecht C, Haioun C, Salles G, Golfier JB, Ertault M, et al. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). *Cancer* 2009;**115**(19):4540-6.

Rutgeerts 2004

Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. *Gastroenterology* 2004;**126**(2):402-13.

Saurat 2008

Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). *British Journal of Dermatology* 2008;**158**(3):558-66.

Schroder 2006

Schroder O, Blumenstein I, Stein J. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study. *European Journal of Gastroenterology and Hepatology* 2006;**18**(1):11-6.

Sibilia 2007

Sibilia J, Westhovens R. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. *Clinical and Experimental Rheumatology* 2007;**25** Suppl(5):46-56.

Soubrier 2009

Soubrier M, Puechal X, Sibilia J, Mariette X, Meyer O, Combe B, et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. *Rheumatology* 2009;**48**(11):1429-34.

Tesser 2004

Tesser J, Fleischmann R, Dore R, Bennett R, Solinger A, Joh T, et al. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis. *Journal of Rheumatology* 2004;**31**(4):649-54.

Tornero 2006

Tornero Molina J. The AIM study: Efficacy of abatacept in patients with rheumatoid arthritis and inadequate response to methotrexate. [Spanish]. *Reumatologia Clinica Suplementos* 2006;**1**(2):25-33.

Tyring 2006

Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. *Lancet* 2006;**367**(9504):29-35.

Van der Heijde 2006c

Van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. *Arthritis and Rheumatism* 2006;**54**(4):1063-74.

Van der Heijde 2008b

Van der Heijde D, Pangan AL, Schiff MH, Braun J, Borofsky M, Torre J, et al. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. *Annals of the Rheumatic Diseases* 2008;**67**(9):1218-21.

Van Heeckeren 2006

Van Heeckeren WJ, Vollweiler J, Fu P, Cooper BW, Meyerson H, Lazarus HM, et al. Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device. *British Journal of Haematology* 2006;**132**(1):42-55.

Van Riel 2006

Van Riel PLCM, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. *Annals of the Rheumatic Diseases* 2006;**65**(11):1478-83.

Xu 2008

Xu W, Li JY, Zhang ZH, Qiu HX, Qian SX, Wu HX, et al. Comparison between efficacy and safety of rituximab plus CHOP regimen and CHOP regimen for treatment of newly diagnosed patients with diffuse large B-cell lymphoma. [Chinese]. *Journal of Experimental Hematology / Chinese Association of Pathophysiology* 2008;**16**(4):933-7.

Zachariae 2008

Zachariae C, Mork N-J, Reunala T, Lorentzen H, Falk E, Karvonen S-L, et al. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. *Acta Dermato-Venerologica* 2008;**88**(5):495-501.

Additional references

Alonso-Ruiz 2008

Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. *BMC Musculoskeletal Disorders* 2008;**9**(52):1-27.

Becker 2008

Becker LA, Oxman AD. Chapter 22: Overviews of Reviews. In: Higgins JP, Green S, editors, *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www.cochranehandbook.org.

Behm 2008

Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. *Cochrane Database of Systematic Reviews* 2008, Issue 1. [DOI: [10.1002/14651858.CD006893](https://doi.org/10.1002/14651858.CD006893)]

Blumenauer 2002

Blumenauer BBTB, Judd M, Wells GA, Burls A, Cranney A, Hochberg MC, et al. Infliximab for the treatment of rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2002, Issue 3. [DOI: [10.1002/14651858.CD003785](https://doi.org/10.1002/14651858.CD003785)]

Blumenauer 2003

Blumenauer BBTB, Cranney A, Burls A, Coyle D, Hochberg MC, Tugwell P, et al. Etanercept for the treatment of rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2003, Issue 3. [DOI: [10.1002/14651858.CD004525](https://doi.org/10.1002/14651858.CD004525)]

Bongartz 2006

Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic

review and meta-analysis of rare harmful effects in randomized controlled trials. *JAMA* 2006 May 17;**295**(19):2275-85.

Doherty 2009

Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC. Interventions for prevention of post-operative recurrence of Crohn's disease. *Cochrane Database of Systematic Reviews* 2009, Issue 4. [DOI: [10.1002/14651858.CD006873.pub2](https://doi.org/10.1002/14651858.CD006873.pub2)]

Drugs.com 2006

Drug Information Online. Drugs.com. FDA Approves First Rheumatoid Arthritis Indication for Rituxan. <http://www.drugs.com/news/fda-approves-first-rheumatoid-arthritis-indication-rituxan-1745.html> 03/01/2006.

FDA 1998a

Food, Drug Administration. Etanercept Product Approval Information- Licensing Action 12/2/1998. <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080536.htm> 1998.

FDA 1998b

Food, Drug Administration. Medication Guide: Enbrel® (etanercept). http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/103795s5359lbl.pdf.

FDA 1999

Food, Drug Administration. Remicade® (infliximab) for IV Injection. <http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm107722.pdf> 1999.

FDA 2001

Food, Drug Administration. Kineret® (anakinra) Physician packet insert: Kineret® (anakinra) prescribing information. <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080650.htm> 2001.

FDA 2002a

Food, Drug Administration. Humira® (adalimumab): Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125057s114lbl.pdf.

FDA 2002b

Food, Drug Administration. Package Insert. HUMIRA® (adalimumab). Abbott Laboratories. <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080610.htm> 2002.

FDA 2005

Food, Drug Administration. Patient Information Sheet. Abatacept (marketed as Orencia®). <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/FastTrackApprovalReports/ucm082380.htm> 2005.

FDA 2006

Food, Drug Administration. Rituxan® (rituximab). <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150747.htm>.

FDA 2009a

FDA: FDA Center for Drug Evaluation and Research. SIMPONI® (Golimumab) Summary Review. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/125289s000_SumR.pdf 2009.

FDA 2009b

FDA. SIMPONI® (Golimumab) Physician Packet Insert: Highlights of Prescribing Information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125289s000lbl.pdf 2009.

FDA 2009c

Food, Drug Administration. Cimzia® (Certolizumab): Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125160s092lbl.pdf 2009.

FDA 2009d

Food, Drug Administration. Drug details: Orencia®. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125118s0086lbl.pdf 2009.

FDA 2009e

Food, Drug Administration. Remicade® (infliximab) for IV Injection. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/103772s5234lbl.pdf 2009.

FDA 2010

FDA: Food, Drug Administration. Medication Guide. Actemra (Tocilizumab). <http://www.fda.gov/downloads/Drugs/DrugSafety/UCM197463.pdf> 2010.

FDA 2010b

Food and Drug Administration. Department of Health and Human Services: Safety. MedWatch: The FDA Safety information and adverse event reporting program: Reporting serious problems to FDA: What is a serious adverse event?. <http://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm>. Page last updated 12/15/2010.

Golicki 2009

Golicki D, Macioch T, Niewada M, Jakubczyk M, Tlustochowicz M, Owczarek W, Tlustochowicz W. TNF-alpha inhibitors for psoriatic arthritis. *Cochrane Database of Systematic Reviews* 2009, Issue 3. [DOI: [10.1002/14651858.CD007940](https://doi.org/10.1002/14651858.CD007940)]

Guyatt 2011

Guyatt G, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence-imprecision. *Journal of Clinical Epidemiology* 2011;**64**:1283-93.

Harris 1990

Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. *New England Journal of Medicine* 1990;**322**(18):1277-89.

Higgins 2011

Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

Keystone 2009b

Keystone E. Recent concepts in the inhibition of radiographic progression with biologics. *Current Opinion in Rheumatology* 2009;**21**(3):231-7.

Kvien 2004

Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. *Pharmacoeconomics* 2004;**22** Suppl 1(2):1-12.

Kvien 2005

Kvien TK, Uhlig T. Quality of life in rheumatoid arthritis. *Scandinavian Journal of Rheumatology* 2005;**34**(5):333-41.

Lee 2008

Lee YH, Woo JH, Rho YH, Choi SJ, Ji JD, Song GG. Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. *Rheumatology International* 2008 April;**28**(6):553-9.

Lubeck 2004

Lubeck DP. Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. *Pharmacoeconomics* 2004;**22** Suppl 1(2):27-38.

Maxwell 2009

Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2009, Issue 4. [DOI: [10.1002/14651858.CD007277](https://doi.org/10.1002/14651858.CD007277)]

Menge 2008

Menge T, et al. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. *Drugs* 2008;**68**(17):2445-68.

Mertens 2009

Mertens M, Singh JA. Anakinra for rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2009, Issue 1. [DOI: [10.1002/14651858.CD005121](https://doi.org/10.1002/14651858.CD005121)]

Navarro-Sarabia 2005

Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2005, Issue 3. [DOI: [10.1002/14651858.CD005113.pub2](https://doi.org/10.1002/14651858.CD005113.pub2)]

Ntzoufras 2008

Ntzoufras I. Wiley Series in Computational Statistics, in Bayesian Modeling Using WinBUGS. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2008. [DOI: [10.1002/9780470434567.scard](https://doi.org/10.1002/9780470434567.scard)]

Odegard 2005

Odegard S, Finset A, Kvien TK, Mowinckel P, Uhlig T. Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the

Oslo RA register. *Scandinavian Journal of Rheumatology* 2005;**34**(6):441-7.

Pincus 1983

Pincus T, Summey JA, Soraci SA, Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. *Arthritis and Rheumatism* 1983;**26**(11):1346-53.

Pogue 1997

Pogue JM, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. *Controlled Clinical Trials* 1997 Dec;**18**(6):580-93.

Rozenblit 2009

Rozenblit M, Lebwohl M. New biologics for psoriasis and psoriatic arthritis. *Dermatologic Therapy* 2009;**22**(1):56-60.

Ruiz Garcia 2011

Ruiz Garcia V, Jobanputra P, Burls A, Cabello JB, Gálvez Muñoz JG, Saiz Cuenca ESC, Fry-Smith A. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. *Cochrane Database of Systematic Reviews* 2011, Issue 2. [DOI: [10.1002/14651858.CD007649.pub2](https://doi.org/10.1002/14651858.CD007649.pub2)]

Schulz 2007

Schulz H, Bohlius J, Skoetz N, Trelle S, Kober T, Reiser M, et al. Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. *Cochrane Database of Systematic Reviews* 2007, Issue 4. [DOI: [10.1002/14651858.CD003805.pub2](https://doi.org/10.1002/14651858.CD003805.pub2)]

Schünemann 2008a

Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.

Schünemann 2008b

Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.

Scott 2006

Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. *New England Journal of Medicine* 2006;**355**(7):704-12.

Singh 2009a

Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. *Cochrane Database of Systematic Reviews* 2009, Issue 4. [DOI: [10.1002/14651858.CD007848.pub2](https://doi.org/10.1002/14651858.CD007848.pub2)]

Singh 2009b

Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. *Canadian Medical Association Journal* 2009;**181**(11):787-96.

Singh 2010a

Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2010, Issue 7. [DOI: [10.1002/14651858.CD008331](https://doi.org/10.1002/14651858.CD008331)]

Singh 2010b

Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2010, Issue 1. [DOI: [10.1002/14651858.CD008341](https://doi.org/10.1002/14651858.CD008341)]

Spiegelhalter 2003

Spiegelhalter D, Thomas A, Best N, Lunn D. WinBUGS user manual. Version 1.4. [Cambridge, UK]: BUGS Project; <http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/manual14.pdf> 2003 Jan.

Strand 2008

Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. *American Journal of Managed Care* 2008;**14**(4):234-54.

Strand 2010

Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. *Drugs*. 2010;**70**(2):121-45.

Vidal 2009

Vidal L, Gafter-Gvili A, Leibovici L, Shpilberg O. Rituximab as maintenance therapy for patients with follicular lymphoma. *Cochrane Database of Systematic Reviews* 2009, Issue 2. [DOI: [10.1002/14651858.CD006552.pub2](https://doi.org/10.1002/14651858.CD006552.pub2)]

Wiens 2010

Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. *Pharmacotherapy* 2010 April;**30**(4):339-53.

Yelin 2007

Yelin E. Work disability in rheumatic diseases. *Current Opinion in Rheumatology* 2007;**19**(2):91-6.

Zochling J

Zochling J, Maxwell L, Beardmore J, Boonen A. TNF-alpha inhibitors for ankylosing spondylitis. *Cochrane Database of Systematic Reviews* 2009, Issue 1. [DOI: [10.1002/14651858.CD005468](https://doi.org/10.1002/14651858.CD005468)]

ADDITIONAL TABLES

Table 1. Details on doses used for the dose-adjusted analysis

	Approved dose and range	Dose used for adjustment
Etanercept	25 mg SQ twice a week	50 mg qweek
Infliximab	3-5 mg/kg Q8 weeks; may increase to 10 mg/kg	3 mg/kg q8weeks
Adalimumab	40 mg SQ Q2 weeks	40 mg q2weeks
Golimumab	50 mg SQ Q4 weeks	50 mg q4weeks
Certolizumab pegol	400 mg SQ initially, then 200-mg Qother week or 400 mg monthly	400 mg monthly
Anakinra	100 mg SQ Qday	100 mg qday
Rituximab	500 or 1000 mg -2 infusions, 2 weeks apart	500-1000 mg 2wks apart
Abatacept	500, 750 or 1000 mg Q4 weeks	500-1000 mg Q4weeks
Tocilizumab	4 mg/kg IV Q4 weeks; may increase to 8mg/kg Q8 weeks	4 mg/kg q4weeks

Table 2. Summary of characteristics of included studies

Characteristic	Randomized-controlled trials, N=160	Open-label extension studies, N=46
<i>Type of intervention</i>		
abatacept	7	2
adalimumab	22	10
anakinra	5	2
certolizumab pegol	6	1
etanercept	39	10
golimumab	8	1
infliximab	40***	18
rituximab	29	1
tocilizumab	5	1
<i>Type of condition</i>		
rheumatoid arthritis	62	18
cancer	25	0
psoriasis	14	8
IBD	12	1
ankylosing spondylitis	10	10
psoriatic arthritis	7	7
Crohn's disease	6	0
ulcerative colitis	6	0
other*	18	2
<i>Trial duration, months mean(SD; median)</i>	9.8 (11.5; 6.0)	20.7 (17.9; 13.5)
Trial duration, short < 6 months , N studies	98	9
Trial duration: intermediate (6< mo. ≤12), N studies	27	12
Trial duration: long >12 months , N studies	35	25
<i>Age, years mean(SD; median)</i>	49.9 (8.2; 51)	79.9 (24.2; 87.0)
<i>% Female mean(SD; median)</i>	58.9 (20.4; 61)	57.3 (24.5; 61.7)

Table 2. Summary of characteristics of included studies (Continued)

% Caucasian mean(SD; median)	85.4(17; 89.7)	79.9 (24.2; 87.0)
------------------------------	----------------	-------------------

IBD = inflammatory bowel disease; SD = standard deviation; *other conditions for RCT include: heart failure, multiple sclerosis, COPD, alcoholic hepatitis, diabetes, lupus, active spondylarthropathy, osteoarthritis, asthma, cardiac or renal transplantation, Sjogren's syndrome, polymyalgia rheumatica, autoimmune inner ear disease, giant cell arteritis, pulmonary sarcoidosis, Hepatitis C, cancer anorexia/weight loss syndrome, Wegener's granulomatosis; other conditions for OLE = sarcoidosis, axial spondylarthritis; *** one study (Schiff 2008) had two treatment arms (abatacept and infliximab)

Table 3. Summary of findings table 1

Biologics for any condition except HIV/AIDS: standard drug dose* and control event rate						
Outcome	Comparison intervention	Illustrative comparative risks	Relative effect (95% CI)	Number of participants (studies)	Quality of the evidence (GRADE)	NNTH (95% CI)
	Assumed risk with comparator	Corresponding risk with intervention (95% CI)				
	Control	Biologics**				
Serious adverse events	118 per 1000	127 per 1000 (115 to 142)	OR 1.09 (0.97 to 1.24)	21,152 (76 studies)	⊕⊕⊕⊖ moderate ¹	Not statistically significant
Total adverse events	724 per 1000	770 per 1000 (741 to 797)	OR 1.28 (1.09 to 1.50)	14,959 (48 studies)	⊕⊕⊕⊕ high	22 (14 to 60)
Withdrawals due to adverse events	98 per 1000	137 per 1000 (115 to 168)	OR 1.47 (1.20 to 1.86)	22,636 (83 studies)	⊕⊕⊕⊖ moderate ¹	26 (15 to 58)
Serious infections	26 per 1000	35 per 1000 (27 to 46)	OR 1.37 (1.04 to 1.82)	21,853 (70 studies)	⊕⊕⊕⊖ moderate ¹	108 (50 to 989)
Tuberculosis reactivation	4 per 10,000	20 per 10,000	OR 4.68 (1.18 to 18.60)	30,671 (71 studies)	⊕⊕⊖⊖ low ⁴	681 (143 to 14706)
Lymphoma	9 per 10000	1 per 1000	OR 0.53 (0.17 to 1.66)	21,260 (52 studies)	⊕⊕⊖⊖ low ⁴	Not statistically significant
Congestive heart failure	8 per 1000	6 per 1000 (1 to 21)	OR 0.69 (0.18 to 2.69)	8847 (24 studies)	⊕⊕⊖⊖ low ⁴	Not statistically significant

* = standard drug dose was used for serious adverse events, total adverse events, withdrawals due to adverse events and serious infections only. All doses were combined for tuberculosis reactivation, lymphoma and congestive heart failure because of very limited data.

** = all nine biologics as a group

95% CI = 95% confidence interval or 95% credible interval; NNTH = Number needed to treat for harm; OR = odds ratio

Control event rates based on the number of events in the included studies.

¹ The 95% credible interval around the pooled effect includes both no effect and appreciable benefit or harm.

² Out of 19 studies, two studies (Buske 2009; Eve 2009) had inadequate allocation concealment; four studies (Eve 2009; Forstpointner 2004; Hainsworth 2005; Herold 2007) reported no blinding of personnel, participants and outcome assessors; two studies (Buske 2009; Salles 2007) reported no blinding of personnel and participants only.

³ Out of 15 studies, two (Buske 2009; Hiddemann 2005) had inadequate allocation concealment; four studies (Coiffier 1998; Forstpointner 2004; Hainsworth 2005; Hiddemann 2005) reported no blinding of personnel, participants and outcome assessors; two studies (Forstpointner 2002; Salles 2007) reported no blinding of personnel and participants only.

⁴ Very few events.

Table 4. Summary of findings table 2

Biologics for any condition except HIV/AIDS: standard drug dose* and control event rate							
Intervention	Comparison intervention	Illustrative comparative risks		Relative effect (95% CI)	Number of participants (studies)	Quality of the evidence (GRADE)	NNTH (95% CI)
		Assumed risk with comparator	Corresponding risk with intervention (95% CI)				
		Control	Biologic				
Serious adverse events							
Abatacept	control	118 per 1000	116 per 1000 (76 to 144)	OR 0.89 (0.61 to 1.26)	2052 (5 studies)	⊕⊕⊕⊕ high	Not statistically significant
Adalimum-ab	control	118 per 1000	114 per 1000 (90 to 145)	OR 0.96 (0.74 to 1.27)	4662 (15 studies)	⊕⊕⊕⊖ moderate ¹	Not statistically significant
Anakinra	control	118 per 1000	122 per 1000 (82 to 180)	OR 1.04 (0.67 to 1.64)	1900 (3 studies)	⊕⊕⊕⊕ high	Not statistically significant
Certolizum-ab pegol	control	118 per 1000	174 per 1000 (124 to 237)	OR 1.57 (1.06 to 2.32)	2421 (6 studies)	⊕⊕⊕⊖ moderate ¹	18 (9 to 162)
Etanercept	control	118 per 1000	142 per 1000 (111 to 184)	OR 1.24 (0.93 to 1.69)	3931 (21 studies)	⊕⊕⊕⊖ moderate ¹	Not statistically significant
Golimumab	control	118 per 1000	123 per 1000 (82 to 184)	OR 1.05 (0.67 to 1.69)	1564 (8 studies)	⊕⊕⊕⊖ moderate ¹	Not statistically significant
Infliximab	control	118 per 1000	133 per 1000 (102 to 174)	OR 1.15 (0.85 to 1.57)	3403 (14 studies)	⊕⊕⊕⊖ moderate ¹	Not statistically significant
Rituximab	control	118 per 1000	186 per 1000 (85 to 375)	OR 1.71 (0.69 to 4.49)	377 (2 studies)	⊕⊕⊕⊖ moderate ¹	Not statistically significant

Table 4. Summary of findings table 2 (Continued)

Tocilizumab	control	118 per 1000	93 per 1000 (52 to 163)	OR 0.77 (0.41 to 1.45)	842 (3 studies)	⊕⊕⊕⊖ moderate ¹	Not statistically significant
All nine biologics	control	118 per 1000	127 per 1000 (115 to 142)	OR 1.09 (0.97 to 1.24)	21,152 (76 studies)	⊕⊕⊕⊖ moderate ¹	Not statistically significant
Total adverse events							
Abatacept	control	724 per 1000	766 per 1000 (654 to 849)	OR 1.25 (0.72 to 2.15)	1818 (4 studies)	⊕⊕⊕⊕ high	Not statistically significant
Adalimumab	control	724 per 1000	730 per 1000 (637 to 802)	OR 1.03 (0.67 to 1.54)	3266 (10 studies)	⊕⊕⊕⊕ high	Not statistically significant
Anakinra	control	724 per 1000	791 per 1000 (677 to 876)	OR 1.44 (0.80 to 2.68)	2033 (4 studies)	⊕⊕⊕⊕ high	Not statistically significant
Certolizumab pegol	control	724 per 1000	754 per 1000 (651 to 837)	OR 1.17 (0.71 to 1.95)	1829 (5 studies)	⊕⊕⊕⊕ high	Not statistically significant
Etanercept	control	724 per 1000	784 per 1000 (677 to 866)	OR 1.38 (0.80 to 2.46)	1600 (7 studies)	⊕⊕⊕⊕ high	Not statistically significant
Golimumab	control	724 per 1000	765 per 1000 (672 to 839)	OR 1.24 (0.78 to 1.98)	1187 (6 studies)	⊕⊕⊕⊕ high	Not statistically significant
Infliximab	control	724 per 1000	803 per 1000 (726 to 860)	OR 1.55 (1.01 to 2.35)	2330 (9 studies)	⊕⊕⊕⊕ high	13 (8 to 505)
Rituximab	control	724 per 1000	802 per 1000 (562 to 924)	OR 1.54 (0.49 to 4.63)	377 (2 studies)	⊕⊕⊕⊖ moderate ¹	Not statistically significant
Tocilizumab	control	724 per 1000	775 per 1000 (599 to 888)	OR 1.31 (0.57 to 3.01)	519 (2 studies)	⊕⊕⊕⊕ high	Not statistically significant

Table 4. Summary of findings table 2 (Continued)

All nine biologics	control	724 per 1000	770 per 1000 (741 to 797)	OR 1.28 (1.09 to 1.50)	14,959 (48 studies)	⊕⊕⊕⊕ high	22 (14 to 60)
Withdrawals due to adverse events							
Abatacept	control	98 per 1000	113 per 1000 (59 to 208)	OR 1.17 (0.58 to 2.41)	2054 (5 studies)	⊕⊕⊕⊖ moderate ¹	Not statistically significant
Adalimumab	control	98 per 1000	128 per 1000 (81 to 194)	OR 1.35 (0.82 to 2.22)	5268 (18 studies)	⊕⊕⊕⊖ moderate ¹	Not statistically significant
Anakinra	control	98 per 1000	150 per 1000 (69 to 301)	OR 1.63 (0.68 to 3.96)	1963 (3 studies)	⊕⊕⊕⊖ moderate ¹	Not statistically significant
Certolizumab pegol	control	98 per 1000	125 per 1000 (70 to 226)	OR 1.32 (0.69 to 2.69)	2421 (6 studies)	⊕⊕⊕⊖ moderate ¹	Not statistically significant
Etanercept	control	98 per 1000	124 per 1000 (82 to 191)	OR 1.30 (0.82 to 2.17)	5189 (25 studies)	⊕⊕⊕⊖ moderate ¹	Not statistically significant
Golimumab	control	98 per 1000	127 per 1000 (64 to 241)	OR 1.34 (0.63 to 2.92)	1549 (7 studies)	⊕⊕⊕⊖ moderate ¹	Not statistically significant
Infliximab	control	98 per 1000	203 per 1000 (132 to 310)	OR 2.34 (1.40 to 4.14)	2973 (15 studies)	⊕⊕⊕⊖ moderate ¹	10 (5 to 30)
Rituximab	control	98 per 1000	229 per 1000 (45 to 756)	OR 2.74 (0.43 to 28.48)	377 (2 studies)	⊕⊕⊖⊖ low ^{1,3}	Not statistically significant
Tocilizumab	control	98 per 1000	166 per 1000 (65 to 371)	OR 1.83 (0.64 to 5.42)	842 (3 studies)	⊕⊕⊕⊖ moderate ¹	Not statistically significant
All nine biologics	control	98 per 1000	137 per 1000 (115 to 168)	OR 1.47 (1.20 to 1.86)	22,636 (83 studies)	⊕⊕⊕⊖ moderate ¹	26 (15 to 58)

Table 4. Summary of findings table 2 (Continued)

Serious infection

Abatacept	control	26 per 1000	25 per 1000 (11 to 58)	OR 0.97 (0.40 to 2.31)	2052 (5 studies)	⊕⊕⊕⊕ high	Not statistically significant
Adalimumab	control	26 per 1000	32 per 1000 (17 to 60)	OR 1.23 (0.65 to 2.40)	4847 (15 studies)	⊕⊕⊕⊖ moderate ¹	Not statistically significant
Anakinra	control	26 per 1000	98 per 1000 (32 to 310)	OR 4.05 (1.22 to 16.84)	3436 (4 studies)	⊕⊕⊕⊖ moderate ¹	14 (4 to 181)
Certolizumab pegol	control	26 per 1000	113 per 1000 (39 to 330)	OR 4.75 (1.52 to 18.45)	1683 (4 studies)	⊕⊕⊕⊕ high	12 (4 to 79)
Etanercept	control	26 per 1000	33 per 1000 (19 to 61)	OR 1.29 (0.72 to 2.45)	4630 (19 studies)	⊕⊕⊕⊖ moderate ¹	Not statistically significant
Golimumab	control	26 per 1000	29 per 1000 (12 to 65)	OR 1.11 (0.45 to 2.59)	1334 (6 studies)	⊕⊕⊕⊖ moderate ¹	Not statistically significant
Infliximab	control	26 per 1000	36 per 1000 (20 to 65)	OR 1.41 (0.75 to 2.62)	2652 (13 studies)	⊕⊕⊕⊖ moderate ¹	Not statistically significant
Rituximab	control	26 per 1000	7 per 1000 (1 to 55)	OR 0.26 (0.03 to 2.16)	377 (2 studies)	⊕⊕⊕⊖ low ^{1,2}	Not statistically significant
Tocilizumab	control	26 per 1000	22 per 1000 (5 to 87)	OR 0.84 (0.20 to 3.56)	842 (3 studies)	⊕⊕⊕⊖ moderate ¹	Not statistically significant
All nine biologics	control	26 per 1000	35 per 1000 (27 to 46)	OR 1.37 (1.04 to 1.82)	21,853 (70 studies)	⊕⊕⊕⊖ moderate ¹	108 (50 to 989)
Tuberculosis reactivation							

Table 4. Summary of findings table 2 (Continued)

All nine bio- logics	control	4 per 10,000	20 per 10,000	OR 4.68 (1.18 to 18.60)	30,671 (71 studies)	⊕⊕⊕⊕ low ⁴	681 (143 to 14706)
Lymphoma							
All nine bio- logics	control	9 per 10000	1 per 1000	OR 0.53 (0.17 to 1.66)	21,260 (52 studies)	⊕⊕⊕⊕ low ⁴	Not statistically signif- icant
Congestive heart failure							
All nine bio- logics	control	8 per 1000	6 per 1000 (1 to 21)	OR 0.69 (0.18 to 2.69)	8847 (24 studies)	⊕⊕⊕⊕ low ⁴	Not statistically signif- icant

* = standard drug dose was used for serious adverse events, total adverse events, withdrawals due to adverse events and serious infectious only. All doses were combined for tuberculosis reactivation, lymphoma and congestive heart failure because of very limited data.

95% CI = 95% confidence interval or 95% credible interval; NNTH = Number needed to treat for harm; OR = odds ratio

Control event rates based on the number of events in the included studies.

¹ The 95% credible interval around the pooled effect includes both no effect and appreciable benefit or harm.

² Out of 19 studies, two studies (Buske 2009; Eve 2009) had inadequate allocation concealment; four studies (Eve 2009; Forstpointner 2004; Hainsworth 2005; Herold 2007) reported no blinding of personnel, participants and outcome assessors; two studies (Buske 2009; Salles 2007) reported no blinding of personnel and participants only.

³ Out of 15 studies, two (Buske 2009; Hiddemann 2005) had inadequate allocation concealment; four studies (Coiffier 1998; Forstpointner 2004; Hainsworth 2005; Hiddemann 2005) reported no blinding of personnel, participants and outcome assessors; two studies (Forstpointner 2002; Salles 2007) reported no blinding of personnel and participants only.

⁴ Very few events.

Table 5. Incidence of safety outcomes from RCTs

Outcome	Total # studies with data	# Events*: biologic group	# People: biologic group	Incidence in biologic group	# Events*: control group	# people: control group	Incidence in control group	Total # events	Total # peo- ple studied	Total duration of studies (mths (yrs))
SAE	125	2926	26032	11.24%	1747	13,614	12.83%	4673	39,646	2613 (217.8)
S Infec- tions	117	731	25,486	2.87%	325	13,741	2.37%	1056	39,227	2923 (243.6)
Total AE	115	20,686	24,208	85.45%	11,115	13,241	83.94%	31,801	37,449	2462 (205.2)

Table 5. Incidence of safety outcomes from RCTs (Continued)

With d/t AE	128	1577	26,553	5.94%	683	14,172	4.82%	2260	40,725	2909.2 (242.4)
TB	71	32	20,765	0.154%	3	9915	0.030%	35	30,671	646.1 (53.8)
Lym-phoma	52	14	14,254	0.098%	6	7006	0.086%	20	21,260	518.3 (43.2)
CHF	24	27	5768	0.468%	17	3079	0.552%	44	8847	255.6 (21.3)

All drug doses included

Events* = number of events or people with events

Table 6. Standard meta-analyses results

	Serious adverse events	Total adverse events	Withdrawals due to adverse events	Serious Infection	TB reactivation	Lymphoma	Congestive heart failure
Abatacept	0.90 (0.64 to 1.28)	1.24 (0.97 to 1.60)	0.97 (0.57 to 1.63)	1.06 (0.52 to 2.16)	0.50 (0.03 to 8.11)	1.52 (0.06 to 37.53)	1.56 (0.06 to 38.44)
Adalimum-ab	0.95 (0.74 to 1.22)	0.99 (0.63 to 1.56)	1.21 (0.84 to 1.75)	1.03 (0.53 to 2.01)	2.14 (0.33 to 13.78)	0.95 (0.10 to 9.19)	Not estimable
Anakinra	1.04 (0.68 to 1.61)	1.69 (0.84 to 3.42)	0.65 (0.09 to 4.50)	3.24 (0.97 to 10.82)	Not estimable	0.08 (0.00 to 2.08)	Not estimable
Certolizum-ab	1.24 (0.85 to 1.80)	1.16 (0.86 to 1.56)	1.17 (0.69 to 1.97)	3.15 (1.24 to 7.98)	4.43 (0.50 to 39.09)	0.33 (0.01 to 8.09)	Not estimable
Etanercept	1.12 (0.87 to 1.44)	1.14 (0.88 to 1.48)	0.98 (0.73 to 1.32)	1.12 (0.73 to 1.70)	1.48 (0.06 to 36.93)	2.40 (0.38 to 15.31)	0.84 (0.05 to 14.26)
Golimumab	1.04 (0.64 to 1.68)	1.30 (0.85 to 1.99)	1.26 (0.57 to 2.79)	1.24 (0.61 to 2.53)	3.04 (0.12 to 75.13)	Not estimable	2.84 (0.11 to 71.99)
Infliximab	1.06 (0.82 to 1.37)	1.51 (0.92 to 2.47)	1.99 (1.04 to 3.80)	1.34 (0.85 to 2.12)	2.82 (0.65 to 12.18)	3.00 (0.12 to 74.79)	Not estimable
Rituximab	1.59 (0.51 to 4.89)	1.69 (0.97 to 2.96)	1.93 (0.18 to 21.22)	0.39 (0.07 to 2.11)	---	---	---

Table 6. Standard meta-analyses results *(Continued)*

Tocilizumab	0.90 (0.51 to 1.61)	1.36 (0.95 to 1.96)	1.49 (0.74 to 3.01)	1.28 (0.34 to 4.82)	Not estimable	---	Not estimable
	1.04 (0.94 to 1.16)	1.28 (1.11 to 1.48)	1.22 (1.02 to 1.47)	1.23 (0.99 to 1.52)	2.30 (0.95 to 5.55)	1.05 (0.36 to 3.06)	1.46 (0.25 to 8.63)

Table 7. Treatment comparison to control: serious adverse events - network meta-analysis MTC

OR	Standard Dose
RE Model	Model
	Median (95% CI)
Abatacept	0.89 (0.61 to 1.26)
Adalimumab	0.96 (0.74 to 1.27)
Anakinra	1.04 (0.67 to 1.64)
Certolizumab	1.57 (1.06 to 2.32)*
Etanercept	1.24 (0.93 to 1.69)
Golimumab	1.05 (0.67 to 1.69)
Infliximab	1.15 (0.85 to 1.57)
Rituximab	1.71 (0.69 to 4.49)
Tocilizumab	0.77 (0.41 to 1.45)
Overall	1.09 (0.97, 1.24)
Data points	(133)
Residual deviance	153.8
DIC	758.95

* = statistically significant; OR = odds ratio; RE model = random-effects model; 95% CI = 95% credible interval; DIC = Deviance information criteria

Table 8. Treatment comparison to control: total adverse events - network meta-analysis MTC

OR	Standard Dose
RE Model	Model
	Median (95% CI)
Abatacept	1.25 (0.72 to 2.15)
Adalimumab	1.03 (0.67 to 1.54)
Anakinra	1.44 (0.80 to 2.68)
Certolizumab	1.17 (0.71 to 1.95)
Etanercept	1.38 (0.80 to 2.46)
Golimumab	1.24 (0.78 to 1.98)
Infliximab	1.55 (1.01 to 2.35)*

Table 8. Treatment comparison to control: total adverse events - network meta-analysis MTC *(Continued)*

Rituximab	1.54 (0.49 to 4.63)
Tocilizumab	1.31 (0.57 to 3.01)
Overall	1.28 (1.09, 1.50)*
Data points	(101)
Residual deviance	113
DIC	642.73

* = statistically significant; OR = odds ratio; RE model = random-effects model; 95% CI = 95% credible interval; DIC = Deviance information criteria

Table 9. Treatment comparison to control: withdrawals due to adverse events - network meta-analysis MTC

OR	Standard Dose
RE Model	Model
	Median (95% CI)
Abatacept	1.17 (0.58 to 2.41)
Adalimumab	1.35 (0.82 to 2.22)
Anakinra	1.63 (0.68 to 3.96)
Certolizumab	1.32 (0.69 to 2.69)
Etanercept	1.30 (0.82 to 2.17)
Golimumab	1.34 (0.63 to 2.92)
Infliximab	2.34 (1.40 to 4.14)*
Rituximab	2.74 (0.43 to 28.48)
Tocilizumab	1.83 (0.64 to 5.42)
Overall	1.47 (1.20, 1.86)*
Data points	(165)
Residual deviance	161.1
DIC	764.72

* = statistically significant; OR = odds ratio; RE model = random-effects model; 95% CI = 95% credible interval; DIC = Deviance information criteria

Table 10. Treatment comparison to control: serious infections - network meta-analysis MTC

OR	Standard Dose
RE Model	Model

Table 10. Treatment comparison to control: serious infections - network meta-analysis MTC *(Continued)*

	Median (95% CI)
Abatacept	0.97 (0.40 to 2.31)
Adalimumab	1.23 (0.65 to 2.40)
Anakinra	4.05 (1.22 to 16.84)*
Certolizumab	4.75 (1.52 to 18.45)*
Etanercept	1.29 (0.72 to 2.45)
Golimumab	1.11 (0.45 to 2.59)
Infliximab	1.41 (0.75 to 2.62)
Rituximab	0.26 (0.03 to 2.16)
Tocilizumab	0.84 (0.20 to 3.56)
Overall	1.37 (1.04, 1.82)*
Data points	(115)
Residual deviance	123.2
DIC	494.12

* = statistically significant; OR = odds ratio; RE model = random-effects model; 95% CI = 95% credible interval; DIC = Deviance information criteria

Table 11. Pairwise treatment comparison: serious adverse events - network meta-analysis MTC

Comparison	Standard Dose Model OR (95% CI)
Adalimumab vs Etanercept	0.78 (0.52 to 1.16)
Certolizumab vs Etanercept	1.27 (0.77 to 2.06)
Golimumab vs Etanercept	0.85 (0.49 to 1.44)
Abatacept vs Etanercept	0.71 (0.44 to 1.12)
Infliximab vs Etanercept	0.93 (0.60 to 1.42)
Rituximab vs Etanercept	1.38 (0.53 to 3.84)
Anakinra vs Etanercept	0.84 (0.49 to 1.43)
Tocilizumab vs Etanercept	0.62 (0.30 to 1.24)
Certolizumab vs Adalimumab	1.63 (1.01 to 2.62)*

Table 11. Pairwise treatment comparison: serious adverse events - network meta-analysis MTC (Continued)

Golimumab vs Adalimumab	1.09 (0.64 to 1.88)
Abatacept vs Adalimumab	0.92 (0.58 to 1.42)
Infliximab vs Adalimumab	1.19 (0.79 to 1.79)
Rituximab vs Adalimumab	1.77 (0.68 to 4.82)
Anakinra vs Adalimumab	1.08 (0.64 to 1.82)
Tocilizumab vs Adalimumab	0.79 (0.40 to 1.59)
Golimumab vs Certolizumab	0.67 (0.37 to 1.23)
Abatacept vs Certolizumab	0.56 (0.33 to 0.94)
Infliximab vs Certolizumab	0.73 (0.45 to 1.21)
Rituximab vs Certolizumab	1.09 (0.41 to 3.07)
Anakinra vs Certolizumab	0.66 (0.37 to 1.21)
Tocilizumab vs Certolizumab	0.49 (0.23 to 1.03)
Abatacept vs Golimumab	0.84 (0.47 to 1.48)
Infliximab vs Golimumab	1.09 (0.62 to 1.90)
Rituximab vs Golimumab	1.63 (0.59 to 4.75)
Anakinra vs Golimumab	0.99 (0.52 to 1.90)
Tocilizumab vs Golimumab	0.73 (0.34 to 1.59)
Infliximab vs Abatacept	1.30 (0.84 to 2.08)
Rituximab vs Abatacept	1.94 (0.73 to 5.43)
Anakinra vs Abatacept	1.17 (0.67 to 2.14)
Tocilizumab vs Abatacept	0.86 (0.42 to 1.81)
Rituximab vs Infliximab	1.49 (0.57 to 4.13)
Anakinra vs Infliximab	0.91 (0.53 to 1.57)
Tocilizumab vs Infliximab	0.67 (0.33 to 1.34)

Table 11. Pairwise treatment comparison: serious adverse events - network meta-analysis MTC (Continued)

Anakinra vs Rituximab	0.60 (0.21 to 1.68)
Tocilizumab vs Rituximab	0.44 (0.14 to 1.37)
Tocilizumab vs Anakinra	0.74 (0.34 to 1.60)

*=statistically significant; OR = odds ratio; 95% CI = 95% credible interval

Table 12. Pairwise treatment comparison: total adverse events - network meta-analysis MTC

Comparison	Standard Dose Model OR (95% CI)
Adalimumab vs Etanercept	0.74 (0.36to 1.45)
Certolizumab vs Etanercept	0.85 (0.39to 1.77)
Golimumab vs Etanercept	0.90 (0.43 to 1.83)
Abatacept vs Etanercept	0.90 (0.40 to 1.94)
Infliximab vs Etanercept	1.12 (0.54 to 2.22)
Rituximab vs Etanercept	1.11 (0.31 to 3.80)
Anakinra vs Etanercept	1.04 (0.45 to 2.36)
Tocilizumab vs Etanercept	0.95 (0.34 to 2.54)
Certolizumab vs Adalimumab	1.14 (0.60 to 2.24)
Golimumab vs Adalimumab	1.20 (0.65 to 2.30)
Abatacept vs Adalimumab	1.22 (0.61 to 2.45)
Infliximab vs Adalimumab	1.51 (0.84 to 2.76)
Rituximab vs Adalimumab	1.50 (0.45 to 4.93)
Anakinra vs Adalimumab	1.40 (0.69 to 3.00)
Tocilizumab vs Adalimumab	1.27 (0.51 to 3.29)
Golimumab vs Certolizumab	1.06 (0.53 to 2.10)
Abatacept vs Certolizumab	1.07 (0.50 to 2.22)

Table 12. Pairwise treatment comparison: total adverse events - network meta-analysis MTC (Continued)

Infliximab vs Certolizumab	1.32 (0.68 to 2.53)
Rituximab vs Certolizumab	1.31 (0.38 to 4.40)
Anakinra vs Certolizumab	1.22 (0.57 to 2.73)
Tocilizumab vs Certolizumab	1.11 (0.42 to 2.94)
Abatacept vs Golimumab	1.01 (0.49 to 2.07)
Infliximab vs Golimumab	1.26 (0.66 to 2.33)
Rituximab vs Golimumab	1.25 (0.36 to 4.07)
Anakinra vs Golimumab	1.16 (0.55 to 2.52)
Tocilizumab vs Golimumab	1.06 (0.41 to 2.74)
Infliximab vs Abatacept	1.24 (0.65 to 2.39)
Rituximab vs Abatacept	1.23 (0.35 to 4.23)
Anakinra vs Abatacept	1.15 (0.52 to 2.66)
Tocilizumab vs Abatacept	1.05 (0.39 to 2.8)
Rituximab vs Infliximab	0.99 (0.30 to 3.24)
Anakinra vs Infliximab	0.93 (0.45 to 1.98)
Tocilizumab vs Infliximab	0.84 (0.33 to 2.16)
Anakinra vs Rituximab	0.93 (0.27 to 3.44)
Tocilizumab vs Rituximab	0.85 (0.21 to 3.50)
Tocilizumab vs Anakinra	0.91 (0.32 to 2.52)

* = statistically significant; OR = odds ratio; 95% CI = 95% credible interval

Table 13. Pairwise treatment comparison: withdrawals due to adverse events - network meta-analysis MTC

Comparison	Standard Dose Model
	OR (95% CI)

Table 13. Pairwise treatment comparison: withdrawals due to adverse events - network meta-analysis MTC (Continued)

Adalimumab vs Etanercept	1.04 (0.51 to 2.02)
Certolizumab vs Etanercept	1.02 (0.44 to 2.32)
Golimumab vs Etanercept	1.03 (0.41 to 2.514)
Abatacept vs Etanercept	0.90 (0.38 to 2.10)
Infliximab vs Etanercept	1.81 (0.89 to 3.68)
Rituximab vs Etanercept	2.11 (0.30 to 22.43)
Anakinra vs Etanercept	1.26 (0.45 to 3.34)
Tocilizumab vs Etanercept	1.41 (0.43 to 4.53)
Certolizumab vs Adalimumab	0.98 (0.43 to 2.33)
Golimumab vs Adalimumab	1.00 (0.40 to 2.49)
Abatacept vs Adalimumab	0.87 (0.37 to 2.09)
Infliximab vs Adalimumab	1.74 (0.86 to 3.70)
Rituximab vs Adalimumab	2.04 (0.30 to 22.18)
Anakinra vs Adalimumab	1.21 (0.44 to 3.32)
Tocilizumab vs Adalimumab	1.36 (0.42 to 4.43)
Golimumab vs Certolizumab	1.01 (0.35 to 2.78)
Abatacept vs Certolizumab	0.88 (0.33 to 2.31)
Infliximab vs Certolizumab	1.77 (0.75 to 4.22)
Rituximab vs Certolizumab	2.07 (0.28 to 23.37)
Anakinra vs Certolizumab	1.23 (0.40 to 3.65)
Tocilizumab vs Certolizumab	1.39 (0.39 to 4.85)
Abatacept vs Golimumab	0.87 (0.31 to 2.48)
Infliximab vs Golimumab	1.75 (0.70 to 4.53)
Rituximab vs Golimumab	2.05 (0.27 to 24.09)
Anakinra vs Golimumab	1.22 (0.38 to 3.90)

Table 13. Pairwise treatment comparison: withdrawals due to adverse events - network meta-analysis MTC (Continued)

Tocilizumab vs Golimumab	1.36 (0.37 to 5.12)
Infliximab vs Abatacept	2.01 (0.87 to 4.77)
Rituximab vs Abatacept	2.35 (0.32 to 26.5)
Anakinra vs Abatacept	1.40 (0.45 to 4.32)
Tocilizumab vs Abatacept	1.57 (0.44 to 5.65)
Rituximab vs Infliximab	1.16 (0.17 to 12.87)
Anakinra vs Infliximab	0.70 (0.24 to 1.91)
Tocilizumab vs Infliximab	0.78 (0.24 to 2.54)
Anakinra vs Rituximab	0.59 (0.05 to 4.61)
Tocilizumab vs Rituximab	0.67 (0.05 to 5.67)
Tocilizumab vs Anakinra	1.12 (0.29 to 4.49)

* = statistically significant; OR = odds ratio; 95% CI = 95% credible interval

Table 14. Pairwise treatment comparison: serious infections - network meta-analysis MTC

Comparison	Standard Dose Model OR (95% CI)
Adalimumab vs Etanercept	0.95 (0.38 to 2.29)
Certolizumab vs Etanercept	3.68 (1.01 to 16.3)*
Golimumab vs Etanercept	0.86 (0.28 to 2.39)
Abatacept vs Etanercept	0.76 (0.25 to 2.12)
Infliximab vs Etanercept	1.09 (0.45 to 2.56)
Rituximab vs Etanercept	0.20 (0.02 to 1.74)
Anakinra vs Etanercept	3.15 (0.80 to 14.5)
Tocilizumab vs Etanercept	0.65 (0.13 to 3.07)

Table 14. Pairwise treatment comparison: serious infections - network meta-analysis MTC (Continued)

Certolizumab vs Adalimumab	3.90 (1.03 to 17.17)*
Golimumab vs Adalimumab	0.90 (0.29 to 2.63)
Abatacept vs Adalimumab	0.80 (0.26 to 2.33)
Infliximab vs Adalimumab	1.15 (0.46 to 2.81)
Rituximab vs Adalimumab	0.21 (0.02 to 1.89)
Anakinra vs Adalimumab	3.33 (0.83 to 15.4)
Tocilizumab vs Adalimumab	0.69 (0.14 to 3.32)
Golimumab vs Certolizumab	0.23 (0.04 to 0.97)*
Abatacept vs Certolizumab	0.20 (0.04 to 0.86)*
Infliximab vs Certolizumab	0.29 (0.07 to 1.08)
Rituximab vs Certolizumab	0.05 (0.004 to 0.59)*
Anakinra vs Certolizumab	0.86 (0.14 to 5.18)
Tocilizumab vs Certolizumab	0.17 (0.02 to 1.08)
Abatacept vs Golimumab	0.88 (0.26 to 3.07)
Infliximab vs Golimumab	1.27 (0.45 to 3.81)
Rituximab vs Golimumab	0.24 (0.02 to 2.26)
Anakinra vs Golimumab	3.68 (0.84 to 19.96)
Tocilizumab vs Golimumab	0.75 (0.15 to 4.32)
Infliximab vs Abatacept	1.44 (0.53 to 4.07)
Rituximab vs Abatacept	0.27 (0.02 to 2.68)
Anakinra vs Abatacept	4.20 (0.96 to 22.06)
Tocilizumab vs Abatacept	0.86 (0.16 to 4.76)
Rituximab vs Infliximab	0.19 (0.02 to 1.65)
Anakinra vs Infliximab	2.90 (0.75 to 13.41)

Table 14. Pairwise treatment comparison: serious infections - network meta-analysis MTC *(Continued)*

Tocilizumab vs Infliximab	0.60 (0.12 to 2.88)
Anakinra vs Rituximab	15.73 (1.42 to 238.30)*
Tocilizumab vs Rituximab	3.20 (0.25 to 49.00)
Tocilizumab vs Anakinra	0.20 (0.03 to 1.35)

* = statistically significant; OR = odds ratio; 95% CI = 95% credible interval

Table 15. Stratified meta-analysis findings (unadjusted for dose)

Factor	Total adverse events		Serious adverse effects		Serious infections		Withdrawals due to adverse effects	
	OR (95% CI)	Tau squared	OR (95% CI)	Tau squared	OR (95% CI)	Tau squared	OR (95% CI)	Tau squared
Overall biologics (vs control)	1.06 (1.03 to 1.10) P = 0.0006	1.064	1.17 (0.90 to 1.53) P = 0.2448	0.846	1.39 (1.18 to 1.64) P = 0.0003	1.187	1.43 (1.23 to 1.66) P < 0.0001	1.126
By drug (vs Control)	P = 0.0216	1.064	P = 0.3126	0.897	P = 0.0043	1.144	P = 0.0006	1.075
Abatacept	1.05 (0.93 to 1.17)		1.01 (0.77 to 1.31)		1.11 (0.66 to 1.87)		1.14 (0.71 to 1.84)	
Adalimumab	1.00 (0.93 to 1.08)		0.92 (0.74 to 1.15)		1.24(0.81 to 1.88)		1.21 (0.86 to 1.71)	
Anakinra	1.01 (0.88 to 1.16)		1.00 (0.67 to 1.49)		1.83(0.85 to 3.95)		1.61 (0.86 to 3.01)	
Certolizumab pegol	1.05 (0.91 to 1.21)		1.49 (1.06 to 2.02)		2.82 (1.27 to 6.29)		1.39 (0.85 to 2.29)	
Etanercept	1.10 (1.01 to 1.20)		1.13 (0.90 to 1.41)		1.10 (0.74 to 1.65)		1.25 (0.90 to 1.72)	
Golimumab	1.06 (0.93 to 1.20)		1.00 (0.71 to 1.41)		1.37 (0.77 to 2.44)		1.35 (0.79 to 2.30)	
Infliximab	1.16 (1.07 to 1.27)		1.19 (0.99 to 1.43)		1.97 (1.41 to 2.75)		2.15 (1.60 to 2.89)	
Rituximab	1.04 (0.96 to 1.13)		1.02 (0.84 to 1.23)		1.12 (0.81 to 1.54)		1.21 (0.77 to 1.89)	
Tocilizumab	1.10 (0.97 to 1.26)		1.14 (0.79 to 1.63)		1.67 (0.92 to 3.06)		1.54 (0.88 to 2.67)	
TNF-alpha inhibitor:	P = 0.0021	1.031	P = 0.4927	0.858	P = 0.0002	1.121	P < 0.0001	1.061
Yes	1.07 (1.03 to 1.12)		1.25 (0.92 to 1.71)		1.41 (1.13 to 1.75)		1.41 (1.18 to 1.68)	
No	1.06 (1.00 to 1.12)		0.99 (0.62 to 1.59)		1.37 (1.05 to 1.78)		1.50 (1.13 to 1.99)

Table 15. Stratified meta-analysis findings (unadjusted for dose) (Continued)

Type of Biologic:	P = 0.0097	1.033	P = 0.7289	0.868	P = 0.0004	1.097	P < 0.0001	1.042
TNF-alpha antibody	1.06 (1.01 to 1.12)		1.30 (0.91 to 1.87)		1.48 (1.15 to 1.90)		1.63 (1.09 to 2.43)	
TNF-alpha receptor	1.09 (1.00 to 1.19)		1.11 (0.59 to 2.09)		1.17 (0.74 to 1.83)		1.79 (0.95 to 3.38)	
Others	1.06 (1.00 to 1.12)		1.00 (0.62 to 1.60)		1.37 (1.05 to 1.78)		1.72 (0.96 to 3.08)	
Trial duration:	P < 0.0001	0.634	P < 0.0001	N.E.	P < 0.0001	1.031	P < 0.0001	0.809
Short (<6 mo)	1.08 (1.03 to 1.13)		1.03 (0.93 to 1.15)		1.60 (1.23 to 2.08)		1.76 (1.22 to 2.52)	
Intermediate (6-12 mo)	1.04 (0.97 to 1.12)		1.10 (0.96 to 1.27)		1.38 (0.96 to 1.99)		1.29 (0.69 to 2.40)	
Long (>12mo)	1.04 (0.97 to 1.12)		0.83 (0.76 to 0.90)		1.19 (0.93 to 1.54)		1.56 (0.88 to 2.78)	
Concomitant medication:	P = 0.0723	1.066	P = N/A	0.831	P = 0.0176	1.210	P = 0.0004	1.148
MTX +Other DMARD	1.06 (1.01 to 1.12)		1.18 (0.80 to 1.74)		1.26 (0.96 to 1.65)		1.36 (1.08 to 1.71)	
MTX	1.04 (0.90 to 1.21)		1.74 (0.63 to 4.84)		1.72 (0.90 to 3.30)		1.33 (0.79 to 2.26)	
Other DMARD(s)	1.08 (1.02 to 1.14)		1.05 (0.71 to 1.54)		1.31 (1.00 to 1.72)		1.65 (1.26 to 2.15)	
None	1.05 (0.96 to 1.14)		1.33 (0.71 to 2.50)		1.79 (1.14 to 2.80)		1.34 (0.91 to 1.96)	
Disease condition:	P = 0.0166	1.087	P < 0.0001	0.679	P < 0.0001	1.013	P < 0.0001	0.982
Ankylosing spondylitis	1.25 (1.08 to 1.44)		1.58 (0.56 to 4.48)		1.45 (0.27 to 7.74)		3.34 (0.78 to 14.24)	
Cancer	1.05 (0.96 to 1.15)		1.00 (0.47 to 2.10)		1.15 (0.80 to 1.67)		2.48 (0.84 to 7.32)	
IBD	0.98 (0.88 to 1.09)		0.70 (0.31 to 1.60)		1.28 (0.67 to 2.44)		1.01 (0.37 to 2.77)	

Table 15. Stratified meta-analysis findings (unadjusted for dose) (Continued)

Psoriasis	1.17 (1.06 to 1.30)	1.25 (0.5 to 3.08)	0.70 (0.28 to 1.77)	1.34 (0.52 to 3.45)
Psoriatic arthritis	1.03 (0.87 to 1.22)	0.59 (0.18 to 2.01)	0.29 (0.07 to 1.25)	1.26 (0.31 to 5.07)
Rheumatoid arthritis	1.05 (1.00 to 1.09)	1.31 (0.92 to 1.88)	1.55 (1.23 to 1.95)	1.44 (0.95 to 2.20)
Other*	1.07 (0.96 to 1.19)	1.37 (0.77 to 2.44)	1.61 (1.09 to 2.36)	3.65 (1.67 to 8.18)

N = number of; OR = odds ratio; CI = confidence interval; P = P value; TNF-alpha inhibitor = tumor necrosis factor - alpha inhibitor; N/A = not applicable; N.E. = not estimable; MTX = methotrexate; DMARD = disease modifying anti-rheumatic drug; IBD = inflammatory bowel disease; Other* = other disease conditions - includes: heart failure, multiple sclerosis, COPD, alcoholic hepatitis, diabetes, lupus, active spondylarthropathy, osteoarthritis, asthma, cardiac or renal transplantation, Sjogren's syndrome, polymyalgia rheumatica, autoimmune inner ear disease, giant cell arteritis, pulmonary sarcoidosis, Hepatitis C, cancer anorexia/weight loss syndrome, Wegener's granulomatosis, Crohn's disease and ulcerative colitis.

The results in this table are not adjusted for dose.

Note: we defined the comparison of TNF antibody versus receptor versus other as follows: TNF antibody (infliximab, golimumab, certolizumab pegol, adalimumab) versus TNF receptor (etanercept) versus other (tocilizumab, rituximab, abatacept). The 'other' types of concomitant medication included DMARDs, steroids and/or NSAIDs.

Note: we did not have enough data for the models to run on the stratified analysis for congestive heart failure, lymphoma, and TB reactivation outcomes.

Table 16. Estimates of safety outcomes from extension studies

	Abatacept	Adalimumab	Anakinra	Certolizumab pegol	Etanercept	Golimumab	Infliximab	Rituximab	Tocilizumab
Patients	604	2564	427	781	5342	137	917	1039	143
Estimated Patient Months	22926	34526	8113	9372	173016	1644	17855	49872	8580
Outcome measure	Counts	Risk Counts	Risk Counts	Risk Counts	Risk Counts	Risk Counts	Risk Counts	Risk Counts	Risk Counts
Serious AE, events	132	46.0%227	9.0%.	. 93	11.9%355	10.4%22	16.1%116	12.9%316	30.4%77
Serious AE, patients	287	.	2522	.	. 781	. 3406	. 898	. 1039	. 143
Serious Infections, events	.	.	62	2.5%.	. 7	0.9%178	3.9%3	2.2%42	5.1%84
Serious Infections, patients	.	.	2476	.	. 781	. 4577	. 137	. 831	. 1039

Table 16. Estimates of safety outcomes from extension studies (Continued)

TB, events	0	0.0%2	0.1%. .	5	0.6%1	0.0%0	0.0%1	0.1%0	0.0%. .	
TB, patients	287	. 2275	. . .	781	. 3198	. 137	. 746	. 1039	. . .	
Lymph cancer, events	0	0.0%4	0.2%. .	1	0.1%9	0.4%0	0.0%1	0.1%0	0.0%. .	
Lymph cancer, patients	287	. 2417	. . .	781	. 2279	. 137	. 668	. 1039	. . .	
Cong. Heart Failure, events	. .	2	0.1%. .	. .	. 5	0.3%1	0.7%0	0.0%. .	. . .	
Cong. Heart Failure, patients	. .	2275	. . .	. .	. 1712	. 137	. 668	. .	. . .	
WD d/t AE, events	59	9.8%143	6.5%46	10.8%87	5.0%240	5.5%11	8.0%70	7.8%38	3.7%32	22.4%
WD d/t AE, patients	604	. 2214	. 427	. 781	. 4327	. 137	. 898	. 1039	. 143	.

APPENDICES

Appendix 1. Systematic review search strategy

The Cochrane Library, Issue 1, 2010

Cochrane Database of Systematic Reviews (limited to Reviews only):

DARE:

HTA:

CENTRAL:

- #1 MeSH descriptor Antibodies, Monoclonal explode all trees
- #2 MeSH descriptor Monokines explode all trees
- #3 MeSH descriptor Receptors, Interleukin-1 explode all trees
- #4 MeSH descriptor Receptors, Interleukin-6 explode all trees
- #5 MeSH descriptor Immunoglobulin G explode all trees
- #6 MeSH descriptor Immunoconjugates explode all trees
- #7 MeSH descriptor Polyethylene Glycols explode all trees
- #8 MeSH descriptor Immunoglobulin Fab Fragments explode all trees
- #9 MeSH descriptor T-Lymphocytes explode all trees
- #10 adalimumab:ti,ab
- #11 humira:ti,ab
- #12 trudexa:ti,ab
- #13 abatacept:ti,ab
- #14 orenicia:ti,ab
- #15 anakinra:ti,ab
- #16 kineret:ti,ab
- #17 Certolizumab:ti,ab
- #18 cimzia:ti,ab
- #19 Etanercept:ti,ab
- #20 enbrel:ti,ab
- #21 Golimumab:ti,ab
- #22 simponi:ti,ab
- #23 rituximab:ti,ab
- #24 rituxan:ti,ab
- #25 mabthera:ti,ab
- #26 Tocilizumab:ti,ab
- #27 actemra:ti,ab
- #28 RoActemra:ti,ab

#29 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28)

Appendix 2. RCT, CCT, open label extension update search strategy

I. MEDLINE 2005 to January Week 4 2010

1. exp antibodies, monoclonal/
2. exp monokines/
3. exp receptors, interleukin-1/
4. exp receptors, interleukin-6/
5. exp immunoglobulin g/
6. exp immunoconjugates/
7. exp polyethylene glycols/
8. exp immunoglobulin fab fragments/
9. exp t-lymphocytes/
10. adalimumab.tw.
11. humira.tw.
12. trudexa.tw.
13. abatacept.tw.
14. orenicia.tw.
15. anakinra.tw.
16. kineret.tw.
17. Certolizumab.tw.
18. cimzia.tw.
19. Etanercept.tw.
20. enbrel.tw.
21. Golimumab.tw.
22. simponi.tw.
23. rituximab.tw.
24. rituxan.tw.
25. mabthera.tw.
26. Tocilizumab.tw.
27. actemra.tw.
28. RoActemra.tw.
29. or/1-28
30. limit 29 to (yr="2005 -Current" and randomized controlled trial)

II. EMBASE 2006 to 2010 Week 05

1. adalimumab/

2. adalimumab.tw.
3. humira.tw.
4. trudexa.tw.
5. abatacept/
6. abatacept.tw.
7. orenzia.tw.
8. recombinant interleukin 1 receptor blocking agent/
9. anakinra.tw.
10. kineret.tw.
11. certolizumab pegol/
12. Certolizumab.tw.
13. cimzia.tw.
14. etanercept/
15. Etanercept.tw.
16. enbrel.tw.
17. golimumab/
18. Golimumab.tw.
19. simponi.tw.
20. rituximab/
21. rituximab.tw.
22. ritux?n.tw.
23. mabthera.tw.
24. atlizumab/
25. Tocilizumab.tw.
26. actemra.tw.
27. RoActemra.tw.
28. or/1-27
29. (random\$ or placebo\$).ti,ab.
30. ((single\$ or double\$ or triple\$ or treble\$) and (blind\$ or mask\$)).ti,ab.
31. controlled clinical trial\$.ti,ab.
32. RETRACTED ARTICLE/
33. or/29-32
34. (animal\$ not human\$).sh,hw.
35. 33 not 34
36. 28 and 35

37. limit 36 to yr="2006 -Current"

Appendix 3. Adverse event search strategy

I. MEDLINE 1950 to January Week 4 2010

1. adalimumab.tw.
2. humira.tw.
3. trudexa.tw.
4. abatacept.tw.
5. orenzia.tw.
6. anakinra.tw.
7. kineret.tw.
8. Certolizumab.tw.
9. cimzia.tw.
10. Etanercept.tw.
11. enbrel.tw.
12. Golimumab.tw.
13. simponi.tw.
14. rituximab.tw.
15. rituxan.tw.
16. mabthera.tw.
17. Tocilizumab.tw.
18. actemra.tw.
19. RoActemra.tw.
20. or/1-19
21. (safe or safety).tw.
22. side effect\$.tw.
23. ((adverse or undesirable or harms\$ or serious or toxic) adj3 (effect\$ or reaction\$ or event\$ or outcome\$)).tw.
24. exp product surveillance, postmarketing/
25. exp adverse drug reaction reporting systems/
26. clinical trials, phase iv/
27. Clinical Trials, Phase III/
28. exp poisoning/
29. exp substance-related disorders/
30. exp drug toxicity/
31. exp abnormalities, drug induced/
32. exp drug monitoring/

- 33. exp drug hypersensitivity/
- 34. (toxicity or complication\$ or noxious or tolerability).tw.
- 35. exp Postoperative Complications/
- 36. exp Intraoperative Complications/
- 37. extension.tw.
- 38. continuation.tw.
- 39. (follow-on or follow-up).tw.
- 40. long-term data.tw.
- 41. or/21-40
- 42. 20 and 41

II. EMBASE 1980 to 2010 Week 05

- 1. adalimumab.tw.
- 2. humira.tw.
- 3. trudexa.tw.
- 4. abatacept.tw.
- 5. orenzia.tw.
- 6. anakinra.tw.
- 7. kineret.tw.
- 8. Certolizumab.tw.
- 9. cimzia.tw.
- 10. Etanercept.tw.
- 11. enbrel.tw.
- 12. Golimumab.tw.
- 13. simponi.tw.
- 14. rituximab.tw.
- 15. ritux?n.tw.
- 16. mabthera.tw.
- 17. Tocilizumab.tw.
- 18. actemra.tw.
- 19. RoActemra.tw.
- 20. or/1-19
- 21. (ae or si or to or co).fs.
- 22. (adverse adj (effect\$ or reaction\$ or event\$ or incident\$)).tw.
- 23. toxic\$.tw.
- 24. ((injurious or undesirable) adj (effect\$ or reaction\$ or event\$ or incident\$)).tw.

25. safety.tw.
26. ((drug or chemical\$) adj induced).tw.
27. extension.tw.
28. continuation.tw.
29. follow-on.tw.
30. (follow-up adj5 trial).tw.
31. long-term data.tw.
32. or/21-31
33. 20 and 32

Appendix 4. Treatment comparison to control: serious adverse events - network meta-analysis MTC

OR	Standard Dose	Unadjusted	Dose Adjusted
RE Model	Model	Model	Model
	Median (95% CI)	Median (95% CI)	Median (95% CI)
Abatacept	0.89 (0.61 to 1.26)	1.02 (0.71 to 1.47)	0.88 (0.45 to 1.70)
Adalimumab	0.96 (0.74 to 1.27)	0.90 (0.67, to 1.20)	1.01 (0.64 to 1.59)
Anakinra	1.04 (0.67 to 1.64)	1.05 (0.61 to 1.85)	1.06 (0.58 to 1.94)
Certolizumab	1.57 (1.06 to 2.32)*	1.66 (1.08 to 2.59)*	1.57 (0.96 to 2.57)
Etanercept	1.24 (0.93 to 1.69)	1.25 (0.92 to 1.72)	1.29 (0.90 to 1.87)
Golimumab	1.05 (0.67 to 1.69)	1.06 (0.68 to 1.63)	1.03 (0.60 to 1.74)
Infliximab	1.15 (0.85 to 1.57)	1.24 (0.97 to 1.62)	1.13 (0.79 to 1.62)
Rituximab	1.71 (0.69 to 4.49)	1.38 (1.03 to 1.86)*	1.44 (0.57 to 3.59)
Tocilizumab	0.77 (0.41 to 1.45)	1.11 (0.70 to 1.77)	1.16 (0.25 to 4.77)
Overall	1.09 (0.97 to 1.24)		
Data points	(133)	(211)	(261)
Residual deviance	153.8	285.6	282.7
DIC	758.95	1368.36	1377.79

Footnotes

* = statistically significant; OR = odds ratio; RE model = random-effects model; 95% CI = 95% credible interval; DIC = Deviance information criteria

Appendix 5. Treatment comparison to control: total adverse events - network meta-analysis MTC

OR	Standard Dose	Unadjusted	Dose Adjusted
RE Model	Model	Model	Model
	Median (95% CI)	Median (95% CI)	Median (95% CI)
Abatacept	1.25 (0.72 to 2.15)	1.10 (0.73 to 1.66)	1.24 (0.74 to 2.07)
Adalimumab	1.03 (0.67 to 1.54)	1.04 (0.75 to 1.45)	0.86 (0.51 to 1.44)
Anakinra	1.44 (0.80 to 2.68)	1.19 (0.74 to 1.92)	1.38 (0.79 to 2.41)
Certolizumab	1.17 (0.71 to 1.95)	1.18 (0.77 to 1.80)	1.17 (0.74 to 1.88)
Etanercept	1.38 (0.80 to 2.46)	1.13 (0.71 to 1.81)	1.20 (0.71 to 2.06)
Golimumab	1.24 (0.78 to 1.98)	1.18 (0.81 to 1.69)	1.15 (0.74 to 1.79)
Infliximab	1.55 (1.01 to 2.35)*	1.54 (1.17 to 2.03)*	1.45 (0.98 to 2.11)
Rituximab	1.54 (0.49 to 4.63)	1.49 (0.94 to 2.40)	1.28 (0.49 to 3.37)
Tocilizumab	1.31 (0.57 to 3.01)	1.34 (0.85 to 2.10)	1.11 (0.53 to 2.28)
Overall	1.28 (1.09 to 1.50)*		
Data points	(101)	(160)	(163)
Residual deviance	113	178.4	175.9
DIC	642.73	1012.58	1016.75

Footnotes

* = statistically significant; OR = odds ratio; RE model = random-effects model; 95% CI = 95% credible interval; DIC = Deviance information criteria

Appendix 6. Treatment comparison to control: withdrawals due to adverse events - network meta-analysis MTC

OR	Standard Dose	Unadjusted	Dose Adjusted
RE Model	Model	Model	Model
	Median (95% CI)	Median (95% CI)	Median (95% CI)
Abatacept	1.17 (0.58 to 2.41)	1.21 (0.69 to 2.12)	1.04 (0.51 to 2.12)
Adalimumab	1.35 (0.82 to 2.22)	1.16 (0.77 to 1.74)	1.38 (0.87 to 2.20)
Anakinra	1.63 (0.68 to 3.96)	1.63 (0.78 to 3.48)	1.62 (0.73 to 3.71)
Certolizumab	1.32 (0.69 to 2.69)	1.32 (0.75 to 2.40)	1.31 (0.70 to 2.52)
Etanercept	1.30 (0.82 to 2.17)	1.35 (0.92 to 2.02)	1.36 (0.88 to 2.16)

(Continued)

Golimumab	1.34 (0.63 to 2.92)	1.43 (0.78 to 2.66)	1.28 (0.62 to 2.67)
Infliximab	2.34 (1.40 to 4.14)*	2.32 (1.63 to 3.37)*	2.29 (1.45 to 3.73)*
Rituximab	2.74 (0.43 to 28.48)	2.50 (1.36 to 4.88)*	1.78 (0.38 to 8.43)
Tocilizumab	1.83 (0.64 to 5.42)	1.47 (0.79 to 2.79)	1.57 (0.63 to 3.90)
Overall	1.47 (1.20 to 1.86)*		
Data points	(165)	(264)	(266)
Residual deviance	161.1	268.6	270.6
DIC	764.72	1247.06	1259.71

Footnotes

* = statistically significant; OR = odds ratio; RE model = random-effects model; 95% CI = 95% credible interval; DIC = Deviance information criteria

Appendix 7. Treatment comparison to control: serious infections - network meta-analysis MTC

OR	Standard Dose	Unadjusted	Dose Adjusted
RE Model	Model	Model	Model
	Median (95% CI)	Median (95% CI)	Median (95% CI)
Abatacept	0.97 (0.40 to 2.31)	1.19 (0.62 to 2.27)	1.08 (0.48 to 2.48)
Adalimumab	1.23 (0.65 to 2.40)	1.26 (0.74 to 2.20)	1.30 (0.73 to 2.42)
Anakinra	4.05 (1.22 to 16.84)*	3.96 (1.27 to 15.75)*	4.03 (1.29 to 16.22)*
Certolizumab	4.75 (1.52 to 18.45)*	4.65 (1.61 to 16.22)*	4.67 (1.58 to 16.15)*
Etanercept	1.29 (0.72 to 2.45)	1.19 (0.72 to 2.01)	1.28 (0.73 to 2.30)
Golimumab	1.11 (0.45 to 2.59)	1.30 (0.65 to 2.65)	1.14 (0.49 to 2.55)
Infliximab	1.41 (0.75 to 2.62)	1.58 (1.08 to 2.36)*	1.17 (0.65 to 2.09)
Rituximab	0.26 (0.03 to 2.16)	1.17 (0.76 to 1.85)	0.46 (0.16 to 1.15)
Tocilizumab	0.84 (0.20 to 3.56)	1.52 (0.72 to 3.32)	0.78 (0.22 to 2.60)
Overall	1.37 (1.04 to 1.82)*		
Data points	(115)	(163)	(208)
Residual deviance	123.2	221.8	221.5
DIC	494.12	895.53	902.03

Footnotes

* = statistically significant; OR = odds ratio; RE model = random-effects model; 95% CI = 95% credible interval; DIC = Deviance information criteria

Appendix 8. Sensitivity/meta-regression analysis for serious infection (certolizumab versus placebo)

Model	OR (95% credible interval)
Random effects (RE)	4.75 (1.52, 18.45)
Fixed effects (FE)	4.16 (1.69, 12.57)
RE remove cancer trials	4.71 (1.51, 18.10)
RE meta-regression control rate	4.67 (1.46, 18.06)
RE meta-regression trial length	5.26 (1.52, 24.35)

Appendix 9. Pairwise treatment comparison: serious adverse events - network meta-analysis MTC

Comparison	Standard Dose Model OR (95% CI)	Unadjusted Dose Model OR (95% CI)	Dose Adjusted Model OR (95% CI)
Adalimumab vs Etanercept	0.78 (0.52 to 1.16)	0.71 (0.70 to 1.77)	0.78 (0.43 to 1.40)
Certolizumab vs Etanercept	1.27 (0.77 to 2.06)	1.32 (0.46 to 1.09)	1.22 (0.66 to 2.26)
Golimumab vs Etanercept	0.85 (0.49 to 1.44)	0.84 (0.77 to 2.28)	0.80 (0.42 to 1.53)
Abatacept vs Etanercept	0.71 (0.44 to 1.12)	0.81 (0.49 to 1.42)	0.68 (0.31 to 1.47)
Infliximab vs Etanercept	0.93 (0.60 to 1.42)	0.99 (0.50 to 1.31)	0.88 (0.53 to 1.47)
Rituximab vs Etanercept	1.38 (0.53 to 3.84)	1.10 (0.66 to 1.49)	1.12 (0.41 to 3.00)
Anakinra vs Etanercept	0.84 (0.49 to 1.43)	0.84 (0.72 to 1.70)	0.82 (0.41 to 1.67)
Tocilizumab vs Etanercept	0.62 (0.30 to 1.24)	0.89 (0.44 to 1.59)	0.91 (0.18 to 3.89)
Certolizumab vs Adalimumab	1.63 (1.01 to 2.62)*	1.85 (0.51 to 1.55)	1.56 (0.80 to 3.06)
Golimumab vs Adalimumab	1.09 (0.64 to 1.88)	1.18 (1.10 to 3.14)*	1.03 (0.50 to 2.06)
Abatacept vs Adalimumab	0.92 (0.58 to 1.42)	1.14 (0.70 to 1.99)	0.87 (0.38 to 1.96)
Infliximab vs Adalimumab	1.19 (0.79 to 1.79)	1.39 (0.71 to 1.81)	1.12 (0.63 to 2.01)
Rituximab vs Adalimumab	1.77 (0.68 to 4.82)	1.54 (0.95 to 2.07)	1.43 (0.51 to 4.01)

(Continued)

Anakinra vs Adalimumab	1.08 (0.64 to 1.82)	1.18 (1.02 to 2.33)	1.05 (0.49 to 2.27)
Tocilizumab vs Adalimumab	0.79 (0.40 to 1.59)	1.24 (0.63 to 2.22)	1.15 (0.23 to 5.11)
Golimumab vs Certolizumab	0.67 (0.37 to 1.23)	0.64 (0.72 to 2.15)	0.66 (0.32 to 1.35)
Abatacept vs Certolizumab	0.56 (0.33 to 0.94)	0.61 (0.34 to 1.18)	0.56 (0.24 to 1.27)
Infliximab vs Certolizumab	0.73 (0.45 to 1.21)	0.75 (0.34 to 1.08)	0.72 (0.39 to 1.33)
Rituximab vs Certolizumab	1.09 (0.41 to 3.07)	0.83 (0.45 to 1.24)	0.92 (0.32 to 2.57)
Anakinra vs Certolizumab	0.66 (0.37 to 1.21)	0.64 (0.49 to 1.41)	0.67 (0.31 to 1.47)
Tocilizumab vs Certolizumab	0.49 (0.23 to 1.03)	0.67 (0.31 to 1.29)	0.74 (0.14 to 3.32)
Abatacept vs Golimumab	0.84 (0.47 to 1.48)	0.97 (0.35 to 1.27)	0.85 (0.36 to 2.00)
Infliximab vs Golimumab	1.09 (0.62 to 1.90)	1.18 (0.55 to 1.70)	1.10 (0.58 to 2.10)
Rituximab vs Golimumab	1.63 (0.59 to 4.75)	1.31 (0.72 to 1.97)	1.40 (0.48 to 4.03)
Anakinra vs Golimumab	0.99 (0.52 to 1.90)	1.00 (0.78 to 2.23)	1.03 (0.46 to 2.31)
Tocilizumab vs Golimumab	0.73 (0.34 to 1.59)	1.06 (0.49 to 2.03)	1.14 (0.22 to 5.12)
Infliximab vs Abatacept	1.30 (0.84 to 2.08)	1.22 (0.56 to 1.98)	1.29 (0.61 to 2.79)
Rituximab vs Abatacept	1.94 (0.73 to 5.43)	1.36 (0.80 to 1.90)	1.64 (0.52 to 5.11)
Anakinra vs Abatacept	1.17 (0.67 to 2.14)	1.04 (0.85 to 2.16)	1.20 (0.49 to 3.01)
Tocilizumab vs Abatacept	0.86 (0.42 to 1.81)	1.09 (0.53 to 2.02)	1.33 (0.25 to 6.41)
Rituximab vs Infliximab	1.49 (0.57 to 4.13)	1.11 (0.61 to 1.98)	1.27 (0.47 to 3.40)
Anakinra vs Infliximab	0.91 (0.53 to 1.57)	0.85 (0.75 to 1.63)	0.94 (0.46 to 1.88)
Tocilizumab vs Infliximab	0.67 (0.33 to 1.34)	0.90 (0.46 to 1.56)	1.03 (0.21 to 4.45)
Anakinra vs Rituximab	0.60 (0.21 to 1.68)	0.76 (0.52 to 1.51)	0.74 (0.25 to 2.22)
Tocilizumab vs Rituximab	0.44 (0.14 to 1.37)	0.81 (0.41 to 1.44)	0.81 (0.13 to 4.45)

(Continued)

Tocilizumab vs Anakinra	0.74 (0.34 to 1.60)	1.06 (0.47 to 1.39)	1.10 (0.21 to 5.15)
-------------------------	---------------------	---------------------	---------------------

Footnotes

*=statistically significant; OR = odds ratio; 95% CI = 95% credible interval

Appendix 10. Pairwise treatment comparison: total adverse events - network meta-analysis MTC

Comparison	Standard Dose Model OR (95% CI)	Unadjusted Dose Model OR (95% CI)	Dose Adjusted Model OR (95% CI)
Adalimumab vs Etanercept	0.74 (0.36 to 1.45)	1.04 (0.51 to 2.02)	0.72 (0.34 to 1.51)
Certolizumab vs Etanercept	0.85 (0.39 to 1.77)	1.02 (0.44 to 2.32)	0.98 (0.48 to 1.99)
Golimumab vs Etanercept	0.90 (0.43 to 1.83)	1.03 (0.42 to 2.51)	0.96 (0.47 to 1.92)
Abatacept vs Etanercept	0.90 (0.40 to 1.94)	0.90 (0.38 to 2.10)	1.03 (0.49 to 2.16)
Infliximab vs Etanercept	1.12 (0.54 to 2.22)	1.81 (0.89 to 3.68)	1.21 (0.61 to 2.32)
Rituximab vs Etanercept	1.11 (0.31 to 3.80)	2.11 (0.30 to 22.4)	1.06 (0.35 to 3.19)
Anakinra vs Etanercept	1.04 (0.45 to 2.36)	1.26 (0.45 to 3.34)	1.15 (0.53 to 2.48)
Tocilizumab vs Etanercept	0.95 (0.34 to 2.54)	1.41 (0.43 to 4.53)	0.92 (0.37 to 2.25)
Certolizumab vs Adalimumab	1.14 (0.60 to 2.24)	0.98 (0.43 to 2.33)	1.37 (0.68 to 2.76)
Golimumab vs Adalimumab	1.20 (0.65 to 2.30)	1.00 (0.40 to 2.49)	1.34 (0.68 to 2.65)
Abatacept vs Adalimumab	1.22 (0.61 to 2.45)	0.87 (0.37 to 2.09)	1.44 (0.70 to 3.00)
Infliximab vs Adalimumab	1.51 (0.84 to 2.76)	1.74 (0.86 to 3.70)	1.68 (0.88 to 3.20)
Rituximab vs Adalimumab	1.50 (0.45 to 4.93)	2.04 (0.30 to 22.18)	1.49 (0.50 to 4.45)
Anakinra vs Adalimumab	1.40 (0.69 to 3.00)	1.21 (0.44 to 3.32)	1.60 (0.75 to 3.45)
Tocilizumab vs Adalimumab	1.27 (0.51 to 3.29)	1.36 (0.42 to 4.43)	1.29 (0.52 to 3.15)
Golimumab vs Certolizumab	1.06 (0.53 to 2.10)	1.01 (0.35 to 2.78)	0.98 (0.51 to 1.87)
Abatacept vs Certolizumab	1.07 (0.50 to 2.22)	0.88 (0.33 to 2.31)	1.06 (0.53 to 2.11)
Infliximab vs Certolizumab	1.32 (0.68 to 2.53)	1.77 (0.75 to 4.22)	1.23 (0.67 to 2.25)
Rituximab vs Certolizumab	1.31 (0.38 to 4.40)	2.07 (0.28 to 23.37)	1.09 (0.37 to 3.20)

(Continued)

Anakinra vs Certolizumab	1.22 (0.57 to 2.73)	1.23 (0.40 to 3.65)	1.17 (0.57 to 2.43)
Tocilizumab vs Certolizumab	1.11 (0.42 to 2.94)	1.39 (0.39 to 4.85)	0.94 (0.39 to 2.22)
Abatacept vs Golimumab	1.01 (0.49 to 2.07)	0.87 (0.31 to 2.48)	1.08 (0.55 to 2.13)
Infliximab vs Golimumab	1.26 (0.66 to 2.33)	1.75 (0.70 to 4.54)	1.26 (0.70 to 2.26)
Rituximab vs Golimumab	1.25 (0.36 to 4.07)	2.05 (0.27 to 24.09)	1.11 (0.38 to 3.23)
Anakinra vs Golimumab	1.16 (0.55 to 2.52)	1.22 (0.38 to 3.90)	1.19 (0.59 to 2.47)
Tocilizumab vs Golimumab	1.06 (0.41 to 2.74)	1.36 (0.37 to 5.12)	0.96 (0.41 to 2.26)
Infliximab vs Abatacept	1.24 (0.65 to 2.39)	2.01 (0.87 to 4.77)	1.17 (0.63 to 2.14)
Rituximab vs Abatacept	1.23 (0.35 to 4.23)	2.35 (0.32 to 26.50)	1.03 (0.34 to 3.11)
Anakinra vs Abatacept	1.15 (0.52 to 2.66)	1.40 (0.45 to 4.33)	1.11 (0.52 to 2.38)
Tocilizumab vs Abatacept	1.05 (0.39 to 2.8)	1.57 (0.44 to 5.65)	0.90 (0.37 to 2.17)
Rituximab vs Infliximab	0.99 (0.30 to 3.24)	1.16 (0.17 to 12.87)	0.88 (0.31 to 2.51)
Anakinra vs Infliximab	0.93 (0.45 to 1.98)	0.70 (0.24 to 1.91)	0.95 (0.49 to 1.89)
Tocilizumab vs Infliximab	0.84 (0.33 to 2.16)	0.78 (0.24 to 2.54)	0.77 (0.34 to 1.73)
Anakinra vs Rituximab	0.93 (0.27 to 3.44)	0.59 (0.05 to 4.61)	1.08 (0.35 to 3.29)
Tocilizumab vs Rituximab	0.85 (0.21 to 3.50)	0.67 (0.05 to 5.67)	0.87 (0.25 to 2.89)
Tocilizumab vs Anakinra	0.91 (0.32 to 2.52)	1.12 (0.29 to 4.50)	0.81 (0.32 to 1.99)

Footnotes

* = statistically significant; OR = odds ratio; 95% CI = 95% credible interval

Appendix 11. Pairwise treatment comparison: withdrawals due to adverse events - network meta-analysis MTC

Comparison	Standard Dose Model	Unadjusted Dose Model	Dose Adjusted Model
	OR (95% CI)	OR (95% CI)	OR (95% CI)

(Continued)

Adalimumab vs Etanercept	1.04 (0.51 to 2.02)	0.86 (0.48 to 1.49)	1.02 (0.53 to 1.91)
Certolizumab vs Etanercept	1.02 (0.44 to 2.32)	0.98 (0.49 to 1.96)	0.96 (0.44 to 2.08)
Golimumab vs Etanercept	1.03 (0.41 to 2.514)	1.07 (0.51 to 2.19)	0.94 (0.40 to 2.20)
Abatacept vs Etanercept	0.90 (0.38 to 2.10)	0.90 (0.45 to 1.75)	0.76 (0.33 to 1.75)
Infliximab vs Etanercept	1.81 (0.89 to 3.68)	1.72 (1.02 to 2.91)*	1.69 (0.89 to 3.20)
Rituximab vs Etanercept	2.11 (0.30 to 22.43)	1.87 (0.90 to 3.94)	1.31 (0.27 to 6.47)
Anakinra vs Etanercept	1.26 (0.45 to 3.34)	1.21 (0.52 to 2.82)	1.19 (0.47 to 3.01)
Tocilizumab vs Etanercept	1.41 (0.43 to 4.53)	1.09 (0.52 to 2.28)	1.15 (0.41 to 3.13)
Certolizumab vs Adalimumab	0.98 (0.43 to 2.33)	1.14 (0.57 to 2.33)	0.95 (0.44 to 2.12)
Golimumab vs Adalimumab	1.00 (0.40 to 2.49)	1.24 (0.59 to 2.58)	0.93 (0.39 to 2.22)
Abatacept vs Adalimumab	0.87 (0.37 to 2.09)	1.05 (0.52 to 2.08)	0.75 (0.32 to 1.76)
Infliximab vs Adalimumab	1.74 (0.86 to 3.70)	2.00 (1.17 to 3.49)*	1.66 (0.87 to 3.23)
Rituximab vs Adalimumab	2.04 (0.30 to 22.18)	2.17 (1.04 to 4.74)*	1.29 (0.26 to 6.55)
Anakinra vs Adalimumab	1.21 (0.44 to 3.32)	1.41 (0.61 to 3.32)	1.17 (0.46 to 3.03)
Tocilizumab vs Adalimumab	1.36 (0.42 to 4.43)	1.27 (0.60 to 2.69)	1.14 (0.41 to 3.15)
Golimumab vs Certolizumab	1.01 (0.35 to 2.78)	1.09 (0.46 to 2.51)	0.97 (0.37 to 2.57)
Abatacept vs Certolizumab	0.88 (0.33 to 2.31)	0.91 (0.40 to 2.03)	0.79 (0.30 to 2.05)
Infliximab vs Certolizumab	1.77 (0.75 to 4.22)	1.75 (0.89 to 3.47)	1.75 (0.79 to 3.84)
Rituximab vs Certolizumab	2.07 (0.28 to 23.37)	1.89 (0.82 to 4.55)	1.36 (0.26 to 7.27)
Anakinra vs Certolizumab	1.23 (0.40 to 3.65)	1.24 (0.48 to 3.16)	1.24 (0.44 to 3.46)
Tocilizumab vs Certolizumab	1.39 (0.39 to 4.85)	1.11 (0.47 to 2.60)	1.20 (0.39 to 3.59)
Abatacept vs Golimumab	0.87 (0.31 to 2.48)	0.84 (0.37 to 1.94)	0.81 (0.30 to 2.24)
Infliximab vs Golimumab	1.75 (0.70 to 4.53)	1.62 (0.79 to 3.34)	1.80 (0.76 to 4.28)
Rituximab vs Golimumab	2.05 (0.27 to 24.09)	1.76 (0.73 to 4.30)	1.38 (0.26 to 7.74)
Anakinra vs Golimumab	1.22 (0.38 to 3.90)	1.14 (0.44 to 3.02)	1.27 (0.43 to 3.81)

(Continued)

Tocilizumab vs Golimumab	1.36 (0.37 to 5.12)	1.03 (0.43 to 2.49)	1.23 (0.38 to 3.95)
Infliximab vs Abatacept	2.01 (0.87 to 4.77)	1.92 (1.01 to 3.71)*	2.21 (0.98 to 5.09)
Rituximab vs Abatacept	2.35 (0.32 to 26.5)	2.07 (0.91 to 4.92)	1.72 (0.32 to 9.40)
Anakinra vs Abatacept	1.40 (0.45 to 4.32)	1.35 (0.53 to 3.47)	1.57 (0.53 to 4.68)
Tocilizumab vs Abatacept	1.57 (0.44 to 5.65)	1.22 (0.53 to 2.84)	1.51 (0.47 to 4.78)
Rituximab vs Infliximab	1.16 (0.17 to 12.87)	1.09 (0.53 to 2.26)	0.78 (0.16 to 3.85)
Anakinra vs Infliximab	0.70 (0.24 to 1.91)	0.71 (0.31 to 1.60)	0.71 (0.28 to 1.80)
Tocilizumab vs Infliximab	0.78 (0.24 to 2.54)	0.64 (0.31 to 1.30)	0.68 (0.24 to 1.88)
Anakinra vs Rituximab	0.59 (0.05 to 4.61)	0.65 (0.24 to 1.68)	0.91 (0.16 to 5.16)
Tocilizumab vs Rituximab	0.67 (0.05 to 5.67)	0.59 (0.24 to 1.40)	0.88 (0.15 to 5.20)
Tocilizumab vs Anakinra	1.12 (0.29 to 4.49)	0.90 (0.34 to 2.41)	0.97 (0.28 to 3.22)

Footnotes

* = statistically significant; OR = odds ratio; 95% CI = 95% credible interval

Appendix 12. Pairwise treatment comparison: serious infections - network meta-analysis MTC

Comparison	Standard Dose Model OR (95% CI)	Unadjusted Dose Model OR (95% CI)	Dose Adjusted Model OR (95% CI)
Adalimumab vs Etanercept	0.95 (0.38 to 2.29)	1.06 (0.51 to 2.23)	1.03 (0.45 to 2.35)
Certolizumab vs Etanercept	3.68 (1.01 to 16.3)*	3.91 (1.19 to 15.01)*	3.63 (1.07 to 14.16)*
Golimumab vs Etanercept	0.86 (0.28 to 2.39)	1.09 (0.46 to 2.57)	0.89 (0.32 to 2.36)
Abatacept vs Etanercept	0.76 (0.25 to 2.12)	0.99 (0.43 to 2.28)	0.84 (0.31 to 2.28)
Infliximab vs Etanercept	1.09 (0.45 to 2.56)	1.32 (0.69 to 2.53)	0.92 (0.40 to 2.00)
Rituximab vs Etanercept	0.20 (0.02 to 1.74)	0.98 (0.50 to 1.94)	0.36 (0.11 to 1.02)
Anakinra vs Etanercept	3.15 (0.80 to 14.5)	3.33 (0.95 to 14.30)	3.16 (0.87 to 13.69)

(Continued)

Tocilizumab vs Etanercept	0.65 (0.13 to 3.07)	1.28 (0.51 to 3.20)	0.61 (0.15 to 2.30)
Certolizumab vs Adalimumab	3.90 (1.03 to 17.17)*	3.67 (1.12 to 14.45)*	3.57 (1.03 to 14.11)*
Golimumab vs Adalimumab	0.90 (0.29 to 2.63)	1.03 (0.42 to 2.49)	0.87 (0.30 to 2.33)
Abatacept vs Adalimumab	0.80 (0.26 to 2.33)	0.94 (0.40 to 2.16)	0.82 (0.30 to 2.30)
Infliximab vs Adalimumab	1.15 (0.46 to 2.81)	1.25 (0.64 to 2.44)	0.89 (0.39 to 2.02)
Rituximab vs Adalimumab	0.21 (0.02 to 1.89)	0.92 (0.46 to 1.86)	0.35 (0.10 to 1.02)
Anakinra vs Adalimumab	3.33 (0.83 to 15.4)	3.14 (0.88 to 13.50)	3.08 (0.82 to 13.88)
Tocilizumab vs Adalimumab	0.69 (0.14 to 3.32)	1.21 (0.47 to 3.06)	0.59 (0.14 to 2.25)
Golimumab vs Certolizumab	0.23 (0.04 to 0.97)*	0.28 (0.07 to 1.01)	0.24 (0.05 to 0.94)*
Abatacept vs Certolizumab	0.20 (0.04 to 0.86)*	0.25 (0.06 to 0.89)*	0.23 (0.05 to 0.91)*
Infliximab vs Certolizumab	0.29 (0.07 to 1.08)	0.34 (0.09 to 1.06)	0.25 (0.06 to 0.85)*
Rituximab vs Certolizumab	0.05 (0.004 to 0.59)*	0.25 (0.07 to 0.80)*	0.10 (0.02 to 0.40)*
Anakinra vs Certolizumab	0.86 (0.14 to 5.18)	0.85 (0.16 to 4.68)	0.87 (0.16 to 4.79)
Tocilizumab vs Certolizumab	0.17 (0.02 to 1.08)	0.33 (0.08 to 1.22)	0.17 (0.03 to 0.85)
Abatacept vs Golimumab	0.88 (0.26 to 3.07)	0.91 (0.35 to 2.38)	0.95 (0.30 to 3.07)
Infliximab vs Golimumab	1.27 (0.45 to 3.81)	1.22 (0.54 to 2.73)	1.03 (0.39 to 2.86)
Rituximab vs Golimumab	0.24 (0.02 to 2.26)	0.90 (0.39 to 2.08)	0.40 (0.11 to 1.38)
Anakinra vs Golimumab	3.68 (0.84 to 19.96)	3.06 (0.79 to 14.64)	3.62 (0.88 to 17.70)
Tocilizumab vs Golimumab	0.75 (0.15 to 4.32)	1.17 (0.42 to 3.37)	0.69 (0.15 to 2.99)
Infliximab vs Abatacept	1.44 (0.53 to 4.07)	1.33 (0.64 to 2.86)	1.09 (0.40 to 2.94)
Rituximab vs Abatacept	0.27 (0.02 to 2.68)	0.98 (0.45 to 2.22)	0.42 (0.11 to 1.44)
Anakinra vs Abatacept	4.20 (0.96 to 22.06)	3.35 (0.902 to 15.30)	3.79 (0.90 to 19.04)
Tocilizumab vs Abatacept	0.86 (0.16 to 4.76)	1.28 (0.48 to 3.56)	0.72 (0.16 to 3.08)

(Continued)

Rituximab vs Infliximab	0.19 (0.02 to 1.65)	0.74 (0.41 to 1.34)	0.39 (0.12 to 1.15)
Anakinra vs Infliximab	2.90 (0.75 to 13.41)	2.50 (0.74 to 10.50)	3.47 (0.94 to 15.64)
Tocilizumab vs Infliximab	0.60 (0.12 to 2.88)	0.97 (0.41 to 2.28)	0.67 (0.16 to 2.54)
Anakinra vs Rituximab	15.73 (1.42 to 238.30)*	3.40 (0.99 to 14.21)	9.04 (2.05 to 49.06)*
Tocilizumab vs Rituximab	3.20 (0.25 to 49.00)	1.31 (0.53 to 3.17)	1.71 (0.35 to 8.37)
Tocilizumab vs Anakinra	0.20 (0.03 to 1.35)	0.38 (0.08 to 1.53)	0.19 (0.03 to 1.05)

Footnotes

* = statistically significant; OR = odds ratio; 95% CI = 95% credible interval

FEEDBACK

Feedback from Lode Dewulf, 13 December 2011

Summary

Our feedback cannot be submitted through this website without losing the formatting of the tables and texts.

Our feedback has, however, already been submitted by email to Dr Singh (author) on Dec 1, 2011, and to Jordi Pardo Pardo (acting managing editor) on Dec 13, 2011.

It is for this feedback that I, on behalf of the author group, accept the below rules and terms of use.

With limited head-to-head data available, systematic reviews and meta-analyses have been used by clinicians and other decision makers to assess potential differences in safety and efficacy between agents in order to guide treatment choices.

Cochrane reviews are acknowledged as one of the definitive sources of systematic reviews and provide a useful resource for practicing physicians and reimbursement bodies. The recent Cochrane meta-analysis by Singh et al. 2011 is one of the most ambitious reviews of biologics to date and is the first systematic assessment of the safety of the nine biologics licensed for the treatment of rheumatoid arthritis (RA). Using a network meta-analysis approach, the authors endeavored to address the important question of whether or not there are differences in safety outcomes between the agents. Based on the authors' hypothesis that "most adverse events from medications are independent of the underlying diagnoses for which the medication is being used", safety data were pooled across a very broad patient population including studies conducted in both rheumatological and non-rheumatological diseases. While the work conducted by Singh et al. represents an important first attempt to compare the safety of the biologic agents using a systematic approach and raises some important questions for further research, it is important to understand some of the potential limitations of the approach and methods used in such a broad review.

In view of the importance given to meta-analyses for guiding treatment decisions, in this letter attention is drawn to the fact that the conclusions made in the Singh et al. 2011 article are not in line with clinical trial data and findings from other meta-analyses and therefore should be interpreted with caution. The authors' conclusions relating to serious infectious events (SIEs) are discussed to illustrate a number of important concerns relating to the methodology and assumptions made in the article. The objective is to help readers better understand the methods employed and their potential limitations in order to avoid the risk of misinterpretation. It is hoped that this letter will stimulate discussion and provide insights and learning for future meta-analyses to ensure that appropriate assumptions and adjustments for confounding factors are made and that readers are able to more critically interpret findings.

Submitter conflict of interest statement:

I am currently employed as Chief Medical Affairs Officer by UCB, marketing authorization holder of certolizumab Pegol. I have no other disclosures to make.

Reply

We thank Dr. Dewulf for his letter and concerns raised. This network meta-analysis (NMA), similar to the traditional meta-analysis (MA), made certain assumptions, and tested those assumptions to the extent possible - heterogeneity, assessed with tau-squared; and pooling of AEs across all diagnoses, tested with subgroup analyses by diagnosis. Given that some assumptions are needed to be made in order to perform a NMA, why should anyone ever care to perform NMA of biologics in RA? In the last decade nine biologics to treat RA have been launched. However, with the exception of Schiff et al., there have been no published studies that directly compare one biologic to another. In the meantime, clinicians and patients struggle to choose between these medications. Therefore, indirect comparisons using NMA methodology are needed to compare these biologics.

Dr. Dewulf also states that our NMA results do not agree with “clinical trial data and findings of other meta-analyses”, without referencing any of these data and analyses, whether it be published or unpublished. Without providing the specific data and analyses, we are unable to respond directly to this comment. However, we found consistency between our review and the published systematic reviews by Alonso-Ruiz 2008, who reported higher withdrawal rates due to adverse events in infliximab compared to control treatment (Alonso-Ruiz A et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskeletal Disorders 2008;9(52):1-27.) and Wiens 2010, that reported no difference in serious infections or serious adverse events between adalimumab, etanercept and infliximab, compared to control (Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 2010 April;30(4):339-53).

The example of serious infections was cited, with a caution to interpret the findings considering the limitations. We found that certolizumab pegol was associated with statistically significantly higher odds of serious infections compared to control, and higher odds than 5 other biologics in indirect comparison (about 4 times higher for certolizumab). As an example of robustness of our findings, 5 sensitivity analyses were conducted from several perspectives and we found that the OR for certolizumab pegol versus control for serious infections ranged between 4.12 and 4.81, a statistically significant result in each instance. Similarly, for comparing biologics to each other, three sensitivity analyses were performed, namely, a standard dose model, an unadjusted dose model and a dose-adjusted model. The significant differences between certolizumab pegol and five other biologics in the standard dose model (main model), persisted in sensitivity analyses in the unadjusted and dose-adjusted models for each comparison, with one minor exception of certolizumab versus golimumab, where confidence interval crossed one (0.28, 95% CI 0.07 to 1.01) in an unadjusted dose model.

Finally, without any mention of what confounding factors should have been adjusted for, we are unable to respond to the issue of unadjusted confounding.

We agree that like any research study, our systematic review has certain limitations. We explicitly stated these limitations in the abstract and discussion section of our paper. However one must not overlook the strengths of our systematic review and network meta-analysis and the robustness of its findings. We hope that this NMA will generate more interest in this topic. Advances in NMA methodology will further advance this field in the future.

Contributors

Jasvinder Singh, George Wells, Robin Christensen, Elizabeth Tanjong Ghogomu, John Macdonald, Rachelle Buchbinder, Peter Tugwell on behalf of the authors.

WHAT'S NEW

Date	Event	Description
26 April 2016	Amended	Links to references corrected

HISTORY

Protocol first published: Issue 10, 2010

Review first published: Issue 2, 2011

Date	Event	Description
5 August 2015	Amended	minor edits (P value for serious infections corrected; P = 0.015)

Date	Event	Description
28 March 2013	Amended	Authors' affiliations updated
15 January 2013	Amended	Minor edits
12 April 2012	Amended	Minor edits
5 January 2012	Amended	Statistical re-analyses.
5 January 2012	Feedback has been incorporated	Responses to queries from Lode Dewulf, Chief Medical Affairs Officer, UCB Pharma.
12 April 2011	Amended	Summary of Findings table revised.

CONTRIBUTIONS OF AUTHORS

Concept: JS, RC, GW, PT, RB

Title registration: JS, RB

Protocol draft: JS

Protocol editing: JS, GW, RC, ETG, NS, JKM, GF, LL, GG, ML, LM, JS, PT, RB

Title and abstract review: ETG, GF, JKM, PT, DF, Michelle Foote

Data abstraction: JS, ETG, NS, JKM, GF, LL, GG, ML, LM, JSchmitt, PT, RB, DF, TW, HS, SH, JR, RJ, Michelle Foote, Bharbhoor Dhaliwal

Data analysis: GW, RC, CC

Drafting the review: JS, RB, LM, EG

Editing and revising the review: JS, GW, RC, ETG, LM, NS, JKM, GF, LL, GG, ML, DF, JSchmitt, TW, PT, RB

DECLARATIONS OF INTEREST

JS: speaker honoraria from Abbott; research grants from AMGEN, Allergan, Takeda, Savient; consultant fee from Savient, URL Pharma, Novartis and Takeda.

GW: research grant and consultant fee from Bristol-Myers Squibb; consultant fees from Abbott, Amgen, UCB; Data Safety Monitoring for Novartis.

RC: has received consulting fees, honoraria, research or institutional support, educational grants, equipment, services or expenses from: Abbott, Astellas Pharma, Axellus, Bristol-Myers Squibb, Cambridge Nutritional Foods, Centocor, DSM Nutritional Products, Hypo-Safe, MSD, MundiPharma, NorPharma, Pharmavie, Pfizer, Roche, Sanofi-Aventis, Scandinavian Clinical Nutrition.

ETG: none

NS: none

JKM: none

Filippini: none

DF: none

Lopes: none

La Mantia: none

Guyatt: in the last 5 years, Dr Guyatt has received grant funding from Pfizer, Lotte and John Hecht Foundation, Bristol-Myers-Squibb, and Astra Zeneca. Dr Guyatt has also received consultation fee from Up-To-Date and Eli Lilly Canada. To our knowledge, none of these are conflicted with the subject matter of this submission.

Lunn: honoraria from Baxter in relation to advisory boards on the use of IVIG.

LM: none

Schmitt: research grant from Wyeth.

PT: grants/honoraria from Bristol Myers, Chiltern International, and UCB

RB: honoraria for the 3e initiative in 2010 funded by Abbott; Principal Investigator for the Australian Rheumatology Association Database (ARAD) - The Australian Rheumatology Association has received unrestricted educational grants from Abbott, Amgen, Roche and Wyeth for ARAD.

JR: none

SH: none

TW: none

HS: none

RJ: none

CC: none

SOURCES OF SUPPORT

Internal sources

- Institute of Population Health, University of Ottawa, Canada.

Logistic support

- The Parker Institute: Musculoskeletal Statistics Unit, Copenhagen University Hospital, Denmark.

The Oak Foundations provide support to the Parker Institute

External sources

- Canadian Institutes of Health Research, Knowledge Synthesis Grant, Canada.

Funding for logistics, organization and administrative support

- National Institutes of Health Research, Cochrane Review Incentive Scheme 2009, UK.

Funding for administrative support

INDEX TERMS

Medical Subject Headings (MeSH)

Antibodies, Monoclonal [*adverse effects]; Biological Products [*adverse effects]; Immunologic Factors [*adverse effects]; Patient Dropouts [statistics & numerical data]; Randomized Controlled Trials as Topic

MeSH check words

Humans